

THE MANUAL OF PSYCHEDELIC SUPPORT

A Practical Guide to Establishing
and Facilitating Care Services
at Music Festivals and Other Events

Second Edition

Multidisciplinary Association for Psychedelic Studies (MAPS)

THE MANUAL OF PSYCHEDELIC SUPPORT



GWYLLM LLWYDD • *The Chemist* (dedicated to Sasha Shulgin), 2013 • multimedia, digital collage
<http://www.gwyllm-art.com>

THE MANUAL OF PSYCHEDELIC SUPPORT



MAPS

Second Edition

Multidisciplinary Association for Psychedelic Studies (MAPS)

Copies of this Manual may be downloaded freely from

<http://www.psychsitter.com>

Sales of this book will help fund psychedelic harm reduction.

The Manual of Psychedelic Support

Second Edition (2017) Multidisciplinary Association for Psychedelic Studies (MAPS)

Printed in China by Asia Pacific Offset

ISBN 978-0-9982765-1-9

L I C E N S I N G & C O P Y R I G H T

This work, *excluding all art and photos*, is licensed under a Creative Commons Attribution–Non-Commercial 4.0 International licence. You are free to Share (copy/redistribute in any medium) and Adapt (remix, transform, build upon) the text of this work, as long as you attribute its original source to *The Manual of Psychedelic Support* and provide a link to the CC BY-NC 4.0 licence <https://creativecommons.org/licenses/by-nc/4.0/>. Additionally, no part of this work may be used directly for commercial purposes. Art and photos in this work are copyright by their respective artists and photographers.

EDITORS

ANNIE OAK

Founder of the [Women’s Visionary Congress](#) and the [Full Circle Tea House](#)

JON HANNA

Co-founder of [Mind States](#)

KAYA

SVEA NIELSEN

Psychologist, Vision Board Coach, Nikken Consultant, and Mama of fine organic children

TWILIGHT

ZEVIC MISHOR, PhD

FOREWORDS

FIRE & EARTH EROWID

Co-founders of [Erowid Center](#), [Erowid.org](#), and [EcstasyData.org](#)

DIOGO RUIVO

Founder of [Good Mood Productions](#) and the [Boom Festival](#)

RICK DOBLIN, PhD

Founder & Executive Director of the [Multidisciplinary Association for Psychedelic Studies \(MAPS\)](#)

ALICIA DANFORTH, PhD

Clinical Psychedelics Researcher

SAM CUTLER

Former Tour Manager for the Rolling Stones and the Grateful Dead

AUTHORS

ALEXANDRE QUARANTA, PhD

Writer, Tantric Yoga Teacher, and Lucid Dreaming Trainer

ALICIA DANFORTH, PhD

Clinical Psychedelics Researcher

ANNIE OAK

Founder of the [Women’s Visionary Congress](#) and the [Full Circle Tea House](#)

BEN ATKINSON

Critical Incident Debriefing/Crisis Care Worker

BEN HOLDEN

Board Member & Lead Volunteer for [KosmicAid](#), and Harm Reduction Outreach Worker (Leeds, United Kingdom)

BERRY

CHRISTOPHER J. WARD

CONSTANCE RODRIGUES

Clinical Psychologist, Somatic-Psychotherapist, Pilot for [KosmiCare Boom Festival \(2010\)](#), Teacher & Co-founder of the [Portuguese Center of Jungian Studies](#)

CONSTANTINOS EFSTRATIOU

DANIEL LEUENBERGER	Trance-lator, DJ Almacalma, and Daddy
ELISSA HARWOOD	Researcher
EMMA METCALF	
GASTONE ZANETTE (Gas), MD	Anaesthesiologist
GRACE LIEW	
IGOR DOMSAC	Psychonaut, Artist, Father, and Founder of Alter Consciens
ISLA CAMILLE DUPORGE	
JACK LIEBERMAN	
JACOB POTKONYAK	
JOAN OBIOLS-LLANDRICH, MD, PhD	Psychiatrist and Anthropologist
JOÃO GONÇALVES	
JON HANNA	Co-founder of Mind States
JONAS DI GREGORIO	
KAI SCHULZE	
KARIN SILENZI DE STAGNI	Coordinator of KosmicAid
KAYA	
KIM PENDERS	
LEVENTE MÓRÓ	Coordinator for DÁT2 Psy Help
LINNAE PONTÉ	Former Director of Harm Reduction (Zendo Project) for MAPS
MARC B. AIXALÀ	
MARIA CARMO CARVALHO	Lecturer at the Faculty of Education, Catholic University of Portugal at Porto, and Pilot & Research Coordinator for KosmiCare Boom Festival (2010)
MARIANA PINTO DE SOUSA	Researcher for KosmiCare Boom Festival
MIMI PELEG	Director of Large Scale Cannabis Training at MECHKAR Israel, and Clinical Research Associate for the MAPS
MINTY DE LA PLAYA	
NATACHA RIBEIRO	
RICK DOBLIN, PhD	Founder & Executive Director of MAPS
SNU VOOGELBREINDER	Ethnobotanical Author and Psychonaut
SVEA NIELSEN	Psychologist, Vision Board Coach, Nikken Consultant, and Mama of fine organic children
TIMOTHY BAKAS	
TOM SHUTTE	Psychotherapist
TRACY DUNNE	Secretary & Care Service Leader for KosmicAid
TWILIGHT	
XAVIER URQUIAGA A.	
VINCE CAKIC	
ZEVIC MISHOR, PhD	
ARTISTS	
ALEX GREY	http://www.alexgrey.com
ALLYSON GREY	http://www.allysongrey.com

FRED TOMASELLI
GWYLLM LLWYDD
JON HANNA
LUKE BROWN
LUKE GRAY
MARK HENSON
MARTINA HOFFMANN
NAOTO HATTORI
ROBERT VENOSA
SHANNON THERON
SHANTIQ
VIBRATA CHROMODORIS
ZEVIC MISHOR, PhD

<http://www.jamescohan.com/artists/fred-tomaselli>
<http://www.gwyllm-art.com>
<http://www.mindstates.org>
<http://www.spectraleyes.com>
<http://www.lukegray.net>
<http://www.markhensonart.com>
<http://www.martinahoffmann.com>
<http://www.naotohattori.com>
<http://www.venosa.com>
<http://plus.google.com/+ShannonTheron/posts>
<http://www.saatchiart.com/shantiq>
<http://www.vibrata.com>

PHOTOGRAPHERS

DAVID ARNSON
EROWID
GREG MANNING
JEN ZARIAT
JOHN COCKTOASTEN
JON HANNA
LEANDRO REINALDO
MADDIE RADNAN
SUSANA SANTOS
VIBRATA CHROMODORIS
ZEVIC MISHOR, PhD

Founder of the Insect Surfers and the Raw Power Rangers
<http://www.erowid.org>

<http://www.zariat.com>

Co-founder of *Mind States*

Anaesthesiologist, Medical Doctor

Co-founder of *Yo! Mad Dreadlocks*, BSc. (Hons) Student, and Psychonaut

Social Worker

<http://www.vibrata.com>

DESIGN TEAM

BLAKE HANNA
DAVE KING
JON HANNA
LUKE GRAY
MARK PLUMMER
SARAH JORDAN

Proofreader • Educator and Cat Whisperer

Web Design • Co-director of *Breaking Convention*

Art & Photography Editor • Co-founder of *Mind States*

Cover Artwork • <http://www.lukegray.net>

Book & Cover Design

Production

CONTRIBUTORS

ANA PAULA SILVA COSTA
D.J. SIMMS
DAVE KING
GWYLLM LLWYDD
IKER PUENTE
JOANNA TARNAVA

Co-director of *Breaking Convention*

<http://www.gwyllm-art.com>

NAMES within this Manual are generally arranged alphabetically by first name. Specific authors for each chapter are listed under that chapter's heading, with **bold type** indicating the chapter leads—those who were responsible for coordinating the writing of that chapter.

DISCLAIMER

This book is designed to present helpful information and motivation to our readers on the subjects addressed. It is provided with the understanding that its editors and its authors are not offering any type of psychological, medical, legal, or any other kind of professional advice. The content of each chapter is the sole expression and opinion of its authors, and not necessarily that of the editors.

This book is not meant to be used, nor should it be used, to diagnose nor treat any medical, psychological, and/or physiological condition. For diagnosis or treatment of any medical, psychological, or physiological problem, consult a licensed physician. The editors and authors are not responsible for any specific health needs that may require medical supervision and shall not be held liable for any damages or negative consequences from any treatment, action, application, or preparation undertaken by and/or provided to any person reading or following the information in this book.

References are provided for informational purposes only and do not constitute endorsement of any websites or other sources. Readers should be aware that the URLs listed in this book and/or the contents of their web sites may change at any time.


Every situation is different. The advice and strategies contained in this Manual may not be suitable for your situation. The editors and authors make no representations or warranties of any kind and specifically disclaim any implied warranties of merchantability or fitness of use for a particular purpose. Neither the editors nor the authors shall be held liable to any person or entity for any loss, or for physical, psychological, emotional, financial, and/or commercial damages, including, but not limited to, special, incidental, consequential or other damages caused, or alleged to have been caused, directly or indirectly by the information contained herein. The authors and editors retain their own views and rights. Readers are responsible for their own choices and results.

FEEDBACK


This Manual is an ongoing work, and we appreciate any comments or suggestions regarding its content. Feedback may be given at <http://www.psychsitter.com>.

DEDICATED...

with deep respect to
Dr. Andrew Sewell,
a courageous healer
and researcher
who helped develop
the principles presented
in this Manual
and applied them
with great compassion;




with love to
David K. Lord,
a precious friend
on the Path
who chose to go
his own way.
Travel well,
dear Dave;



1. Drs. Albert Hofmann and Andrew Sewell displaying the Polish edition of *LSD—My Problem Child*. Photo by Jon Hanna, 2008.
2. David K. Lord. Photographer unknown.
3. Sasha Shulgin on the playa in Black Rock City, Nevada, at the Burning Man Festival. Photo by Greg Manning, 2007.
4. David Best's *Temple of Honor*, Black Rock City, Nevada, at the Burning Man Festival. Photo by Jon Hanna, 2003.

and in gratitude to
Alexander T. Shulgin,
pioneering chemist
and pharmacologist
who created
numerous valuable
psychedelic tools.



Contents

Forewords.....	1
Introduction.....	13
1. A History of Psychedelic Care Services.....	19
2. The Principles and Ethics of Psychedelic Support.....	37
3. Legal Considerations.....	49
4. Planning and First Steps for a New Project.....	59
5. Recruiting a Team.....	67
6. Supporting Roles.....	79
7. Building and Training a Team.....	87
8. Logistics.....	105
9. The Care Space.....	133
10. Running the Service.....	147
11. Screening.....	157
12. Complementary Therapies.....	167
13. Team Welfare.....	185
14. Working With Other Organisations.....	191
15. Risk Management and Performance Improvement.....	199
16. Case Studies and Impressions.....	213
17. Online Resources and Obtaining Assistance.....	263
Final Words.....	275
Appendix A	
Street Names for	
Commonly Encountered Psychoactives.....	279
Appendix B	
Monitoring, Evaluating and Researching—	
Recommendations from an Academic Perspective	
for an Evidence-Based Approach to Psychoactive	
Crisis Intervention.....	303
Guide to Drug Effects and Interactions.....	331
About the Publisher.....	379



NAOTO HATTORI • *Mind Form 03*, 2012 • acrylic on board
<http://naotohattori.com>

FOREWORDS

Fire Erowid

Earth Erowid

Co-founders

of:

[Erowid Center](#)

[Erowid.org](#)

[EcstasyData.org](#)

The psychedelic and empathogenic states

engendered by psychoactive drugs are some of the most profound states of consciousness that humans experience. These substances can also trigger some of the most challenging, confusing, and stressful moments of a person's life.

Concerts, electronic dance music parties, and festivals offer rich aesthetic and social environments that some attendees choose to explore with psychoactive drugs. Those who take ecstasy, LSD, cannabis, or other recreational drugs at these events are generally hoping to have a fun time with a sense of connection, interest, and wonder. But a combination of factors—inexperienced users, novel substances, festival chaos, contaminated or misidentified drugs, et cetera—creates a context where some participants may have psychologically difficult or physically dangerous experiences.

Emergency medical services are present at most large events, but these are set up to handle physical health issues, not emotional or psycho-spiritual crises. Individuals who find themselves overwhelmed by a psychedelic or empathogen need a different kind of support: a service designed to help those in mental turmoil who need a quiet space, a friendly voice, or assistance in recovering from internal and/or external chaos. The presence of trained and prepared care givers can have a strong positive impact on delicate psychedelic mind states, whether those states be fearful or joyous.

The authors of *The Manual of Psychedelic Support* have created a practical guide for designing, organising, and implementing psychedelic/psychological care services. It covers topics ranging from interfacing with festival organisers to complex legal considerations, from checklists for assembling physical structures to therapeutic grounding techniques. Whilst framed primarily for producing formal services at larger events, many of the recommendations are useful for any size gathering where psychoactive drugs are likely to be consumed.

In 1998, when we wrote the “[Psychedelic Crisis FAQ](#)”, there were few publicly available resources describing how to help people in the midst of a difficult psychedelic experience. At the time, psychedelic support spaces were not provided at Burning Man or many other large events, and medical tents were the default destination for people experiencing “bad trips”. This Manual shows how much the art and engineering of psychedelic support services have evolved over the last twenty years, and sets a new high bar for the manner in which these services should be run and what they can accomplish.

Psychedelic care services at festivals are now even more important, as a wildly increasing variety of psychoactive drugs has become available. The presence of novel psychoactive substances complicates all aspects of medical and psychological care. According to the United Nations Office on Drugs and Crime, [over 250 new drugs appeared on the international scene between 2000 and 2013](#). Large festivals are the front lines where users (many of them young) encounter new drugs.

Regardless of the exact identity of the drugs, some use will result in challenging, dark experiences. Crisis care organisers are there to help transform stressful sessions into positive ones by offering a safe context and gentle support. Whilst it is hardly a new idea that set and setting are important, the last fifty years have taught us that the wisdom with which challenges are handled can make the difference between psychological casualties and enriched experimenters.

Although not the norm, difficult or “bad” trips also aren’t rare. In [a 2006 survey](#) of visitors to Erowid.org who reported having tried LSD, 14.5% disclosed having had at least one experience they considered a “very” or “extremely” bad trip. An additional 20.8% reported a “mild” or “somewhat” bad trip. Even in research settings where psychedelics are administered under controlled conditions, extremely fearful experiences are fairly common. In research published in *Psychopharmacology* by [Griffiths et al. in 2011](#), 39% of carefully screened, healthy adults given a strong dose of psilocybin experienced “extreme ratings of fear, fear of insanity, or feeling trapped” at some point during a session. Yet, despite

these periods of intense fear, the comforting environment and trained sitter led to 90% of participants reporting increased well-being and life satisfaction.

Experienced users know that even fearful ordeals whilst under the influence of psychedelics, empathogens, or cannabis can ultimately lead to positive outcomes. When asked to look back on their lifetime of psychedelic use as part of Erowid's pilot "Wisdom Cycle" survey, over 80% of elders said that their difficult psychedelic experiences had also proven beneficial to some degree. Unfortunately, few young people are taught how to navigate psychedelic states by their more experienced elders.

The Manual of Psychedelic Support assembled here addresses the fact that festivals and large events are hubs for psychedelic and empathogen use, where challenging psychological states will inevitably occur. The authors argue that beyond simply providing basic medical care, festival producers and harm-reduction organisations need to offer psychological care as well. Avoiding physical harm at events can no longer be viewed as the only measure of health-related success. This book brings together experts in event planning, therapy, and crisis intervention to create a blueprint for producing psychedelic care services for large and small gatherings alike: improving outcomes, smoothing interactions with law enforcement, and easing the load on medical services. This Manual is an important next step in the sociocultural evolution towards healthier, happier festival attendees.



ANONYMOUS • *Guardian of the Light*, 2014 • watercolour and gouache

Holding Space for the Tribe

Diogo Ruivo

Good Mood Productions

and Founder of the Boom Festival

WHEN setting up a gathering with life transforming potential, the task of the promoters is far beyond that of providing a programme of art, culture, music, and the logistics to make it all run smoothly. As these events often offer the context for experiencing altered states of consciousness, the promoters cannot avoid dealing in a mature and responsible way with the potential “psychedelic emergencies” that may and do arise. In the perspective fostered by many researchers nowadays, which view gatherings involving “ecstatic practices” as a resurfacing of ancient tribal traditions, the promoters become those accountable for “holding the space for the tribe”, and even more so when the event attracts many tens of thousands of people.

It is therefore mandatory to include in the event’s production the construction of one or more spaces devoted to dealing responsibly with such “emergencies”, regardless of the attitudes manifested by the hosting government. As a matter of fact, this would be a more sophisticated way for society as a whole to address the issue of practices leading to altered states of consciousness, which are well-known to occur and are too often (not to say always) dealt with through repressive strategies or utter negligence.

If the setting up of such dedicated spaces within events production (including the necessary training for the people offering the support service) had been a standard procedure since the emergence of music festivals and other large-scale events, the electronic and rock music scenes would probably not have the “bad name” that they have nowadays. If promoters had felt and accepted this responsibility on themselves—by taking care of the event, its participants, and the surrounding community as a whole—we could have avoided many young people hurting themselves and even dying because of mismanaged drug use.

During the years of event production, we at Good Mood have joined a fantastic team of multidisciplinary experts who trained hundreds of volunteers in providing psychedelic support, thus carrying out ground-breaking work in solving difficult cases, saving many lives, and keeping the “community body” harmonious.

Our experience with KosmiCare, Boom's pioneering harm-reduction project, allowed us to become aware of the need for gathering and sharing the information harvested by this and similar ground-breaking initiatives. We are therefore enthusiastic to see this Manual coming to life, as a cornerstone for the promotion and creation of similar projects all around the world. We are very thankful to the team of researchers and healers that has come together to make this happen!

May all states of consciousness be equally cared for, with dignity and respect, in a progressively maturing society!

*An area at the 2009 Symbiosis Festival in Yosemite specifically designated to hold space for the sacred.
Photo by Erowid.*



An Encouraging Sign...

Rick Doblin, PhD

Founder and Executive Director,

[Multidisciplinary Association for Psychedelic Studies \(MAPS\)](#)

THE creation and publication of *The Manual of Psychedelic Support* is an encouraging sign of the maturation and compassion of the global community of psychedelic users. In the midst of the long-awaited but still early crumbling of the counterproductive system of Prohibition (with its explicit goal to increase harms and the perception of risk), this Manual provides essential information about psychedelic harm reduction in a self-regulatory voluntary context. Written by an experienced worldwide team, the Manual helps pave the way to a Post-Prohibition world respectful of people's basic human right to use psychedelics to explore their full range of consciousness—for personal growth, therapy, spirituality, celebration, and recreation—whilst simultaneously being mindful of the perils, pitfalls, and need for support.

The Manual of Psychedelic Support shares techniques that experience has shown can significantly reduce risks, making the transition to a Post-Prohibition world easier to envision.

Whilst Prohibition exacerbates the problems associated with the use of psychedelics, a Post-Prohibition world will not automatically eliminate those problems. Psychedelics are inherently challenging and risky by virtue of their mind-manifesting properties, which bring new ideas and emotions into awareness. Even when psychedelics are administered in clinical settings in which mentally healthy people are given pure substances of known quantities with support by trained facilitators, not all experiences are welcomed or well integrated. The risks of problematic outcomes are even greater when psychedelics of uncertain identity and potency are consumed in recreational settings by people who are not prepared for the full depth of what emerges from their own minds.

At present there are relatively few people who have the understanding to assist someone else through a difficult psychedelic experience. This Manual is a collection of the community's efforts to address the need for accurate information on how to provide such care, which will increase safety and decrease medical and psychiatric emergencies. The psychedelic community has created this Manual as one means of greater self-regulation. The writers of this Manual have put in lots of labour at festivals and have developed compassionate and skilled approaches in working with people who dove into their psyches more deeply than they anticipated.

The search for community, passion, and shared rites of passage are part of what makes us human, and are fundamentally healthy drives. For many people, especially young people, psychedelic festivals are vehicles for the attempted satisfaction of these drives. This Manual is a guide explaining how to create psychedelic support systems at festivals and other gatherings similar in nature to the medical support systems that respond to the inevitable physical injuries that can and do occur. The Manual's content is informed by the renaissance of psychedelic research taking place all over the world, as scientists seek a better understanding of the therapeutic, neuroscientific, and spiritual potentials of psychedelics, as well as their risks. Crises can often be de-escalated quickly with a safe space, compassionate listening, and affirmative guidance. Psychedelic harm reduction services also provide an opportunity through practical experience to train people who want to work in this area as therapists.

This Manual is an evolving document and will grow to include information from additional contributors in the future. Whilst helpful in assisting individuals with their difficult trips, on a larger scale this Manual is part of an effort to help society come into balance, to recover from the difficult trip of the 1960s. We seek by the publication of this Manual to contribute to our cultural evolution into a Post-Prohibition society in which we will all have legal access to ancient and modern technologies of transformation to help us address the existential challenges we face together as humans on a planet in crisis.



In 2001, Portugal mitigated Drug War damages by making personal possession an administrative infraction instead of a criminal offence. Boom Festival attendees can now more easily envision a peaceful Post-Prohibition society. Photo by Jen Zariat, 2008.

Participate

Alicia Danforth, PhD

Clinical Psychedelics Researcher

TEN years ago, a friend told me about an encounter that she had with a stranger at an art and music festival where psychedelics use for personal and collective transformation was common. In the midst of her own revelry, she noticed a young man who was tripping, alone, and frightened. I had never been to a festival or assisted someone who was having a difficult trip. If she tried to get help from law enforcement, I wondered, would he get into legal trouble? Would security or the police handle him roughly? If she sought emergency services, would medics restrain and tranquillise him? My friend stayed by his side, comforting him for hours, until he bolted like a nervous rabbit into the cold and chaos. I imagined better scenarios for both of them. What if there were safe and peaceful places where care providers who knew how to support the physical, mental, and emotional needs of folks experiencing challenging psychedelic voyages were waiting? The next year and every year since, I have volunteered in such places.

Care services for individuals in challenging altered states of consciousness related to psychedelics use are evolving concurrent with the resurgence of legal clinical research with classic hallucinogens. As long as I've been a volunteer at festivals and gatherings, I also have worked as a researcher on legal clinical trials with psychedelic medicines. Both settings inform each other. The intention for all psychedelic support is to create a secure container to attend to body, mind, and spirit for those who enter into vulnerable, sometimes even mystical, states, during which they need humane assistance. Researchers can consult protocols that have been published in peer-reviewed literature for safe and ethical psychedelic-assisted therapy in clinical settings. With the publication of *The Manual of Psychedelic Support*, now event organisers and volunteers have a best-practices guide for creating safe and ethical care services for the multitudes of individuals who are exploring with consciousness-expanding substances outside of Western medical research paradigms.

At the 2010 Boom Festival in Portugal, I met many of the editors and contributing authors of this Manual who volunteered on the KosmiCare team. Event organisers, physicians, drug policy activists, psychiatrists, therapists, scholars, body workers, first-responders, researchers, nurses, project managers, harm-reduction specialists, anthropologists, psychologists, chemists, peer-counsellors, sitters, legal





experts, and experienced psychedelic journeyers collaborated to create the best care service I had ever seen. Portugal decriminalised personal drug use in 2001, and the liberal drug laws there fostered a secure setting for free-flowing information-exchange on the historical, cross-cultural, safety, legal, medical, ethical, therapeutic, pragmatic, and spiritual aspects of running care services in diverse settings. As a result, this Manual covers a broad spectrum of ideological and practical considerations to assist organisers and team leaders in creating scalable services to protect and support their visitors.

The editors, along with multidisciplinary writers from around the world, have created a resource that is current, comprehensive, and compassionate. The contributors' wisdom and guidance is culled from diverse lineages: from the jungle to the desert; from stadiums to sweat lodges; from Grof to Goa, Shulgin to Shambhala. The result is a legacy reference source for event organisers and communities who honour and commit to the responsibility of providing psychedelic care services for individuals working through difficult experiences.

Emergency services volunteers at festivals who are unfamiliar with the psychedelic terrain sometimes whisper to me that someone in their care who was difficult to soothe took "some really bad acid". I know in these situations that, more likely than not, the individual took a *different* powerful psychedelic with effects and durations that they were not expecting, or clean LSD without preparing adequately for their trip. Some care service visitors arrive after getting dosed without their consent. It happens. However, issues most often arise from an improper setting or dose, problematic mindset, lack of ego strength, underlying mental illness, combining incompatible substances, or other unexpected disturbances. The time has come to stop blaming "bad" acid. Now, the focus is on spreading knowledge about how to support individuals who venture, knowingly or unwittingly, into challenging mind states and psycho-spiritual transitions on their psychedelic journeys.

The field of psychedelic support service is young enough for you, the reader, to contribute to the collation and dissemination of evolving care service practices. Read the Manual for what it contains and for what it lacks. Evaluate the content. Contact the editors with your suggestions if you identify areas for improvement. Provide a copy of the Manual to the organisers of the events you attend. If you are an event organiser, share it with your peers. Bring your skills to the volunteer space. Participate.

Psychoactive Drug Use and the Entertainment Industry

Sam Cutler

Former Tour Manager,
the Rolling Stones and the Grateful Dead

I welcome wholeheartedly *The Manual of Psychedelic Support* and congratulate those who have been involved in its production. It is a resource that the entertainment industry has needed for a long time, and I am sure its beneficial effects will go a long way to ameliorating the sometimes sad disturbances and unhappy results of the consumption of the more powerful of the illicit drugs.

The problems of drug consumption have been with the entertainment industry since the industry first existed, but for all practical purposes the experiences this Manual addresses date back to the sixties. It was during that decade that I first began working in the industry, and as is well known, it was during that decade that drug consumption slowly became the ubiquitous force that it is today. The problems of psychedelic drug consumption at rock and roll shows were (initially) not very well understood by either promoters, the police or the public, and matters were not helped by sections of the music community who proactively promoted the consumption of those drugs. Overdoses and psychotic behaviour became commonplace and the response was at best sporadic. Medical services at shows were rudimentary, if not nonexistent, and anyone with a “problem” was simply arrested.

Thankfully, in subsequent decades, the approach to these problems has changed, although it could still be improved. Promoters now accept that they have a legal “duty of care” to their customers at shows and that they are expected to provide emergency services. Large festivals are equipped with medical teams, evacuation helicopters, and various support mechanisms for those who find themselves physically in trouble. That having been said, a coherent and well-thought-out approach to the challenges that sometimes result from psychoactive drug consumption—particularly those of a psychological nature—has unfortunately still been lacking. *The Manual of Psychedelic Support* will go a long way towards filling the gaps in understanding. It will also, most importantly, act as a much needed guide for intervention on the “front lines” of shows, where all too frequently people get into difficulties and need help.

People who get into trouble after having ingested psychoactive substances are in need of sensitive and specialised assistance. They are in a fragile and vulnerable condition and cannot be brutalised into submission nor conveniently given antidotes (which in any case do not exist). There is a substantial body of specialist knowledge that needs to be brought to bear when dealing with such people, and it needs to be spread across all the stakeholders at shows and festivals, from concert-goers, to promoters, and the police.

The problem of drugs—of people having unfortunate reactions to the ingestion of drugs—will simply not go away. It cannot be ignored any longer. Put bluntly, people’s lives and psychological well-being are often seriously at risk. I welcome any and all initiatives that seek to address this problem. We have a long way to go, but through education and a coherent approach I feel confident that progress will be made.



Participants take a two-wheeled trip at the 1st Annual Bicycle Day Parade, April 19, 2014, in Golden Gate Park, to celebrate Albert Hofmann’s 1943 discovery of the psychoactive effects of LSD. Photo by Jon Hanna.




MARTINA HOFFMANN • *Lysergic Summer Dream*, 2006 • oil on canvas

<http://shop.martinahoffmannfineart.com>

INTRODUCTION

Following over four years of work since its inception, and involving the collaboration of more than fifty people from several countries around the world, we are delighted to bring you *The Manual of Psychedelic Support*. It is our hope that the material contained herein will be put to good use in helping people in some of their darkest hours of need. Those with experience in providing such care will know that describing a psychedelic crisis at a music festival or similar event as someone's "darkest hour of need" is often no exaggeration. The power of the psychoactive drugs commonly found in those settings to radically modify consciousness is immense, and the experiences of an individual in such states can be confrontational and very challenging. Whilst presenting valuable opportunities for profound insights and personal transformation, encounters with psychoactive substances can also be traumatic, and may destabilise deep psychological structures that have been laid down over many years. In other cases we find festival-goers who have mixed several psychoactive substances together, taken very high doses, and/or consumed alcohol with these materials, and are not having a difficult trip per se, but rather a "meltdown experience", in which they are simply in need of physical comfort and support. Finally, perhaps the most difficult cases of all are those in which some form of chronic mental illness is involved, often combined with an acute altered mental state induced from the consumption of psychoactive drugs.



leader, through to team leads (if they exist), and ultimately (and importantly), to the care givers who are doing direct work with the guests themselves. This Manual contains material that may be used in the planning stages and lead-up to establishing a care service, resources directly applicable to training the care service team, and information that may be referenced during the actual running of the service. We also envisage it as a valuable document for anybody approaching an event organiser with the intent of setting up a care service for the first time; the scope, thoroughness, and quality of the material contained herein should help persuade organisers of the importance and seriousness of such an undertaking.

From the inception of this project, a key principle has been that this publication should be independent of any external organisation, freely available to all, its content open to adaptation (for example, to be used in training manuals for particular care services), and never to be used directly for commercial ends. We feel that this principle has been upheld, and invite you to make use of this material for any good and wholesome purpose. *The Manual of Psychedelic Support* project was conceived of following the 2010 Boom Festival in Portugal, and it grew out of the experiences of members of the care service there, called KosmiCare.





The main KosmiCare space at the 2010 Boom Festival. Photo by Leandro Reinaldo.

Whilst completely independent of that organisation, we acknowledge the fertile ground that nurtured the roots of this work. Likewise, many of the key people who came on board in the early stages of the project have strong connections to Burning Man (United States) and its Green Dot Rangers, and we similarly acknowledge the deep knowledge and experience of individuals working with that organisation. Yet more people joined from additional walks of life—therapists, scholars, researchers, psychonauts, and others—all bound by a common passion for this field, and a recognition of the importance of helping others. Some became editors, others chapter leads or contributing authors. They formed the core of this project team, and without them it would not have been possible. We are most grateful for their participation and help along the sometimes smooth and sunny, yet at other times difficult and rocky, road. A special thanks to the design team, the artists, and the photographers, who turned the text draft of this Manual into a beautiful finished piece; and to our website designer, who in the final hours carefully constructed our virtual launch pad. Just like the majority of care services that we are familiar with, this project consisted entirely of volunteers (including ourselves, the editors); and so we are doubly grateful.

The result of all this work is the Manual you are now reading. We sincerely hope that it will be used to do good things in the world, and that it will strengthen our collective skills. May it be another small but significant drop in the ocean of work yet to be done in acknowledging and realising the immense power contained in psychoactive drugs for personal transformation, whilst remaining realistic and respectful of their potential dangers.

— The Editors
January 1, 2015





SHANTIQ • *l'ouverture*, 2011 • oil painting
<http://www.saatchiart.com/shantiq>



ROBERT VENOSA • *Hallucinatory Self-Portrait*, 1997 • oil, montage
<http://www.venosa.com>

A HISTORY OF PSYCHEDELIC CARE SERVICES

Annie Oak

Ben Holden

Elissa Harwood

João Gonçalves

Karin Silenzi de Stagni

Levente Móró

Linnae Ponté

Maria Carmo Carvalho

Svea Nielsen

Zevic Mishor

The modern history of psychedelic care services can be traced back to the mid-1960s, when young people began to consume mind-altering substances at concerts and events. Emergency medical services were not trained to provide compassionate support for participants in non-ordinary states of consciousness. In an effort to offer more effective and informed care, a number of groups created their own specialised teams to work with those who were having difficult experiences. This chapter takes a look at some of those early efforts in the United States, as well as a selection of more recent and current ones around the world, and how they developed specialised spaces and techniques as part of their on-site care services. Some of the first attempts at providing support for people who ingest psychedelics and other drugs were launched by the Hog Farmers, the CALM volunteers of the Rainbow Family, Rock Med, White Bird, and the innumerable parking lot medics who went on tour with the Grateful Dead. More recently created psychedelic care services have been developed by the Green Dot Rangers at Burning Man, by KosmiCare at Boom Festival, the Zendo Project, and the Full Circle Tea House. These groups are just a sample of the various services that exist around the world today. See [Chapter 17, “Online Resources and Obtaining Assistance”](#), for a more comprehensive list and links to further information. The groups profiled below represent almost fifty years of creative, compassionate care that has helped innumerable people.

After the perimeter fence was cut down by incoming crowds, the festival became a free event for hundreds of thousands of attendees. Whilst the county declared a state of emergency, the Hog Farmers valiantly fed, comforted, and looked after a flood of participants, effectively launching one of the first large-scale psychedelic care services. For three muddy, historic days, the Hog Farmers found creative ways to support attendees at the site, which lacked adequate sanitation and medical services. Standing on stage one rainy morning during the event, Gravy announced, "What we have in mind is breakfast in bed for 400,000!". The Woodstock Festival was remarkably peaceful considering the conditions and number of people involved. There were two recorded births during the three-day event and two fatalities, one from a suspected heroin overdose and another caused when a tractor accidentally ran over an attendee sleeping in a nearby hay field. After Woodstock, the extended family of Hog Farmers bought a fleet of buses and hit the road to perform theatre shows. The activists and entertainers who made up the collective eventually settled in Northern California, and currently operate a 700-acre ranch where they host large music festivals, run a children's circus camp, and raise money for charitable work around the world.

Grateful Dead Parking Lot Medics

During the long concert tours of the Grateful Dead that began in the 1970s, many ardent fans, known as "Deadheads", followed the band and created lively, temporary communities that took up residence in parking lots near the music venues. After the shows were over, a group of volunteer medics remained behind to assist Deadheads who still roamed the lots. [Rob Savoye](#), who served with one of these loosely organised medic teams from 1978 to 1986, is a founding member of the Ilchester Mountain Search and Rescue group, a collection of rock climbing buddies from West Virginia who provided parking lot services. Savoye says the medics tried to create a calm and secure space for people who were over-stimulated by psychedelic experiences or other psychological challenges. Savoye often brought a bus or truck to the lots—first a VW camper and later a 1964 Ford truck—and created a chill space inside the vehicle to care for guests. The medics, many of whom had formal medical training, also provided first aid for minor injuries. Frequently, says Savoye, law enforcement officers would try to chase the Deadheads from the parking lots, but he would let them hole-up in his parked vehicle for a day or two, often driving them to the next show to reconnect with their friends.

self-destructive. For psychedelic care cases, the CALM and Brew HaHa staff are sensitive about protecting the anonymity of attendees. Guests are asked for information regarding what substance they took, what it looked like and where they got it from, but few formal records are kept. In a non-confrontational manner, care givers sometimes inform the source of the substance about adverse reactions, especially in cases involving “newer” drugs such as GHB and toad venom. According to care givers, suppliers sometimes volunteer information about treatment approaches and usually agree to stop distributing the substance(s) in question.

White Bird

White Bird is a non-profit human service agency based in Eugene, Oregon, that has been serving the people of Lane County and nearby festivals for more than forty years. A collective of largely volunteer care providers, White Bird was founded in 1969 by a Eugene-based community of care givers. The group provides direct service and education that helps people gain control of their social, emotional, and physical well-being. White Bird provides services at the annual Oregon Country Fair, where some participants visit the on-site White Bird clinic to receive their annual check up and primary health care. White Bird also operates three permanent clinics that provide free health and dental care, mental health counselling, and other services to an estimated 12,000 homeless people in the Eugene area. CAHOOTS, or Crisis Assistance Helping Out On The Streets, is a department of White Bird funded by the City of Eugene. CAHOOTS fields a mobile, crisis intervention team—integrated into the city’s public safety system—that responds to more than 85,000 service requests a year. The care givers of CAHOOTS receive 911 dispatch calls and provide services for cases involving severe intoxication, drug overdose, disorientation, mental illness, dispute resolution, non-emergency medical care, first aid, and transport to services. Pioneers in providing on-call psychedelic services and other care to marginalised communities, CAHOOTS operates a van that is staffed and managed by the White Bird Clinic.

Rock Med

For more than forty years, **Rock Med** volunteers have been providing medical care at large concerts and other events in the San Francisco Bay Area. The organisation was founded in 1972 when music promoter Bill Graham asked the Haight Ashbury Free Clinic, a medical service based in San Francisco’s famous Haight-Ashbury neighbourhood, to staff a medical tent at outdoor concerts of the Grateful Dead and Led Zeppelin. Rock Med became a standalone organi-

KosmiCare at Boom Festival

Boom Festival is a week-long biennial event that takes place on the shores of a beautiful lake in Portugal. Launched in 1997 as a psytrance festival, Boom has evolved into a more inclusive event showcasing a variety of music styles and attracting some 30,000 people from 116 nationalities. Boom also features visionary art, sculptures made of natural or recycled materials, performances, fire dancing, and juggling. The Liminal Village hosts lectures, presentations, workshops, and documentaries on forward-thinking topics by international speakers. The Healing Area is devoted to therapeutic treatments including massage, meditation, and yoga. A Baby Boom area offers activities for children. In addition, Boom is an innovator and role model in the development and application of psychedelic care services and sustainability practices for large events.

In 2002 an area was set up in the Liminal Village where info on safer use practices for psychoactive substances was distributed and support was provided to those having challenging experiences. Calling itself **Ground Central Station**, this safe space was produced by Sandra Karpetas, facilitated by a volunteer crew of Canadian harm-reduction advocates from the Higher Knowledge Network, and sponsored by the Multidisciplinary Association for Psychedelic Studies (a U.S. non-profit organisation). In 2004 Boom organisers worked with Karpetas and MAPS to develop and expand effective care techniques by creating a dedicated care facility—a quiet space called **CosmiKiva**—that complemented the festival’s medical services by offering professional attention to people undergoing “psychedelic emergencies”. **CosmiKiva** was renamed **KosmiCare** in 2008, and relocated to a large geodesic dome run by thirty multilingual volunteers. Positioned between the three main music stages, the dome attracted many attendees seeking care and/or information. Representatives from Erowid and Check-In (a Portuguese risk-reduction group) provided computer access and printed materials, and answered questions about psychoactive substances.

Comprised of trained volunteers recruited from amongst Boomers—including medics, psychiatrists, psychologists, nurses, therapists, anthropologists, researchers, and others—**KosmiCare**’s services are coordinated by team members, Boom organisers, on-site medical staff (paramedics), and event security services who assist with particularly difficult cases. The **KosmiCare** team uses a classic “sitting” method to provide peer counselling for attendees, but also offers additional kinds of care such as massage, homeopathy, and other alternative therapies. The **KosmiCare** dome stocks art materials for guests to draw and paint with, and provides information about assorted psychoactive drugs.



Official signs posted by the drug-testing service warn of dangers and deception related to drugs sold at the 2012 Boom Festival. Photo by Zevic Mishor.

Also in 2008, KosmiCare collaborated with Energy Control, a Spanish drug-testing organisation that made its services available at Boom. Working out of a small, well-equipped laboratory, these professionals used thin-layer chromatography (TLC) to assay substances brought to them by festival-goers, or in some cases submitted by the KosmiCare team after the substances had been given to care givers by care space guests. The service provided information regarding the active compounds(s), as well as adulterants, present in the samples tested. This information was very useful not only for individual cases, but also in helping to build a general picture of the kinds of drugs that were being circulated at the festival, and indeed, of trends of disinformation and deception; for example, when one psychoactive was being sold under the guise of another. The photo on the pervious page, taken at Boom 2012 (which hosted a similar testing service), shows the level of honest concern and transparency possible under (and indeed, as part of its emphasis on harm reduction, largely supported by) current Portuguese law. These official signs, unthinkable at present under other jurisdictions in certain countries around the world, help to convey a sense of the atmosphere of openness, saneness, and support that has so far characterised Boom Festival. The article [“Energy Control: TLC and Other Risk Reduction Approaches”](#) by Sylvia Thyssen and Jon Hanna gives some background information on Energy Control, and presents an excellent depiction of their work at the 2008 Boom Festival.

In 2008 the Boom Festival worked closely with paramedics and security to maintain the KosmiCare psychedelic care space and provide effective medical care during a large-scale outbreak of a gastrointestinal illness that was dubbed the “Boom Bug”. This phase of the project is documented in Svea Nielsen and Constance Bettencourt’s essay, [“KosmiCare: Creating Safe Spaces for Difficult Psychedelic Experiences”](#).

In 2006 and 2008, CosmiKiva/KosmiCare launched a strategy to pursue a vision of expanded support and improved guest-outcomes for current and future care services. It consisted of a partnership between Boom organisers, the Faculty of Education and Psychology at the Catholic University of Porto (Portugal), and the Portuguese General-Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD). The purpose of this partnership was to transform the existing care strategy into an *evidence-based crisis intervention model* that addressed the use of psychoactive substances in recreational settings.

The first results of these partnerships were delivered in 2011; psychedelic care resulted in very positive feedback from guests and staff, producing significant improvements in

guests' short-term psychological and physical well-being as a result of treatment. Boom organisers continued to support research related to intervention, and more data was collected at KosmiCare in 2012. As results were made available during 2013, it was possible to verify that other, more quantitative measures of crisis resolution also prove equally positive, with mental state exam indicators increasing significantly between the periods of admission and departure of guests. Please see [Appendix B, "Monitoring, Evaluating and Researching—Recommendations from an Academic Perspective for an Evidence-Based Approach to Psychoactive Crisis Intervention"](#), for further discussion on this research.

At the 2012 Boom Festival the KosmiCare space was moved to a more central area of the event, compared to where it had been set up in 2010, making it easier for participants to locate. An increasingly experienced team of care givers, using tested-and-true methods, continued to provide and improve psychedelic care services, despite budget restrictions.

KosmicAid

KosmicAid is an organisation separate from the original KosmiCare project set up by Boom Festival, but owes much of its philosophy and ethos to that pioneering project. After a successful, challenging, and rewarding time as a volunteer with KosmiCare at the Boom Festival in 2008, Karin Silenzi de Stagni recognised the need for similar services at festivals in the United Kingdom. With support from the Multidisciplinary Association for Psychedelic Studies, Karin formed KosmicAid, using the framework for psychedelic emergency services that MAPS had developed with Diogo Ruivo, chief organiser of the Boom Festival.

Recognising the hard work and innovation of those involved with the original project, KosmicAid gratefully utilised their resources, building upon them to meet the challenges of working at festivals in the United Kingdom. The demands that KosmicAid faces include the harsh climate—often wet and cold even in the summer months—the logistics of attending a number of different festivals across the nation, and the lack of funding. KosmicAid is an independent community project that does not have sponsors, depending entirely on donations and voluntary work. In addition, many small festivals have a limited budget and are able to only just cover basic expenses; nevertheless, the KosmicAid team make every effort to have a presence at as many festivals as possible, because the team really believes in the importance of their project.

Since 2009, KosmicAid has provided care services at several festivals across England, Wales, and Scotland, including Sunrise Celebration, Eden Festival, Waveform, Boomtown

The volunteers staff harm-reduction booths at raves, night-clubs, and other dance events, providing information on drugs, safer sex, and assorted health and safety issues of concern to the electronic dance community. DanceSafe also provides adulterant-screening/pill-testing services for ecstasy (MDMA) users, an important harm-reduction service that may save lives and reduces medical emergencies by helping users avoid fake and/or tainted tablets that can contain substances far more dangerous than actual MDMA. In 2013, the Drug Policy Alliance acknowledged DanceSafe by honouring them with the Dr. Andrew Weil Award for Achievement in the Field of Drug Education.


The Psychedelic Nurses

The Psychedelic Nurses is a European organisation of health care providers that has offered psychedelic support services at parties and festivals in France and Switzerland since 2006. Members of the group base their care on natural healing and holistic therapies, including qigong, tai chi, Reiki, ayurvedic and Thai massage, and shiatsu. Whilst in recent years the Psychedelic Nurses have shifted their focus to offering natural health and exercise services at parties and festivals, they will still provide care for someone experiencing a psychedelic crisis if the need arises.

The Zendo Project


The Zendo Project was launched at the Burning Man Festival in 2012 as an outreach service sponsored by MAPS. Zendo operated from a circular structure near a popular music stage, and was staffed by trained volunteers. Since 2001, MAPS has brought together a diverse team of therapists, doctors, researchers, and experienced peer counselors to provide compassionate care and psychedelic harm reduction at large gatherings. MAPS first provided volunteer recruitment and training for the Sanctuary space at Burning Man in 2003. The organisation later also joined production efforts to help develop a model for psychedelic harm reduction at the Boom Festival (see "[KosmiCare at Boom Festival](#)" above). Following these efforts, MAPS continued to expand its services to a circuit of international events.

The mission of the Zendo Project is to provide a supportive space to support those having difficult psychedelic experiences, reduce the number of psychedelic drug-related arrests and hospitalizations, and train volunteers to provide compassionate care. The Project strives to address the public stigma of psychedelics and encourage honest and responsible conversations about their use. The service clearly demonstrates that it is possible to mitigate the risks associated with the non-medical use of psychedelics at the community



**LUKE
GRAY**
ILLUSTRATION

LUKE GRAY • *Peace Pipe*, 2012 • Staedtler Triplus Fineliner
<http://www.lukegray.net>



MARK HENSON • *Inner Voices*, 1983 • watercolour on paper
<http://markhensonart.com/all-art-gallery-shop/inner-voices>

*The woman is about to enter into a state of communion
with the source of all beingness.
As she passes into the light,
voices of doubt and fear make one more attempt
to direct her thoughts elsewhere.
What if there is no love?
What if there is no caring?
Will I be left out?
As the light comes closer and closer,
the unresolved "Inner Voices" fade,
drawing her through the door of consciousness,
into the love that was there all the time.*

— Commentary by Monti Moore

THE PRINCIPLES AND ETHICS OF PSYCHEDELIC SUPPORT

Annie Oak

Snu Voogelbreinder

A

What is a Psychedelic Care Service?

A **psychedelic care service** assists people who are undergoing challenging experiences during altered states of consciousness or other forms of emotional or mental stress. This chapter reviews some basic principles for providing compassionate care that respects the needs of each person and helps them move from a place of difficulty to a more grounded, calm, and positive perspective. These principles are drawn from the authors' personal knowledge and experience, and from the wisdom of others before us who have found useful ways to support individuals in transition. Our intention is not to impose our beliefs on those in distress nor guide them to any particular outcome. Our intention is to be fully present whilst listening to and protecting those undergoing potentially transformative experiences. In order to provide a consistent level of compassionate care, care givers must act within a clearly defined code of conduct and ethical standards. This code of care should be taught in training sessions and agreed to by everyone who works at the care space.

Ethical Standards for Care Services

2.1

It is essential that care givers act within impeccable ethical standards whilst providing psychedelic support services. Individuals who request these services are often in a vulnerable state and must be treated with respect and dignity. It is important that care givers remain focused on the needs of guests, and act conscientiously whilst providing assistance. The care givers must agree to keep all discussions and events in confidence. They should refrain from sharing their own experiences and beliefs unless it is clear that this exchange is desired by the guest. Request permission from a guest before touching them in any way. Sexual advances from guests should be tactfully deflected. Clearly, sexual advances from a care giver towards a guest are forbidden.

Providing psychedelic support services can be intensely demanding work. The care givers must attentively monitor their own emotional responses and fatigue, recognising their personal limitations and asking for help if needed. Don't try to apply skills you do not possess. If you become ineffective in a given situation, ask another member of the team to replace you. [Chapter 13, "Team Welfare"](#), discusses the importance of taking care of yourself and your team members, for the effective and harmonious operation of the care service.

Seek medical services promptly for any guest who needs them. Antipsychotic medication should only be administered by licensed medical staff, and even then should be considered as a last resort; aborting a crisis experience pharmaceutically without resolving it psycho-spiritually can be detrimental to the guest in the long term, but care givers should not prevent a guest from receiving such intervention if the guest insists on it. Care givers have a duty to protect guests under their care, but do not have the right to make such decisions for them. However, it should be understood that licensed medical staff, when present, have the authority to provide whatever medical intervention they deem appropriate, regardless of the opinion of the guest or the care givers, and care givers must not obstruct them in their duty. [Chapter 6, "Supporting Roles"](#), contains more detailed information regarding working with medics, psychiatrists, and nurses in the care service team.

Request the permission of the guest before using any special techniques in your peer counselling, and avoid pressuring them into accepting. Be open to suggestions from your fellow care givers and mindful of your emotional state. Do not provide care whilst in an altered state of consciousness. Allow yourself to be the grounded energy that helps the guest transition towards their calm, untroubled self.

Provide Compassionate Listening

When providing support, care givers should remain calm and open to the needs of the guests without fussing over them. Guests should be treated as equals and care givers should speak to them without being condescending or patronising. Guests will often feel better simply by having a quiet conversation with someone who will truly listen to them talk about whatever it is they are going through. When we say “listen”, we mean *really* listen to the guest; it is not sufficient or helpful to pretend to listen, or only give partial attention to what the guest is saying. Think carefully about what they tell you, and avoid any instinct towards being dismissive or belittling their experiences and concerns. A guest in an expanded state of consciousness is often exquisitely sensitive to the reactions of those caring for them; if they perceive that they are not being taken seriously, they may become even more anxious or upset and reject further assistance. *Guests are free to leave the care space at any time and for any reason.*

When interacting with guests, it is often useful to respond to what they are telling you. It is also important to let them know that you are listening and that you care about them. Guests will sometimes want to discuss sensitive or personal topics; the care givers should give guests permission to talk about these issues in confidence, whilst maintaining their own emotional and physical boundaries. You should encourage guests to explore their self-awareness and ask them to confirm or clarify your understanding of their situation. Try not to parrot back what they are saying (this could be annoying, or perceived as mocking), but respond in a way that shows that you understand, or are genuinely attempting to understand, what they are trying to communicate. Be honest about your feelings concerning their suggestions for resolution of their distress. If a guest informs you that they intend to do something that could have a drastic outcome, accept the comment seriously, but try to dissuade them from this course of action. Ask them to think about the consequences, not just for themselves, but for others. Suggest that they may want to wait until the next day to assess their decisions in a clearer light.

If guest make seemingly outlandish claims (for example: that they have special psychic powers; that there is a conspiracy against them; that they are royalty), do not argue or express your disbelief. If the claims appear that they may impact the guest’s well-being and safety (such as the belief that someone is trying to kill them), invite the guest to explain the situation as clearly and calmly as possible. Giving guests the time to talk about their concerns will

giver can help guests remain calm and reassured. Emotional struggles and tension may be prompted by a mental effort to fight the experience in an attempt to maintain control. This resistance may arise when the guest is confronted with their fears or unresolved issues from the past. Some people may attempt to avoid this confrontation because it makes them feel afraid, threatened, and uncomfortable. For others, such states may simply be a case of “too much, too soon”, and they may panic or become overwhelmed. Whilst there are other potential causes for distress, the important point is that these experiences are highly unsettling for the person undergoing them and frequently result in deep-seated fear of one kind or another. When unchecked, fear can quickly escalate, aggravating and magnifying the very thoughts and feelings that the guest is trying to avoid.

Removing or reducing resistance and fear helps shift the guest’s mental perspective from “harrowing” to “healing”. Such reassurance helps the guest focus on the personal growth that can be gained from these experiences and helps unknot mental blocks that may be encountered. It can be very beneficial for guests if you tell them this in your own way. Confirm with them that they are in a safe space where they will be treated with compassion and without judgement—somewhere they can unfurl and simply let it all happen. Attempting to outline and discuss the myriad varieties of strange things that people in strong altered states of consciousness may experience and/or believe could fill volumes, so we will avoid trying to over-simplify what care givers may encounter during their work. People differ greatly and are unpredictable; everyone’s experiences are unique. Be kind, attentive, and reassuring.

It is often helpful to remind the guest that they feel the way they do because they have taken a drug (if they have) and that the experience is temporary and will not last forever; in all likelihood, they will feel fine within a matter of hours. This may be a small comfort to the guest, who could be experiencing minutes as hours, but it is important to provide reassurance that the experience *will* end. The same principle applies to guests who may believe that they have gone insane and will stay that way, or who believe that they are dying.

Guests who think they have gone insane may recognise that they have taken a drug, but see this as the trigger for permanent madness, rather than a temporary state. A small number of people are permanently negatively impacted by these states, but it is important to encourage guests to embrace the belief that they will regain their normal mental state. If the guest accepts this, their fear and anxiety may subside and they may be able to explore themselves with a safe

7. [**Not for Profit**] Spiritual practices are to be conducted in the spirit of service. Spiritual guides shall strive to accommodate participants without regard to their ability to pay or make donations.

8. [**Tolerance**] Spiritual guides shall practice openness and respect towards people whose beliefs are in apparent contradiction to their own.

9. [**Peer Review**] Each guide shall seek the counsel of other guides to help ensure the wholesomeness of his or her practices and shall offer counsel when there is need.

Further Reading

(see also Chapter 17, "Online Resources and Obtaining Assistance")

MAPS (2014). *The Zendo Project Harm Reduction Manual*. http://www.zendoproject.org/wp-content/uploads/2016/03/zendo_052015.pdf

Erowid (2005). "Psychedelic Crisis FAQ: Helping Someone Through a Bad Trip, Psychic Crisis, or Spiritual Crisis". http://www.erowid.org/psychoactives/faqs/psychedelic_crisis_faq.shtml

Fadiman, J. (2011). *The Psychedelic Explorer's Guide—Safe, Therapeutic, and Sacred Journeys*. Vermont: Park Street Press. <http://www.psychedelicexplorersguide.com>

Goldsmith, N.M. (2011). *Psychedelic Healing: The Promise of Entheogens for Psychotherapy and Spiritual Development*. Vermont: Healing Arts Press. <http://www.nealgoldsmith.com/psychedelics>

Grof, S. (2008). "Crisis Intervention in Situations Related to Unsupervised Use of Psychedelics". *LSD Psychotherapy*, fourth edition (pages 308–319). California: Multidisciplinary Association for Psychedelic Studies. <http://www.psychedelic-library.org/grof2.htm>

Grof, S. and Grof, C. (1989). *Spiritual Emergency: When Personal Transformation Becomes a Crisis*. New York: Jeremy P. Tarcher/Putnam.

McCabe, O.L. (1977). "Psychedelic Drug Crises: Toxicity and Therapeutics". *Journal of Psychedelic Drugs* 9(2): 107–121.

LEGAL CONSIDERATIONS

Minty De La Playa

This section covering the legal considerations of psychedelic care services explores a range of legal issues that may impact both event participants and personnel involved in providing psychedelic support. An overview of some of the potential legal risks and consequences is provided with regard to situations including: encounters with law enforcement; consent, confidentiality, and privacy issues; legal protections/fiduciary obligations of support personnel; and other potential legal liabilities in providing psychedelic support.

This chapter should not be viewed as constituting legal advice. It is simply intended to highlight some of the legal concerns that should be considered in relation to the provision of psychedelic care services. As laws vary from country to country and from state to state, qualified independent legal advice should be obtained in order for you to determine applicable laws governing your contemplated efforts.

In severe cases, psychedelic care givers will want to ensure that any services provided do not exceed what might reasonably be consented to by an individual in such circumstances. In other words, the care or treatment provided should only go as far as to ensure that the individual does not pose a risk of harm to themselves or others. The extent to which psychedelic support should be provided in such cases will often be difficult to gauge, particularly since the individual may not have the capacity to indicate the types of preventative services they would consent to.

On the other hand, a failure to refer someone who is in medical distress to appropriate medical personnel may result in other liabilities. It may be difficult if not impossible for people without medical training to identify underlying medical conditions, the effects of regularly used prescription medicines, and/or emergent physical symptoms, any of which might result in harmful or even fatal outcomes when combined with a significant psychoactive experience. Specific efforts should be made to adequately gauge the level of care that is required in each case. Whilst most incidents of intense psychedelic experience will probably benefit from some simple harm-prevention techniques, the care giver should be aware of situations that pose serious health risks to guests and that might require immediate medical attention. If there is any concern whatsoever that an individual needs professional medical evaluation, this evaluation must be obtained without delay. Please see [Chapter 11, "Screening"](#), for a more thorough discussion of this subject.

CONFIDENTIALITY AND PRIVACY

As with any patient/practitioner relationship, a duty of confidentiality is required of all care givers with respect to their guest's medical condition and other personal identifying information. The duty will vary by jurisdiction, and will depend on the circumstances of each case. For example, in cases of immediate medical distress, the disclosure of information regarding an individual's consumption of psychoactive drugs may be necessary to ensure proper medical treatment, even though this information may have been conveyed or received in confidence. Typically, a guest's expectations of privacy and confidentiality should be preserved to the greatest extent possible, with the only exception being the "immediate risk of harm" to the individual or others.


"Immediate risk of harm" typically refers to situations where there is a likelihood that the individual may cause harm to themselves or to others. Examples may include ideations of suicide, self-infliction of harm, or violent behaviour towards care givers or other participants. In such cases, it may be

Legal Issues for Care Givers

Legality of Psychedelic Support Services

In some jurisdictions, the promotion or idealisation of drug use may be considered illegal, and various duties are sometimes imposed on festival promoters to identify and report unlawful activity, such as illicit drug use. This raises the question of whether providers of psychedelic care services, by virtue of their focus on the *after-effects* of drug consumption, are actively engaged in the promotion or idealisation of illicit drug use. Yet it is possible that in some cases, law enforcement agencies may consider this to be so.

There are documented cases where a positive duty is placed on festival organisers to actively prevent, eliminate, or report illicit drug activity. It is unclear whether such a duty would extend to psychedelic care providers who interact with users of psychedelic drugs during public events. Although it is presumed by the presence of psychedelic care services that illicit drug use may indeed be occurring at the event, it is more likely that such services will be viewed as being akin to medical care. The duty to report or prevent such activity may, however, be extended to psychedelic care givers depending on the jurisdiction in which the event is being held. Careful consideration should be given to how such care services are likely to be viewed by law enforcement authorities in each particular jurisdiction.



Police officers at the Burning Man Festival in a friendly debate over whether they might have to pull over a "kinetic sculpture" or an "art car".
Photo by Jon Hanna, 2007.

should be cautious about their own interactions with participants to ensure that they are not seen to be participating in the commission of illegal acts. Appropriate training about the laws of the jurisdiction should perhaps be provided to care givers in this regard.


Psychedelic care givers should also be made aware of the possibility of entrapment measures by law enforcement officials posing as festival participants requiring care. Although psychedelic care providers may generally be supportive and sympathetic around users of illegal drugs, they should not place themselves in situations where they are viewed as aiding in the commission of an offence.

The grim tone and content of this last paragraph may rightfully sound disconnected from reality to those who have provided psychedelic care in certain countries (for example, Portugal), and very connected to reality to those who have worked in others (for example, the United States). Each case must be assessed in its own right, taking into account the laws and the norms of its particular jurisdiction.

Potential Liabilities in the Provision of Care: Fiduciary Obligations, Good Samaritan Laws, and so forth

As mentioned above, psychedelic care givers could be held liable for breaches of any duties of care that may be owed to users of their services, even in cases where deemed waiver provisions are provided as a condition of participation at a public event or festival. There may also be fiduciary obligations owed to participants, as well as to festival or event organisers. It is advisable to ensure that such requirements are appropriately researched in advance of providing care. An understanding of local “good Samaritan laws” is also advisable.

Special consideration should be given to the topic of professional medical evaluation. Whilst it may be argued that in the majority of cases, routine medical evaluation—on an ongoing basis once a guest is admitted to the care service—is not necessary, the psychedelic care giver needs to be mindful of the risk of underlying or emergent medical conditions that can have harmful or even fatal outcomes if left without medical intervention. A non-medical care giver who elects to defer or avoid medical evaluation should carefully consider the potential of both legal and personal long-term emotional liability if the participant in distress deteriorates and suffers injury or death. This topic is discussed at much length in various parts of this Manual, and especially in [Chapter 11, “Screening”](#).



VIBRATA CHROMODORIS • *Inspirazione*, 2012 • digital (Adobe Illustrator)
<http://vibrata.com>

PLANNING AND FIRST STEPS FOR A NEW PROJECT

Annie Oak

Svea Nielsen

T**his chapter** presents the steps that organisers of a psychedelic care service should take to plan and direct the project. It includes information on how to describe the project to event organisers, collect needed materials, and attract potential volunteers. Some of these topics are also covered in more detail in [Chapter 14, “Working With Other Organisations”](#).

Determine if the Community Supports a Care Service

4.1

Before approaching the organisers of a festival or event with an offer to provide a care service, it is important to determine if you have local community support for such a project. Attracting and organising people to volunteer for the service, help finance the needed materials, and undertake the physical labour to create the space is hard work. Your first step should be to determine whether you can gather a community to launch this effort. If there is no comparable service that is provided at events in your area, it is more likely that you can recruit local people interested in participating. You may also want to identify some patrons who can donate money, or community organisers who can help you throw fundraising events.

The creation and execution of an effective care space will often require a single person or a small group of people who have the time and organisational skills to complete a very time-intensive project. Organisers should make an honest assessment of their talents and resources before embarking on the creation of a care space. Each organiser should have a specific set of duties that he or she will be responsible for during the project. Determine, for example, who will be the main contact for the festival organisers, for the medical and security services, and so forth.

Once a core group of organisers have decided to launch a care service, they should commit themselves to working through challenges, difficulties, and the inevitable stress that they will encounter. Organisers should make sure that they have adequate support in their own lives for a demanding project and take special care to stay healthy and positive throughout the process. It is important that all organisers resolve to remain friends and acknowledge each other's contributions no matter how the project plays out.

Create a Budget

4.2

Before asking the community to support a care service, it is essential that you create a budget to acquire the needed materials and supplies. Begin by listing all the anticipated materials that the service will need. [Chapters 8, "Logistics"](#) and [9, "The Care Space"](#), provide lists of items that need to be acquired to construct and run a care space. Major budget items may include a structure, beds and bedding, lighting, signs, a heater, cushions, furniture, rugs, water storage, and other supplies. You should also include the costs of transporting materials to the event site, meals and other support for care givers, copying training materials, and an after-party to thank the staff.



FRED TOMASELLI • *Expecting to Fly*, 2002 • photo collage, leaves, acrylic, gouache, resin on wood panel
courtesy James Cohan Gallery, New York/Shanghai
<http://www.jamescohan.com/artists/fred-tomaselli>

RECRUITING A TEAM

Jonas Di Gregorio

Snu Voogelbreinder

Tom Shutte

Zevic Mishor

Great importance rests on recruiting team members who are mentally, emotionally, and socially equipped to deal effectively with guests who come to the care service for help. Choose care givers with a wide range of skills to cover as many needs as possible that may arise in the care space. These skills can include psychotherapy, counselling, massage, aromatherapy, homeopathy, Reiki, and other forms of bodywork (see [Chapter 12, “Complementary Therapies”](#)). Depending on the event, having team members who can speak a range of languages may also be important or even critical to the success of the care service. Due to the nature of the work, the situations care givers encounter, and the general “energy” of the team (both with each other and when working with guests), it is recommended to aim for a more-or-less even mix of male and female care givers. Note that this current chapter does not address specific support staff positions, such as psychiatrist, psychologist, nurse, and so forth; these are covered separately in [Chapter 6, “Supporting Roles”](#).

General Points for Recruiting a Care Service Team

5.1

The care service leader must first make a diligent assessment regarding the size of the team and the various roles required (see Chapter 4, "Planning and First Steps for a New Project"). If possible, it is highly recommended that team leads be individuals with whom the care service leader is already familiar, and with whom he/she has worked before.

Ideally, the bulk of the care givers should also be drawn from people already known to the care service leader and to the team leads. This helps ensure that team leads are aware of the individual personality traits and social skills of their team members, as negative or unwanted traits may not be noticed in newcomers until it is too late. Having said this, and of course depending on the ethos of each particular care service and its leader, it is important that care services do not become "insider cliques" that are completely closed to new members; this is an almost certain path to the ultimate demise of the organisation. There are many great people out there with excellent intentions, good skills, and deep experience, who would make valuable additions to any care service team, and such people should be given a chance to join the care service community.

What to Look For in Care Givers

5.2

The following is a partial list of desirable attributes for a care giver to have. Some of these qualities are very difficult to assess prior to actually working with a person, and so would not form a practical part of the recruitment process (see below); however, these character traits should help the care service leaders form a picture in their minds of the kind of individuals they are looking for:

- A friendly, balanced disposition
- Gets along with a wide range of people, not just with those from their own peer group
- Readily shows compassion and a willingness to help others regardless of how attractive or "cool" the other may be (for example, some people may be good at working with "beautiful people", but their compassion and patience drain away with people who are less attractive, overweight, and so forth)
- Other people feel comfortable around them
- Respects personal space
- Is receptive to social cues and body language

FESTIVAL X – PSYCHEDELIC CARE SERVICE APPLICATION FORM

– PREREQUISITES –

Please note that it is a **prerequisite** for applying to this care service that at least **five** out of the following eleven criteria are true statements regarding your experience. Please circle the number next to any statement that is true for you, and add any relevant comments/clarification at the end.

1. I have had previous experience as a care giver in psychedelic crises situations.
2. I have had professional experience in a psychiatric ward (as a doctor, nurse, or similar).
3. I have had personal experience with psychedelic substances.
4. I have a professional background in healthcare services.
5. I possess therapeutic and/or massage skills.
6. I have undergone first aid and/or CPR training.
7. I have an interest (academic, professional, or personal) in psychedelic science.
8. I am linked to a harm-reduction organisation.
9. I have had prior experience volunteering (in any capacity) at a music festival or similar event.
10. I have been recommended by a previous member of this care service.
(Please write down the name and contact info for the individual recommending you:)

11. I have attended any previous edition of this music festival/event.

Comments/Clarification:

AREA BELOW IS FOR OFFICE USE

BASIC INFORMATION

FIRST NAME(S):

FAMILY NAME:

PREFERRED NICKNAME:

MAILING ADDRESS:

Street Address

Suburb/Town/City

State

Country

Postcode

MOBILE NUMBER:

Will you have your mobile on during the festival? (Yes / No)

EMAIL ADDRESS:

SKYPE ADDRESS: (If you have one.)

The following will only be used to aid in building appropriately diversified shift teams, and in planning logistics.

SEX:

AGE:

COUNTRY OF ORIGIN:

OCCUPATION: (Or, how do you spend most of your time?)

LANGUAGES SPOKEN: (Please indicate level of fluency for each language listed: *basic / competent / fluent*.)

GENERAL PROFESSIONAL EXPERIENCE: Do you have any relevant work experience that you'd like to tell us about (for example, medical, therapeutic, counselling, harm reduction)?

AVAILABILITY FOR SHIFTS: Do you have any restrictions on which shifts/what days you'll be able to work? If so, please explain.

AVAILABILITY FOR TRAINING: Will you be able to attend the full, mandatory training day being held on-site on _____ (date), one day before the official opening of Festival _____ (name)?

VOLUNTEER AGREEMENT

Please review, then print and sign your name (and indicate the date)
on the following declaration of intent:

I, _____, agree to adhere to the following ethical
guidelines for the duration of my care work at Festival X:

- **I will strive to be a calm, loving, and dedicated presence.**
- **I will show up on time for each of my shifts, and support the team lead to the best of my abilities.**
- **I will help keep the care space clean, friendly, and safe.**
- **I will attend the mandatory training session, and agree to do my best to abide by Festival X's rules, policies, and procedures.**

Signature

Date

Please return this application form no later than the ___th of month to:
care_space_volunteers@Festival_X.com

**We appreciate your interest in supporting this care service,
and we will be in touch with you promptly!**



ROBERT VENOSA • *Seconaphim*, 1974 • oil on masonite
<http://www.venosa.com>

SUPPORTING ROLES

Natacha Ribeiro

Annie Oak

Joan Obiols-Llandrich

The attention of care givers, along with the application of complementary therapies, is not always enough for the optimal care of guests. In critical cases or for specific pathologies, whether they are psychiatric or not, qualified help is mandatory. The purpose of this chapter is to set forth the supporting roles that should be provided, and how they fit into the care service structure. All roles discussed in this chapter relate to the psychedelic care service itself, and *not* to the medical services (which may range in size from someone with a first aid kit to a full medical team) supplied by the event organisers, as part of the overall event itself. These medical services are mentioned in this chapter, and they are discussed in more detail in [Chapter 14, “Working With Other Organisations”](#).

6.2

These relationships are especially important when the care service is lacking in doctors and nurses, but of course, *must be established* even if the service has its own full team of medical support staff. Please see [Chapter 14, "Working With Other Organisations"](#), for more detailed information on how to set up such coordinated working relationships.

The Psychiatrist's Role

It is highly recommended that a psychiatrist who joins the care team read this section and carefully consider the information contained herein.

At events where psychedelic substances are likely to be consumed by many of the participants, it seems undeniable that a psychiatrist should be a member of the care service team, to help attend to people having difficult drug experiences. Unfortunately, a psychiatrist will not always be present, and this means that severe cases might be referred to event medical services or sent further afield.

When a psychiatrist is available, he or she should be fully integrated with the care service team, participating in the general training and all the activities scheduled, such as ongoing meetings and so forth. The ideal situation would be to have several psychiatrists on board so that each shift has one of them on duty. If only one psychiatrist is available, this individual should be permanently on-call, contactable by mobile phone, two-way radio, or some other system.

The main role for a psychiatrist at a care service is to offer something as apparently simple as *reassurance* for the care team. The whole team feels more confident knowing that if a guest goes downhill and exhibits extreme psychosis, a trained "expert" is there to deal with the situation. Even for members of the team who might be well-versed in psychopathology and accustomed to treating psychiatric patients, if some medication has to be given (a rare situation), a psychiatrist is needed in order to select and administer the correct drug. So hopefully the team will feel reassured that, if a guest shows severe emotional and/or behavioural disturbances, somebody competent is readily available to handle the situation appropriately.

Some guests who are undergoing difficult experiences and not responding well to the efforts of care givers will also feel reassured when a psychiatrist approaches and presents themselves with an introduction like, "Hi, my name is X, I'm a doctor". Notice that there is a difference between saying "a doctor" versus "a psychiatrist"; the first option works better for the simple reason that being a psychiatrist may bear a stigma, and convey negative connotations associated with

6.3

These kinds of situations require the help of a nurse and a small team of care givers who are ready to adequately restrain the guest. In some cases, where psychotic symptoms are evident but there is a degree of self-insight and self-control, the guest can accept oral neuroleptic medication. Once again, low doses should be enough, such as 1 mg of risperidone (Risperdal), although if necessary this may be increased to 3 mg.

Special Situations

Depending on the type of event, *alcohol intoxication* may be a frequent scenario, either mixed with other substances or by itself. Although they tend not to come to the care service on their own, severely intoxicated individuals are most likely to be brought in by friends (or by the event's security services). There is not much that can be done other than encouraging the guest to rest and making sure that vital signs are present and correct.

Heroin or other types of opioid addiction are not cases that a care service is ordinarily intended or prepared to deal with. Individuals may come to ask for needles (the organisation should decide in advance if this service will be offered) or with abstinence syndrome, in which case the person should be sent to the nearest hospital.

Psychiatric patients may constitute one of the most challenging types of cases for a care service. Many guests of this type are young people who enjoy music festivals and, of course, have a right to attend them and have a good time. Problems arise, however, when they begin to display psychiatric symptoms, and especially when their condition is exacerbated by the consumption of psychoactive and especially psychedelic drugs. Such individuals frequently end up in the care space. It is often difficult for a care giver to gauge, at least in the early stages of their interaction with such guests, that there is an underlying chronic psychiatric issue, since the guest's behaviour, as well as their verbalised thoughts and emotions, will usually (and understandably) be attributed to the influence of the particular psychoactive(s) consumed. Care givers should be made aware of these matters, and team leads especially should be on the look-out for potential underlying psychiatric conditions in guests. When such conditions become apparent, the psychiatrist should be consulted regarding appropriate courses of action. Please refer also to [Chapter 11, "Screening"](#), for further discussion on this subject.



LUKE BROWN • *Alpha Centauri*, 2010 • digital

<http://www.spectraleyes.com>

BUILDING AND TRAINING A TEAM

Zevic Mishor

This chapter provides guidelines for training a care service team, including care givers, team leads, and any other roles that contribute to a particular care service. The guidelines in this chapter become relevant the moment a team is selected and finalised, as covered in [Chapter 5, “Recruiting a Team”](#). Ensuring sufficient and appropriate training for the entire team is a *key responsibility* for the care service leader. Good training is essential for the smooth and successful running of the care service, resulting in team members who understand their roles, follow the correct procedures in different circumstances, and know how to work with guests, whilst simultaneously tending to their own and each other’s welfare and well-being. Conversely, poor training may result in confusion, stress, and inferior care being provided for guests, and may lead to some adverse scenarios. Remember that, although rare, it is possible that care givers may have to deal with a life-and-death situation (such as identifying a life-threatening drug overdose, for example). To a large extent, the team’s appropriate handling of the situation will depend on the quality of training they’ve received.

Leadership

7.1

It is important to understand that the care service leader's, and likewise the team leads', responsibility extends far beyond providing "just" training. Your task is to *lead* and *mould* your team(s) into a coherent whole, facilitating a state of trust, reliance, and loyalty between team members. Such a state is not something that just happens by itself—it must gradually be built-up. Training before an event is the critical stage at which these building processes are set in motion. For a large event, team members may be coming from far-and-wide and many may not yet know one another. Thus, taking into account all of these factors, it is clear that due importance must be accorded to the training phase for the entire care service, whether it begins remotely (long before the event) or not, and whether it consists of several days or just a few hours at the event itself. All necessary steps must be taken to ensure the success of this training phase.

In terms of leadership from the care service leader and the team leads: effective leadership is a topic upon which entire books have been written, and it is beyond the scope of this Manual to give a thorough treatment of the subject. It is important to understand, however, that individuals have their personal leadership style that is most suited to them. Some leaders, for example, are more autocratic, others more democratic, and there is variation along many additional dimensions. No one style is by definition better or worse than any other; all may be equally effective, if practised wholesomely, sincerely and naturally. If three pillars of advice can be given that summarise what it takes to be a successful leader, they are:

(1) *Lead by example.* Whatever you ask of your people, in things small and large—being on time, standards of dress, correct procedures, how to work with guests, being supportive, and on and on—you must absolutely embody and put into action these principles yourself.

(2) *Care for your people.* Actively care for your people, and do your utmost to ensure their welfare. This begins with the smallest of things. For example, simply enquiring with sincerity about a care giver's mood and well-being; or, if somebody asks something of you, making sure you check up on it/do it and then get back to that person. Caring for your people ends with the largest of things, such as doing your best to ensure the provision of facilities, food, and other amenities for your team (see [Chapter 13, "Team Welfare"](#), for further discussion on this point). People are usually quite sensitive and intuitive about such matters, and it will quickly become apparent whether the care service leader or a

TOPIC (from highest to lowest priority)	LOCATION IN MANUAL
<p>1. Getting to know the care service team: Intros, team structure, roles, and responsibilities</p>	
<p>2. The principles and ethics of psychedelic support: Core teachings on how to care for and work with a guest</p>	<p>Chapter 2 "The Principles and Ethics of Psychedelic Support"</p>
<p>3. Legal considerations: Legal obligations and possible consequences that care givers must be aware of</p>	<p>Chapter 3 "Legal Considerations"</p>
<p>4. Dealing with emergencies: Medical emergencies, violent guests, fire, etc.</p>	<p>Chapter 10 "Running the Service"</p> <p>Chapter 11 "Screening"</p>
<p>5. Team welfare: Ensuring one's own and each other's welfare and well-being</p>	<p>Chapter 13 "Team Welfare"</p>
<p>6. Procedures for running the service: "On the ground" procedures for receiving guests, handing over to other care givers, discharging guests, upkeep of the care space, regular meetings, food arrangements, etc.</p>	<p>Chapter 8 "Logistics"</p> <p>Chapter 10 "Running the Service"</p> <p>Chapter 11 "Screening"</p> <p>Chapter 14 "Working With Other Organisations"</p>
<p>7. Screening: Emphasised here, separate from "Procedures for running the service" above, due to its importance. How to screen new arrivals to the care service, correctly make critical first decisions regarding their care, and identify actual or potential emergencies</p>	<p>Chapter 11 "Screening"</p> <p>Guide to Drug Effects and Interactions</p>
<p>8. Documentation and other administration: Any forms and other documentation that need to be completed during the operation of the service</p>	<p>Chapter 10 "Running the Service"</p> <p>Appendix B "Monitoring, Evaluating and Researching—Recommendations from an Academic Perspective for an Evidence-Based Approach to Psychoactive Crisis Intervention"</p>

TOPIC (from highest to lowest priority)	LOCATION IN MANUAL
<p>9. After-care of guests: Discussion about what can be provided for guests once they return to the “ordinary world”, particularly those who have had especially difficult experiences. Guests may also return to the care space days after their initial visit, seeking insight and guidance</p>	
<p>10. Managing risk and improving performance: Drawing awareness to ongoing activities (such as debriefings) that continually improve the quality of the service delivered and help to reduce risks. Also focus on specific known risks (for example, violence, infectious disease, drug overdose), and how they may be mitigated. An important topic for the team lead and above level, but also for the care service as a whole</p>	<p>Chapter 15 “Risk Management and Performance Improvement”</p>
<p>11. Complementary therapies: Therapies and techniques that may be used with guests by care givers who feel comfortable employing them</p>	<p>Chapter 12 “Complementary Therapies”</p>
<p>12. Psychoactive substances: The specific drugs expected to be consumed at that particular event; their different names, possible symptoms and signs of use and overdose, effects, and so forth</p>	<p>Guide to Drug Effects and Interactions Appendix A “Street Names for Commonly Encountered Psychoactives”</p>
<p>13. Discussion of past care experiences: Drawing on the present care givers’ personal experiences from past care services, and also on material contained in this Manual</p>	<p>Chapter 16 “Case Studies and Impressions”</p>
<p>14. The care service in its wider educational role: Discussion of the role of the care service in <i>educating</i> the public at large, particularly event-goers who stop by the care service out of simple curiosity</p>	<p>Final Words</p>
<p>15. History of psychedelic care services: To connect the work at hand to its lineage, broaden the education of your care givers, and reflect on lessons from the past</p>	<p>Chapter 1 “A History of Psychedelic Care Services”</p>
<p>16. Other topics: Whatever else is relevant to that specific care service</p>	

playing scenarios, in teaching care givers to prepare for different situations, and we encourage that care givers be provided with as much opportunity as possible to simulate various scenarios before the opening of a care service.

The following are examples of different formats and ideas that may be used in training:

- A speaker presents a topical lecture to the entire care team
- Facilitators exploit the use of electronic teaching aids, if logistically possible (for example, video and PowerPoint)
- The care team splits up into small groups for discussion and then re-convenes in the general forum
- Similar as above, but care givers split up into pairs
- Groups rotate through “stations”, with a team lead (or someone else) facilitating each of the stations
- Groups each prepare a short presentation or a role-playing exercise, and deliver it to the entire team
- The entire team sits in a circle and has an open discussion
- The entire team sits in a circle. Moving around the circle, each person is given a brief period of time to speak; this is useful, for example, when making introductions. Exercise care with this format, however; with a large group it will take a long time to complete the circle, the process can become tedious, and it often results in people at the beginning of the round speaking a lot, and those at the end speaking very little due to running out of time. It is a good idea to have a predetermined maximum number of minutes that each person can speak and to use a loud kitchen timer to mark when that time that has passed.

Ensure that your schedule allows generous time for discussion within sessions (which, considering the calibre and energy of people in most care service teams, will be lively), and for breaks in between sessions. Training is tiring, and there is only so much information that can be absorbed within a given period. Prioritise your sessions, and *don't leave the important ones until last*.

Materials List for Training

Actual requirements will depend on the training sessions that have been planned. The following list is for a hypothetical care service that is large in size (for example, 30–40 people in total on the care team), has access to electricity, and has the means with which to transport larger items in and out of the event (see also [Chapter 8, “Logistics”](#)):

TIME	SESSION	STAFF	TRAINING ACTIVITIES
PRE-EVENT EMAIL TRAINING (FOR THE ENTIRE CARE SERVICE TEAM)			
Four weeks prior to event	Background for the specific event and care service	Care service leader	<p>Introduce the event and its history, the care service and its history, the care team's structure, and other relevant preliminary points (to be decided upon).</p> <p>Give a brief summary of the individuals who form the team: the team leads' and care givers' names, where they're from, and possibly a little more info. Explain that a proper "meet and greet" will take place on-site.</p> <p>Email a series of clear, easily readable materials.</p>
Three weeks prior to event	The principles and ethics of psychedelic support	Team lead in charge of email training	<p>Introduction to the care approach to be used at this event. Send reading material and a link to at least one relevant video.</p> <p>Ask all care givers to report back, confirming that they've gone over the material.</p> <p>Use material from this Manual.</p>
	Legal considerations	One of the care givers, who happens to be a legal practitioner	<p>Legal issues that may impact both event participants and personnel involved in providing psychedelic support. Discuss potential legal risks and consequences in relation to encounters with law enforcement; consent, confidentiality, and privacy issues; legal protections and fiduciary obligations of support personnel; and other potential legal liabilities in providing psychedelic support.</p> <p>Ask all care givers to answer a twenty-question multiple-choice test and return it via email.</p> <p>Use material from this Manual.</p>
Two weeks prior to event	Drug effects	Team lead in charge of email training	<p>Ask care givers to read about the main drugs that are expected at the event, and have them answer a series of short questions related to specific drugs.</p> <p>Provide care givers with an additional, optional list of substances to read about.</p>
One week prior to event	Case studies	Team lead in charge of email training	<p>Care givers are to read at least <i>three</i> case studies, and write a paragraph about their thoughts and feelings regarding at least one of them (for example, how do they think <i>they</i> might have reacted in the same situation? What would they have done differently?).</p> <p>Use material from this Manual.</p>

TIME	SESSION	STAFF	TRAINING ACTIVITIES
PRE-EVENT FACE-TO-FACE TRAINING (ONE FULL DAY AT SOMEONE'S HOUSE, ATTENDED BY TEAM LEADS ONLY)			
10:00 – 11:00	Meet and greet	Care service leader	Play an "introductions" game. All team leads should talk about themselves, their backgrounds, and why they volunteered for this care service.
11:00 – 12:00	Role of the team lead	Care service leader	Discussion of what being a team lead entails, presenting specific roles and responsibilities.
12:00 – 13:00	Operations and logistics	One of the experienced team leads	Procedures and responsibilities for the team leads: how shifts are run, what documentation is required, and what specific tasks to complete.
13:00 – 14:00	LUNCH		Determine any special dietary needs in advance.
14:00 – 15:00	Training plan	Care service leader	Plan for the two days of on-site training that will be primarily run by the present forum for the entire care service team. How will these days be structured? Who will facilitate each session? What challenges might arise on-site?
15:00 – 16:00	Principles and ethics of psychedelic support	One of the team leads with previous experience	Discuss the core principles of psychedelic care at this event, especially at the team lead level. What is the overall aim of the service, and what is considered the "best outcome" for a guest? How should team leads allocate new guests to care givers? What can happen in extreme scenarios?
16:00 – 16:20	BREAK		Tea, coffee, biscuits.
16:20 – 17:00	Team welfare	One of the experienced team leads	A key responsibility of the team lead is to ensure the welfare of volunteers. Explain how to do this, and what challenges may be encountered.
17:00 – 17:30	Managing risk	Care service leader	Team leads must be aware of key risks and do their best to mitigate them. Whilst care givers usually focus on a single guest at a time, team leads must always be aware of the big picture during their shifts, in order to proactively prevent adverse situations from deteriorating further.
17:30 – 18:30	Final discussion	Care service leader	Have each person talk about their hopes and fears for the upcoming event. Discuss any other topics that people want to raise. Afterwards, go out for a team dinner at a restaurant.

TIME	SESSION	STAFF	TRAINING ACTIVITIES
ON-SITE TRAINING (ATTENDED BY THE ENTIRE CARE SERVICE TEAM)			
TWO DAYS BEFORE CARE SERVICE OPENS			
14:00 – 15:30	Meet and greet + Team structure	Care service leader	<p>Play <i>Hugs</i> (see “Team Building Exercises” above).</p> <p>Everyone plays some sort of an introductions game (in pairs or groups, and then with the entire team).</p> <p>Discuss team structure, and the basic format in which the care service will be run.</p> <p>Finish with the <i>Eye Contact</i> exercise (see “Team Building Exercises” above).</p>
15:30 – 17:30	Principles and ethics of psychedelic support	Team leads	<p>Spend approximately thirty minutes discussing the basic principles of providing psychedelic support in the context of this particular care service.</p> <p>Divide into four groups, and rotate through four “stations”, each one run by a different team lead. Each station should address one key aspect of psychedelic care. This training can be run in the form of a discussion or by role playing.</p>
ONE DAY BEFORE CARE SERVICE OPENS			
09:00 – 10:00	Roll of the care giver	Care service leader	Expectations, requirements, rights, and entitlements of the care giver.
10:00 – 10:30	Talk by festival organiser	Festival organiser	It’s good to have a key staff member from the festival organisers (preferably one of the big “names”) briefly speak to the entire team.
10:30 – 11:00	BREAK		Tea, coffee, biscuits.
11:00 – 12:30	Procedures for running the care service	One of the team leads	“On the ground” procedures for receiving guests, handing over to other care givers, discharging guests, upkeep of the care space, regular meetings, food arrangements, and so forth. Includes an explanation and demonstration of the documentation that needs to be filled out.
12:30 – 13:30	Screening	One of the team leads	More specific focus on the initial screening of guests. Include a role-play exercise or two.
13:30 – 15:00	LUNCH		Determine any special dietary needs in advance.

TIME	SESSION	STAFF	TRAINING ACTIVITIES
ON-SITE TRAINING, CONT. (ATTENDED BY THE ENTIRE CARE SERVICE TEAM)			
15:00 – 16:00	Team welfare	Care service leader	Explain the importance of taking care of oneself and each other (within the care service team). Divide into groups and discuss different themes/questions, then reconvene in the general forum to share thoughts.
16:00 – 17:30	Case studies + General discussion	One of the team leads	Split into pairs and go over some case studies of previous care situations that people have written about. Then reconvene in the general forum for an open discussion about whatever anybody wishes to bring up: hopes, fears, general questions, and so forth.
20:00+	Meditation, chanting, and Opening Party	One of the care givers	Run a meditation/chanting session, and then throw an Opening Party for the entire care service team! Keep it relaxed and low key—big day tomorrow!
DAY OF CARE SERVICE OPENING (ASSUME FIRST SHIFT BEGINS AT 15:00)			
09:00 – 10:00	Dealing with emergencies	Care service leader	Potential emergency situations and how best to deal with them. Discuss with the entire team, and then get a few team leads/care givers to talk about their past experiences.
10:00 – 10:30	After-care of guests	One of the team leads	Round-circle discussion on post-care scenarios; for example, guests who return to the care service to discuss their experiences.
10:30 – 11:00	BREAK		Tea, coffee, biscuits.
11:00 – 12:30	The care service in its wider educational role + General discussion	One of the team leads + Care service leader	Split into groups, discuss, and each group then presents for 5-10 minutes to the entire forum: how do they see the wider educational role of the care service? Care service leader to give some of their own points and emphases, and then in the time remaining, a final discussion on anything at all—whatever topics care givers wish to raise.
12:30 – 13:30	LUNCH		Determine any special dietary needs in advance.
13:30 – 14:30	Any remaining material to cover, and final preparations for opening the care service!		



NAOTO HATTORI • *Untitled* • acrylic on board
<http://naotohattori.com>

LOGISTICS

Alicia Danforth

Annie Oak

Kaya

Natacha Ribeiro

Svea Nielsen

LOGISTICS is the management of material resources, which include supplies, structures, equipment, and personnel. Aspects of logistics include procurement, maintenance, transportation, inventory, storage (warehousing), distribution, recovery, and disposal. The amount of time and resources needed to prepare for each of these aspects can be large. Starting early by familiarising yourself with the content in this chapter can be a significant step towards ensuring that your project runs smoothly. Regardless of the scope of service your event requires, the sections that follow are likely to contain information that will assist you in planning, budgeting, and implementing a well-run care service.

8.4

- Lock boxes for items needing to be secured (and spare keys)
- Tissues
- Gloves (construction as well as protective latex)
- Spare phone chargers

Supplies for Care Givers

This section contains practical tips and lists to help the care service leader and event planners provide for care givers' needs before, during, and after the event. Guests arriving for care may be feeling anxious, vulnerable, and often sensitive to the emotional tone of their surroundings. Taking steps to ensure that the care givers who welcome them are well-fed, rested, and reasonably comfortable goes a long way in making the care space a pleasant place in which to restore and revive during or after a difficult experience.

Some basic questions to ask during the planning phases include:

- Will any care givers or support staff arrive pre-event for set-up? If so, what supplies need to be on hand so that these volunteers can do their work?
- Will care givers or support staff who stay after the event need supplies?
- Will care givers or support staff be provided with food, beverages, and/or snacks as part of the event and/or care service operation?
- Will care givers who unexpectedly work extended shifts have the provisions—food and beverages (coffee/tea)—they need to maintain their stamina and sense of calm?
- What will the care service provide? What will care givers be instructed to bring?

Experienced care givers compiled the checklists below based on a wide variety of event types in different countries. They contain essential supplies for events of any size, as well as “nice to have” items that can help shifts run more smoothly.

SAFETY SUPPLIES

(see also “[Safety/First Aid/Emergency/Medical Supplies](#)” below)

- Fire extinguishers/fire blanket
- Emergency phone numbers/contact information
- First aid kit

Tip: As part of basic training, all care givers should receive instructions on when it is *not* appropriate to provide transportation for guests. There may be medical, personal safety, and/or insurance reasons why guest transport by members of the care service is not recommended in some situations.

Safety/First Aid/Emergency/Medical Supplies

Every country has its own unique laws addressing medical services and the qualifications necessary to provide care; this Manual is unable to provide a comprehensive guide to medical services by country. We encourage you to check with your local medical community regarding questions of care. Please see [Chapter 3, “Legal Considerations”](#), for a more detailed discussion of these issues. For the purpose of this Manual, we offer basic recommendations that are broadly applicable regardless of where the care service is located.

At minimum, it is highly recommended that all care spaces have a first aid kit on hand in order to treat cuts and abrasions, sunburn, headache, and other forms of mild pain.

The supply lists provided below are intended to serve as a guide only, and may not include items relevant to your geographic area. We encourage care service leaders and (ideally) team leads to be trained in first aid. Whenever possible, you should seek to have duly licensed medical personnel on-site (see [Chapters 6, “Supporting Roles”](#) and [14, “Working With Other Organisations”](#)). If previously trained volunteers are not available, we encourage you to provide at least cursory first aid training, sufficient so that care givers will be able to manage minor wound care and understand how vital it is that they protect themselves from infectious disease. It is critical that all care givers be taught that if there is any question whatsoever regarding the possibility of medical need, a medical evaluation by a licensed practitioner must be obtained without delay.

IMPORTANT ITEMS TO CONSIDER FOR YOUR SAFETY PLAN (please see [Chapters 6, “Supporting Roles”](#) and [14, “Working With Other Organisations”](#), for more detailed information)

1. Determine whether the event will have on-site medical services.
2. Consider what is necessary when operating a service without on-site medical support from both a legal and ethical perspective.
3. Plan ahead and contact medical services at the event to establish a relationship.

8.10

Accommodating Rain/Heat/Severe Weather

IN CASE OF RAIN AND COLD

See that the shelter is waterproof and that any electrical connections and devices are kept dry at all times. Ensure that there won't be a river of mud flowing inside if the ground is not flat. If puddles are a possibility, keep some straw to cover the muddy places of your shelter. The care service should also keep a supply of clean used (donated) clothes to give away to guests—for warmth, if needed, and because folks in crisis sometimes take off and lose all of their clothes.

IN CASE OF HEAT AND SEVERE SUN

Some guests may arrive with severe sunburn. If possible, have some soothing lotion for minor sunburns, or consult medical staff for assistance in more severe cases. If heat-related conditions, such as heatstroke, are a possibility, confirm in advance that all care givers are briefed on the signs that indicate that medical attention may be needed.

Make water available to everyone (care givers and guests) all the time. Water has a great relaxing effect.

IN CASE OF WIND

Be sure that everything is properly tied down. If wind is even a remote possibility, include items such as wires, cords, rebar, stakes, or other equipment for securing structures and equipment in your packing lists.

Tip: If your event is located in an area with any potential for serious wind, secure your structures with rebar and ratchet straps on every corner. Uncovered rebar is sharp and presents a serious injury hazard to participants, especially at night, so cover any rebar ends with dedicated plastic caps, old tennis balls, or even plastic bottles, and mark the rebar with LED lights for visibility at night. If the ground does not support rebar (for example, you're on a rocky patch or an asphalt surface), obtain large plastic storage drums and fill them with water, then tie the ends of the structures securely to the plastic drums. A 200-litre (55-gallon) drum full of water weighs over 200 kilos!

8.11

Set-Up and Break-Down

Lists for this section will vary widely depending on the scope of your event. Content for this section is also covered in "Equipping the Service: Preliminary Fundamentals" (on page 106), as well as in Chapter 9, "The Care Space". You can use the suggestions below to start your planning for set-up and break-down, and then add or omit items to customize your lists to meet your unique care space needs.

8.12

- Shipping materials
- Hay bales
- Shower stalls/curtains/camp showers
- Evaporation tubs/pool liners/fans/pumps (for management of grey water)
- Inventory lists/binders

Privacy and Noise Control

Choosing the care space and camp location usually comes with trade-offs. A common question event organisers ask themselves is, "Should we set up the care service near the main event activities (such as dance floors) for visibility and easy access, or is it more important to be away from the core of the action, where the environment is quieter?" Either option has its benefits and drawbacks.

In some cases, making extra provisions for privacy and noise control becomes necessary. Below are checklists and tips to help improve the care space by tending to the privacy and noise control needs of guests.


PRIVACY

Consider what a visit to the care space would be like from a guest's perspective. Would they feel sufficiently out of the public eye to rest and restore themselves? Is the entrance to the care space shielded from curious onlookers? Can accommodations be made in a shared space to partition off some more private areas? Supplies that might assist with the logistics of creating private or "private feeling" spaces include:

- Fabric, tapestries, blankets, or sheets for creating partitions
- Cords, posts, poles, or piping to support partitions
- Eyeshades/sunglasses
- Seating outside of the entrance to the care space for friends or camp-mates waiting for guests
- Small tents or a separate space for guests who feel a strong desire for temporary isolation

NOISE CONTROL

Despite best efforts to locate care services away from major sources of noise, sometimes there is just no way to keep the booming bass, generator noise, revellers, or other audio distractions from interfering with optimal care. Some of the following suggestions, however, may help:



LUKE BROWN • Foxy Methoxy, 2011 • digital

<http://www.spectraleyes.com>

THE CARE SPACE

Kaya

Snu Voogelbreinder

The **care space** is a dedicated area or structure set aside and equipped for the purpose of providing comfort and aid to those in need. It is ideally made available for the duration of the event. A space may be “self-serve”, temporarily staffed, or staffed full time (this Manual is generally based on the latter model). Additionally, a space may be a temporary location, sometimes created spontaneously, in response to a particular and often unanticipated need.


The terms “set” and “setting”, when applied to psychedelic experiences, refer to the “mindset” and “physical environment” influencing the experience of the guest requiring help. A thoughtfully designed space seeks to address the mental and physical needs of the individual in order to move them towards a positive state of mind and body. The design of the space is intended to provide a healing and supportive atmosphere that will facilitate an improvement in guests’ experiences.

If the care team does choose to incorporate music into the space at times, instrumental, non-intrusive music with a harmonising feel and without strong beats is recommended. The music should not be too weird, excessively sentimental, highly religious, or bland. If there are any signs that the music is disturbing somebody's state of mind, it should be faded out and switched off.

Air Quality

It is not uncommon at festivals for people to offer incense or "smudge sticks" of burning sage, and to smudge a space with these materials. For some guests the use of these substances can be beneficial and calming; for others, however, especially considering that some psychoactive drugs increase mucogenesis (phlegm) and congestion, the presence of pungent fragrances can add unnecessary distress, or worse, trigger an asthma attack. Care givers should be made aware of these issues, and act accordingly.

9.5



*Comfort included appropriate ambient sounds in the KosmiCare space at the 2008 Boom Festival.
Photo by Jen Zariat.*

Reception Area


Care should be taken in the reception area of the space. People who enter should be able to approach care givers and ask questions about the function of the service. In fact, this should be encouraged, as it helps spread the message about the kind of work the care service does, and generally educates festival-goers. The reception area and entrance, however, must not become blocked, noisy, or crowded.

Individuals often find it difficult enough to approach someone for help whilst in their altered state; having an entrance filled with people talking busily only serves to repel the cautious, timid, or paranoid potential guest. It can be useful to have some kind of privacy screen at the entrance, as many curious passers-by want to see what goes on inside, their imaginations perhaps fired-up by images of a "house of horrors" within! Such a privacy screen helps reduce unnecessary traffic at the entrance to the space. In order to offer a sense of privacy and separation from the outside, there should also be some division of the inside from the reception area.

Having a "shoes off" policy can help to keep the space clean and set a nice atmosphere; entering the space then becomes a bit of a special exercise. This should not be harshly enforced though, just presented as a guideline. Provide a chair at the entrance where folks can sit to remove their shoes, and have a designated, well-lit space available for storing them (since it should be made as easy as possible for guests to locate their shoes and put them back on with minimal frustration).

A sign near the front door identified and described the KosmiCare space at the 2008 Boom Festival. Photo by Jen Zariat.





FRED TOMASELLI • *Perfect Skin*, 2006 • mixed media, acrylic and resin on wood panel
courtesy James Cohan Gallery, New York/Shanghai
<http://www.jamescohan.com/artists/fred-tomaselli>

RUNNING THE SERVICE

Annie Oak

T**his chapter** addresses the practical tasks that need to be carried out to ensure that the care space serves guests effectively. It includes a list of tasks that care givers should consider when they arrive on-site, during the event, and at the conclusion of the project. Some of the themes dealt with in this chapter are covered in more detail in [Chapters 7, “Building and Training a Team”](#); [8, “Logistics”](#); [9, “The Care Space”](#); [11, “Screening”](#); [13, “Team Welfare”](#); and [14, “Working With Other Organisations”](#).

Once inside the care space, some guests may wish to talk about an experience they are having, others may simply want to rest and rehydrate. If a guest requests medical care, or if it is apparent that they need medical assistance, they should be brought promptly to the nearest medical service area, or a medical provider should swiftly be summoned to provide an evaluation. Guests receiving medical care should be given some privacy, if possible, within the care space. This might be accomplished with curtains and/or other barriers that separate the care space into different areas (see [Chapter 9, “The Care Space”](#)).

Documenting Guests


Care services may elect to collect assorted types of information about each guest who enters the care space. Here we give a brief outline regarding guest documentation; please see [Appendix B, “Monitoring, Evaluating and Researching—Recommendations from an Academic Perspective for an Evidence-Based Approach to Psychoactive Crisis Intervention”](#), for an in-depth presentation of this subject. There are some sound reasons for data collection, but it should be done without making the guest feel uncomfortable. The most important reason to collect information about guests is to provide medical personnel with information about an individual should he or she require medical care. Knowledge of what substances a guest may have taken or any illness that the guest has experienced could be critical for providing effective and timely medical assistance.

The other pressing reason to collect information about guests is to provide continuity of care between different shifts of care givers. Whilst a face-to-face hand off between care givers is ideal (preferably in a way that involves the guest),

10.3




*Even when their shifts were over, members of the 2010 KosmiCare team were still debriefing much of the time.
Photo by Erowid.*



is a key responsibility of the team lead. If a guest expresses any discomfort with a new care giver, that person should be replaced with another care giver. Although this situation is rare, it may happen for a variety of reasons; care givers must accept that it is not anything “personal” about them, but simply a mismatch amplified by the crisis state that the guest is experiencing. Team leads should keep an eye out to determine how well their team members are working with guests and adjust accordingly.

At the end of each shift, the care givers should be given an opportunity to debrief with the colleagues they have just served with. The team leads should check in with their people to see if they need to talk about an experience with a guest or make suggestions for improving the service. Some care service leaders (or for their own shifts, team leads) may institute a “buddy system”, in which care givers are paired together for the duration of the event. They are then encouraged to share experiences and receive support from their buddy at the conclusion of each shift. Since volunteers in psychedelic care services tend to be communicative people, however, this system may not be necessary. The care service leader may also ask team leads to form an advisory group that is accessible to members of the care service for follow-up questions and conversations, both during and after the event. Providing psychedelic crisis services can be challenging work, and every effort should be made to support the care givers. Please see [Chapter 13, “Team Welfare”](#), for more on this topic.



Contacting Other Services

10.5

Prior to opening the care space, the care service team should have a plan for interacting with external organisations, including on-site medical and security services, as well as the festival organisers. Detailed information about working with other groups is provided in [Chapter 14, “Working With Other Organisations”](#).

All care givers should have a basic idea of the other support services at the event, but it is most important for them to understand the emergency medical and security procedures. Care givers must know exactly where the nearest medical service is located and how to contact it. If event medical personnel want specific information about a guest, be prepared to gather basic data on that person and write it down for medical staff to review. It is similarly important to know how the security services at the event operate and how to contact them if required. For a discussion on internal and external communication, see [Chapter 8, “Logistics”](#).


If law enforcement organisations arrive at the care space, make it clear to them that it is a safe space where people in vulnerable states are seeking rest. Suggest that any law enforcement activities take place in some other location, outside of the care space. If they continue to demand entry, do your best to stand firm, and ask them to speak to festival organisers first.

If a guest requests a referral to other event services, including medical, mental health, or law enforcement personnel, locate the appropriate service provider and introduce them to the guest. A private space should be found for such conversations, outside of the care space if possible. If guests say that they would like to obtain follow-up care after the event, suggest that they contact professional counsellors on-site for a referral.

Shutting Down the Care Service

If it is not possible for the care service to assemble enough people for a given shift, it may be important to place a sign on the door of the care space, stating that the service is temporarily closed, and indicating when it will reopen. This may be considered “normal” for some care services, yet entirely unacceptable for others (for example, those who have a prior agreement with event organisers to provide around-the-clock service). If the service runs as planned throughout the event, send out an announcement (if possible) in the last few days, telling event attendees when you will be closing. It is useful to give people advance warning that the service will not be available after a certain time.


10.6



ALLYSON GREY • *Jewel Net of Indra*, 1988 • oil on wood
<http://www.allysongrey.com>

SCREENING

Twilight



Whether at the care space or somewhere on the event grounds, when an event participant who may require assistance presents to the care service, an initial assessment is the first step in determining appropriate support. This chapter covers the necessary factors that must be considered during that assessment: participant and care giver safety, basic medical evaluation, mental and emotional stability, and determining when external assistance is required.

Care services specialise in assisting participants under three broad circumstances:

- Non-life-threatening psychoactive drug issues
- Non-life-threatening emotional or interpersonal issues
- Depression or disturbed mental states

When presented with a possible situation in which care service assistance may be appropriate, the care service team should develop, publish, and train a specific protocol that all care service staff should follow to qualify, route, and treat the affected participant(s) appropriately.

As a prerequisite to the contents and actions covered in this chapter, care givers are expected to have already determined what support exists at the event in terms of emergency services, licensed medical care, security services, any other organised assistive functions, and law enforcement (see Chapter 14, “Working With Other Organisations”).


Situation Safety

11.1

Before starting any initial evaluation of a participant who may need assistance, the first requirement of care givers is to assess the safety of the location. Is it safe to approach the participant without endangering the care giver and/or further endangering the participant? Is there any risk from structural failure, fire, traffic, exposed electrical wires, flowing water, or other potential dangers? *If so, seek immediate assistance from the event organisers or designated responsible parties.* Only proceed when it is safe to do so.

The second consideration applies to care givers, as well as to the participant in distress and other event participants; if there is any threat of violence, particularly if any form of weapon is involved, care givers are—first and foremost—responsible for their own safety. If they attempt care of a violent individual and are injured in the process, there are now two problems: the violent individual *and* the injured care giver. *Regardless of your best intentions, do not compound the problem.*

Once their own safety is assured, care givers should work to help remove the threat from other participants, who may be endangered by an apparently violent individual. This typically means making an immediate request for assistance from other event staff such as security services, medical support, and/or law enforcement. Carefully consider enlisting other event participants to help, particularly if security or medical assistance is not forthcoming.



11.2

CPR: ABC NOW CAB?

In 2010, the American Heart Association changed the order of the steps that one follows whilst performing cardiopulmonary resuscitation (CPR). They now recommend “CAB” over the previous “ABC” approach. This means that one *first* gives the chest compressions (“C”), then performs an airway (“A”) check, and then begins the breathing (“B”) via mouth-to-mouth.

Why is it so important to get help with a violent participant? Many clinical studies have examined correlations between mental health issues and the increased likelihood of homicidal behaviour, particularly when accompanied by the ingestion of alcohol. As individuals using psychedelics may have far more intensely emotional experiences than those using alcohol, the risk of encountering a mentally unstable individual who may engage in violent behaviour must be considered as part of any preparation for the operation of a psychedelic care service.

Immediate Medical Necessity

Evaluate the following:

- Is the individual responsive?
- Does the individual have a pulse?
- Is the individual’s airway clear?
- Is the individual breathing?

If the answer to any of these questions is “no”, this is a crisis: **seek immediate medical assistance**. If the care giver is qualified, remember the ABCs (or, preferably, the CABs) of first aid and take appropriate actions, including CPR if indicated.

- Does the individual show any signs of injury, including bleeding, broken bones, or burns?

If so, **seek immediate medical assistance**.

Next we reach a part of the assessment where the responses will depend upon what services are available at the event. Consider each item carefully and formulate a response based on what services are present.

Immediate Psychiatric Necessity

- Does the participant appear to be suicidal?
- Does the participant appear to be in danger of harming themselves (either on purpose, or by accident)?
- Is this potentially a psychiatric emergency or a significant mental health issue?

These situations indicate a need for psychiatric care. If there are qualified, licensed staff available to help, request their immediate assistance.

If no such people or support organisations exist at the event, carefully weigh your ability to deal with the situation as well as what resources are available to you. For example, consider two scenarios:

11.3

11.6

Situations Requiring Assistance

MEDICAL EMERGENCIES

If at any time during care a guest is believed to be experiencing a medical emergency, notify event medical services immediately. Remain calm and focused, keep the individual safe, pay attention to breathing and other vital signs until the staff from medical services takes charge. Provide the medics with any relevant guest information that you are aware of, referring to the care space documentation on the guest to refresh your memory and for any further details.



When an individual is having a challenging experience with psychedelics, sometimes it is best for everyone to simply monitor that person from a distance. Photo by Erowid, 2008.



ALEX GREY • *Lightweaver*, 1998 • acrylic on linen
<http://alexgrey.com>

COMPLEMENTARY THERAPIES

Snu Voogelbreinder

Alexandre Quaranta

Ben Atkinson

Kaya

Natacha Ribeiro

In addition to human support and talking through an experience, and when medical intervention is not necessary, some supplemental therapies that complement “standard procedure” may be beneficial. The intent of many of these therapies is simply to assist in relaxing and grounding a guest. Some therapies may be used as relatively safe tools to help guests explore their problematic states and find a way out of them. Certain therapies require care givers with some level of specific expertise, whereas others can be facilitated by any care service team member. No complementary therapies should be pushed upon a guest; guests should simply be made aware that these options are available if they wish to use them.

This chapter should *not* be seen as an instruction manual in the use of such therapies—we simply mention some of the relevant and safe options that exist, and describe how they may be useful.

Laughter

If care givers are able to encourage humour and laughter in guests, this can be very beneficial. In many cases it is indeed true that laughter is the best medicine. Preferably this should not be forced, although even laughing for no particular reason can lead to an improvement in mood and outlook.

Deliberate voluntary laughter is a tenet of laughter yoga. Put simply, the body doesn't recognise the difference between actual laughter and fake laughter—it produces the same physiological responses. So, to gently encourage a guest to laugh deliberately for no purpose can be very effective. Laughter can also be contagious. If a care giver consciously initiates a deliberate laugh it can lead a guest into laughter. Make sure, however, that the guest knows you are not laughing at them.

Breathwork

Often the first step in assisting someone who is mentally distressed (which is likely to also manifest in increased heart rate and chaotic, shallow breathing) is to encourage them to breathe slowly and deeply, preferably breathing in through the nose, and breathing out through mouth or nose (whichever is most comfortable for the guest). A team member can assist in this regard by breathing with the person to set an example and give a feeling of solidarity. This should be continued until the person has noticeably calmed down and pulse has returned to normal. More specific meditative focused breathwork may be used later if called for, led by a team member experienced with such techniques.

12.1

12.2



Adjusting your breathing can powerfully change what you are experiencing, as these novice Holotropic Breathwork students are learning at the 2006 Mind States conference in Costa Rica. Photo by Jon Hanna.

Yoga

Care givers may offer guests the opportunity to engage in some bodywork, enhanced body awareness, and light stretching; all this can be done through (gentle) hatha yoga, among other possibilities. Yoga can be of help to ease a guest into a grounded state, and to aid in harmonising body and mind through the clear flow of energy.

In some cases, a yoga (or other bodywork) session in the peak of a psychedelic trip can be a great experience, which at the same time relieves anxiety. However, in other cases it can (at least in the beginning of the session) enhance anxiety because of the increased energy flow and awareness. Guests should be informed that they are, of course, free to stop at any time.

The care giver offering a yoga session should be aware of the state of the guest, and not push the idea of yoga too much if the guest has experienced a strong energy awakening, since yoga could bolster this powerful energy and make the experience much more dramatic and intense. If a guest consents to bringing this on, in order to attempt to resolve an internal crisis, then it may be acceptable to engage in deeper yogic exercises.




*Nude yoga should never be suggested by or involve the care giver.
Photo by Anonymous.*

General Physical Activities

12.8

Taking part in some simple activity, particularly in nature, can be very beneficial in shifting the mindset of the guest. This may work by providing a distraction, or a new area of focus, or even just by becoming active in a recreational way, with any attendant positive changes in the nervous system that such activity may bring. Activities beyond the actual care space should be supervised by a care giver, and the guest may feel more comfortable and able to find benefits if the care giver takes part in the activities as well. Some suggested activities with positive potential include going for a walk, going for a swim or a dip in water, and non-contact recreational games such as throwing and catching a ball or a Frisbee.



Some people who spin poi feel that practicing whilst on psychedelics allows for key improvements in their techniques. Photo at 2008 Boom Festival by Jon Hanna.

Shamanic Therapies

12.9

Shamanism and altered states of consciousness naturally go together, whether the guest has intended this or not. Situations that may best be understood from a shamanic or healing perspective often arise when people undergo difficult psychedelic experiences. However, as this Manual is largely confined to operating within a system of "sitting but not guiding", the intervention of a "shaman", or attempts to engage the guest in a guided shamanic voyage, are ethically precluded without explicit consent from the guest. Nevertheless, there remain some techniques that guests could try themselves that may help and cannot hurt.

altered state of consciousness the effect of this activity on the guest can be profound, and potentially turn around a difficult experience. There is intuitive skill involved in choosing how to suggest this redirection of attention, to contemplate an expression of beauty with a certain freshness and spontaneity. The care giver should have an understanding of the workings of attention in general and what we could call a playfulness and lightheartedness with all the possibilities that are at hand. When a redirection of attention is offered or suggested—ideally without even being noticed—it should be presented as an option, not a duty.

Beauty is in the eye of the beholder. What is viewed as beautiful or inspiring is different for different people. Also, something a person may normally find beautiful could be experienced as horrifying or simply uninteresting when in an altered state of consciousness, and vice versa.

Directing the attention towards the ugly or horrible, or allowing one's self to contemplate such things, is of equal value in developing a balanced and realistic experience of life—indeed, a person may realise that there is beauty even in these things, and learn not to judge by appearances and/or conditioned responses to them. However, it may simply make the situation worse to fill the imagination with (what a guest finds to be) horrible images; so for the sake of assisting an individual to move out of a difficult space, such an approach should not be promoted by care givers (although guests may choose to look at whatever they wish).

Experience has shown that exposure to well-chosen imagery can be effective with cases of anxiety and paranoia. Let's illustrate this with a story. A man in his mid-forties was starting to regress deeply into memories of his birth, and was experiencing anxiety and strong physical pain. He was instructed by the sitter that it was okay to fully experience whatever arose, and to trust the unfolding and blossoming of this memory without resisting. At this point, he started to become a little bit paranoid, whilst at the same time describing lucidly his projection on the sitter, who was hallucinated as the devil with vivid imagery. The situation was becoming very problematic: rising anxiety, rising paranoia, strong hallucinations, and physical pain possibly due to resistance. In other words, it was becoming a hellish state. The sitter spontaneously presented a high-quality and beautiful picture of an Indian mystic (Sri Anandamayi Ma). Since the man was in a strong psychedelic phase, he started to see the face in 3-D and the body within the picture gave the impression of coming out of the page. At the same time he was amazed and awed by the beauty of what he was seeing and the archetypal dimension of what he was connecting with. At that point anxiety was dissolved in wonder, and paranoia was no more. The only

Man or other treeless spaces). Tree grounding can bring harmonisation and pacification of a difficult and powerful psychedelic state, thanks to the presence and “structure” of the tree (both physical and metaphysical, as explored deeply in shamanism). The effect is very positive and can provide excellent results in cases of anxiety, sensory overload, loss of vitality and coordination in the body, and for people who are flying high but off-centre, or concerned by their loss of cognitive or physical functionality. In some cases, when an individual is strongly resisting an experience (because it is not the right moment to go deep into an issue, for example), tree grounding allows the person to dissipate some of the powerful energy, which can be “safely absorbed” by the tree. For people experiencing paranoia or mistrust of others, a tree can be a neutral friend they can turn to. There is no need for any particular beliefs, skills, or world view for this to work. All that is required is a willingness to try it and open up to whatever may happen. Of course, the care giver having personal experience with this and also taking part—as with anything else—will definitely help to give the guest faith in the therapeutic possibilities, rather than worrying about looking or feeling silly by hugging a tree.

The idea here is to offer and structure an opportunity for a guest in which their heightened and amplified sensitivity, imagination (possibly hallucinations), and empathy are focused in sensing a chosen tree, identifying with this tree, and naturally (that is, without any conscious intent in this direction, and simply as a by-product of the special attention paid to the tree in this intense state) experiencing a sense of being grounded and at peace. In other words, the expansion of sensitivity and perception that may have led to anxiety and a problem state is put into the service of restoring well-being and peace through an intense empathic connection with a tree, either by touch or by sitting near it. With the kind encouragement and presence of the care giver, the guest can either simply contemplate the tree or get very physical with it, hugging it, or leaning against it and merging with it, with a sense of the spine becoming the trunk, experiencing the deep roots as being nourishing and stable.

In some rare cases, a guest can be overwhelmed by the amazing perceptions experienced when connecting with a tree, and the guest may feel anxious and want to disconnect. Unless the care giver has subtle perceptions of what is happening and can imagine and suggest options to dissolve this anxiety, so that the guest will fully enter the positive grounding aspect, then the guest’s desire for disconnection must be respected.

In other, less-rare cases, becoming “one” with the tree and being pacified by it transforms into making love to the tree, with highly aroused sexual energy exhibited. Women, especially, may sometimes fuse with a gigantic phallus and experience strong orgasmic waves. This may be a very positive thing for the guest, but the care giver will have to check that allowing this energy to unfold is okay within the context of the situation, and that the dignity of the guest can be protected from onlookers.

Practical concerns in choosing a tree include checking that there are no sharp spines, sticky sap, poison ivy, wasps, ants, stinging caterpillars, or similar deterrents present.

Aromatherapy

Essential oils and aromatic natural substances can be useful in facilitating calmer states of mind in distressed people. Essential oils are usually dispersed into an indoor area with the aid of vapourisers or tea-light “burners”, which heat a mixture of water and essential oils from below. More simply, a bottle of essential oil can be uncapped and held under the nose to inhale the scent. “Aromatic oils” are cheap imitations of essential oils, or blends containing mostly alcohol, and should be avoided.

Burning blended incenses in the care space should generally be avoided as some people may find the smoke irritating, and the aroma crude and heady. The team might wish to have oil vapourisers constantly in use throughout the space, though care should be taken to select scents that most people are likely to find pleasant and therapeutic. For example, many people find patchouli to be too cloying, and some people find scents such as rose geranium and balm of Gilead to be unpleasant. On the other hand, scents including sandalwood, rose, clary sage, tangerine, lavender, lemon balm, lemongrass, and sweet basil are pleasant and acceptable to a large range of people, and can have relaxing and uplifting effects. Peppermint is believed to improve concentration, relieve shock and nausea, and it can also be a mild stimulant (see “Herbal Teas” below). One consideration against the use of essential oils in the care space is that a small minority of people have allergic reactions to a variety of otherwise innocuous scents.

Herbal Teas

In the context of psychedelic care, strongly stimulating herbal teas should be avoided. Relaxing teas and those with noteworthy antioxidant properties are most appropriate. Some common herbs have properties that are usually harmless, but which may strengthen or alter the effects of

12.16

12.17

some medications or psychoactive drugs that the guest may have consumed. For example, passionflower (*Passiflora incarnata*) is often used as a sedative and anxiolytic (relieves anxiety), but its mild inhibition of monoamine oxidase (MAO) enzymes in the body may strengthen the effects of some psychoactives, and/or have unforeseen interactions with some antidepressants. St. John's wort (*Hypericum perforatum*) should also be avoided; it is a weak MAOI that increases serotonin levels, which may be contraindicated with some recreational psychoactives. To avoid breaching the duty of care, large doses of any herbs should not be administered in this context if normal doses appear to be having no effect. Herbs that are generally accepted as safe may not be so for all people if very large amounts are taken at one time or over an extended period.

Some examples of useful herbs are listed below. Note that "infusion" here refers to soaking the herb(s) in water that has just come to the boil; usually with caffeinated tea the infusion takes place for only a few minutes before the herb or tea bag is removed; however, with many herbal teas, where astringent tannins are not as much of an issue, the herb or bag may be left in the cup whilst the tea is being drunk.

CAMOMILE


Camomile (*Anthemis*, *Chamaemelum* and *Matricaria* species) generally has sedative, anxiolytic, antispasmodic and mild analgesic effects. The flowers, and sometimes the leaves and stems, are prepared by infusion. Note that because camomile may cause uterine contractions that can lead to miscarriage, the United States National Institutes of Health recommend that pregnant and nursing mothers avoid consuming it; keep in mind that women may sometimes be pregnant without yet knowing of their condition.

HOPS

Hops (*Humulus lupulus*, female flowers) are generally used in beer brewing for their bitterness, although they also have calming sedative properties and are used for this reason in herbal medicine. Hops may be prepared by infusion. The main drawback is that the herb is very bitter and the taste may not be tolerated, although honey can help somewhat with this.

LAVENDER

Lavender (*Lavandula* species) has anti-inflammatory and antiseptic effects, and it has been purported to help with depression and anxiety, possibly due in part to the aroma of the herb, which most people find very pleasant and com-



LUKE GRAY • PMS, 2013 • Staedtler Triplus Fineliner and watercolour

<http://www.lukegray.net>

TEAM WELFARE

Svea Nielsen

João Gonçalves

This chapter intends to be a microcosm of the macrocosm, as the team's welfare is like a mirror of the welfare they'll be able—or *unable*—to provide to guests who come to the psychedelic care service. Here we wish to offer some basic suggestions regarding what is important in order to run a care service from the perspective of the team working in this environment. As many of these points have been raised in other chapters of the Manual, here we intend to briefly summarise them and make them easily accessible.

The Importance of Team Welfare for the Entire Project

13.1


In many care service projects that we've seen, the main focus is placed on the guests who will be provided with care, and the team behind that care becomes too easily forgotten. Hence, in this chapter we provide some tips and advice that will help the whole project: both the guests and the project's main drivers, the care givers! The care givers have key positions in many additional areas that these kinds of projects seek to fulfil, not solely related to the direct care of the guests. Care givers, for example, are the people who promote these types of projects and create them at events. They are also the people who educate members of the public about the therapeutic, philosophical, and spiritual uses of psychedelics, as opposed to the drugs' negative and often frightening "recreational" image, which is common in most modern societies.

The Basic Needs

13.2

The starting point concerns the basic needs of the team. Events may take place in very harsh conditions in terms of weather, camp arrangements, and noise, not to mention the toll taken by working day after day (depending on the event duration) with guests in crisis. The care service leader must ensure that the team has the following four basic needs fulfilled:

Clearly, it was very important for everyone at the 2009 Symbiosis Festival to be getting enough sleep.
Photo by Erowid.





MARTINA HOFFMANN • *Alien Ascension*, 2007 • oil on canvas

<http://www.martinahoffmann.com>

WORKING WITH OTHER ORGANISATIONS

Annie Oak

Natacha Ribeiro



Whilst providing a psychedelic care service, the care service leader should strive to work effectively with other organisations on-site. This section offers practical suggestions for how to approach and build relationships with the event organisers, medical services, and security personnel. It also offers helpful tips on how to fit into the existing services, publicise the care service, and adjust to the culture of the event. For those producing care services at events in countries that support the on-site testing of drugs, this chapter will consider the benefits of such testing and other harm-reduction strategies. Some of the topics covered in this chapter are also discussed in [Chapter 4, “Planning and First Steps for a New Project”](#), and we recommend that you consult the material there, too.

Contacting Event Organisers

14.1

A well-developed care service can offer great benefits to event organisers, allowing them to provide targeted assistance and complement existing resources. When approaching a festival where a care service may be welcome, the potential care service leader (or leadership team) should first examine the existing services that will be available at the event. They should also determine which event organisers are the primary contacts for proposing a psychedelic care service. If the top organisers have delegated the event's medical and/or mental health services to a subgroup of outside contractors, the care service leader should first contact the central group of organisers and then ask for introductions to outside staff or subcontractors as required.

Once the care team have determined whom to speak with, they should prepare a brief presentation of the services that they would like to offer and begin a dialogue with event organisers to discuss how they could contribute. Appropriate written materials describing the care service should be offered, along with the names of contacts and their qualifications. Parts of this Manual provide examples of written material that may be presented as evidence of the well-considered, rigorous, and professional approach that the care service will adopt and exemplify.

Throughout these discussions, the care team can determine what services are planned for the event and how they can appropriately tailor their own offerings to compliment the culture and expectations of event organisers. If event organisers indicate that they might indeed welcome a psychedelic care service, the care team should share information about their staff selection process and their training strategy. They should indicate who would be the main care service contact people (the care service leaders) during the event, and whether they are seeking help in staffing the care service.

Determining Possible Sponsorship

14.2

The care service leader should also determine whether the event organisers can afford to fund some or all of the care service. Can the event provide free tickets, lodging, and/or meals for care givers? Is there an existing physical structure that can be used for the care space, or can the event help defray the cost of establishing a shelter? If the care service is planning on setting up their own structure, they may need to work with those in charge of placement at the event to determine where the care team can camp or lodge during the event.



SHANTIQ • *ich bin sehr cool*, 2009 (top) • oil painting
aj24ebene, 2008 (bottom) • graphite pencil drawing
<http://www.saatchiart.com/shantiq>

RISK MANAGEMENT AND PERFORMANCE IMPROVEMENT

Twilight

Risk management is a common-sense approach to minimising the likelihood of bad things happening to guests and care givers. This is fundamental harm reduction. Risk management is an essential discipline for anyone responsible for the organisation of harm-reduction efforts. Its applicability extends from very small gatherings to large festivals.

Risk management is important because it allows care givers to do the following:

- Gain increased awareness of the overall concept of risk minimisation
- Consider and anticipate what could go wrong in a situation
- Provide advanced mental preparedness for what might occur, and what steps could be taken to minimise adverse outcomes
- Do the right thing when the need arises
- Eliminate or minimise negative outcomes to guests and staff
- Minimise the likelihood of getting sued



ALEX GREY • *Despair*, 1996 • acrylic on linen
<http://alexgrey.com>

CASE STUDIES AND IMPRESSIONS

Constance Rodrigues

Berry

Constantinos Efstratiou

Grace Liew

Jack Lieberman

Joan Obiols-Llandrich

João Gonçalves

Jonas Di Gregorio

Karin Silenzi de Stagni

Kim Penders

Mimi Peleg

Rick Doblin

Tracy Dunne

Zevic Mishor

The following case studies and impressions were written by different authors, based on their personal experiences as care givers at events. They are presented here to provide readers a “taste” of different situations that may be encountered in a care service setting. These accounts are also well-suited for use in the training phase of a project, as material for thought or discussion, and as suggestions for role-playing scenarios.

Each account is presented in two parts. Accounts begin with a concise “case study” that summarises the service provided. The case studies are broken down into the following seven subheadings:

1. **Initial Observation**
2. **Key Issue**
3. **Psychoactives Involved**
4. **Medical Care**
5. **Time in Care**
6. **Final Outcome**
7. **Notable Points/Lessons Learned**

walking with him anyway. We arrived at his small, one-person tent, by now standing alone (other tents had been taken down) in a clearing. Here I felt a decision point—I could help him take down the tent and pack, and then personally make sure that he connected with his friend, or I could say goodbye and leave him to it. I was physically and emotionally exhausted at this stage; it had been a very long festival. I made a half-hearted offer to help him pack, but he shrugged it off, saying that all was good, that I had done enough, and that he would be fine on his own. We embraced, and I returned to the care space.

As I was packing up my own gear, I felt a growing sense of unease. I had left this person, who had spoken about suicide, alone. Although fellow care givers reassured me that even accompanying Tom to his tent was beyond any obligation I needed to perform, I decided to follow-up on it; I felt it was the most correct thing to do. I went to where I remembered his tent to be, and it was gone. I then went to the installation where he told me he'd be meeting his friend, and spoke to the people there. They knew Tom, but he had not made contact with them. What followed was a horrible few hours, where I walked kilometres in the burning sun, across a massive festival ground, looking for Tom. A feeling of dread grew upon me, and I became almost distraught, fearing the worst. Tom's friends searched for him as well, but to no avail. At one stage they even found clothes by the lakeside, with nobody there, and called my phone to ask me what Tom had been wearing...

After several hours I received a call. Tom had been found! I felt giddy with relief. I spoke to him briefly on the phone, and wished him all the very best.

Working with Tom in the care space was a challenge in itself, but not unpleasant. He was talkative, we formed a good connection, and he disclosed much to me as we built trust. The main point here was to be an attentive listener, and especially, to be absolutely non-judgemental. Even as he told me about some fairly sensitive topics, I accepted him first and foremost as a human being, with all the rest being just the details. The crunch came when I decided to accompany him to his tent; I feel I should have seen it through all the way; that is, made sure that he had physically connected with his friend. Different care services will have different protocols and guidelines on such things, but if somebody talks about suicide, a care giver should exercise an extreme degree of caution—including getting advice from a team lead and/or the care service leader—before deciding on how to “discharge” the guest.

One of the biggest achievements of the project was that a group of people who previously didn't know each other were able to work as a solid team within such a short time of coming together. The care giver felt that he had a supportive network on hand all throughout the intervention of this episode. Perhaps in certain circumstances it would be a good idea for care givers to dress in distinguishable outfits; in that way, our roles would be much more visible to people.

IMPRESSIONS

When I heard of a project that was going to set up a psychedelic care service, I immediately wanted to participate in it; and, as it turns out, it offered me a unique chance to be part of something magical. In this report I recount the most impressive story that I assisted with during my time as a volunteer. From my perspective this story contains a lot of the elements that are important to the job at hand: it was extremely intense, it took a long time, and it didn't really stick to the official "work schedule". It showed clearly how we should expect nothing less than the unexpected when working at a psychedelic care service.

On this particular night I didn't have a shift at the care service. I was simply enjoying my holiday, hanging around watching the setting sun. Eventually I ended up helping out a fellow human being until four o'clock in the morning! I was pretty tired from the previous days. My plans were to see the sun set and then head off to bed, but something else was thrown at me, and before I knew it a story unfolded that seemed surreal at certain points. As the sun set, a young lady (I will call her "Eve"), came to sit next to me and my friend. At first it seemed like nothing out of the ordinary, just a person interested in finding out what exactly we were doing. This happened a lot at the entrance of the service, and we always made sure someone was standing guard in order to explain to these people what we were doing and why they could not enter our installations.

The conversation was mostly about the event, and how we were experiencing it, what we liked and didn't like. After fifteen minutes of chatting it became clear that Eve had taken one hit of acid, about an hour before. It is strange to see how under certain conditions people seem to talk freely about their use of drugs. It is even more interesting to note how the shared experience of using certain drugs seems to transcend any cultural differences that might otherwise be a possible hurdle for making a connection. I guess one might say that the effect of drugs is not bound by cultures.

inside the service also attempting to get a grip on their experiences, I tried to get Eve to keep her voice down. She would only partially react and sometimes still go off into bursts of screaming. As a result, some people who were sitting close to us started to make remarks about this directly towards Eve. It goes without saying that she did not understand, and as a result got even more confused. Apparently these people, who were not from our team, weren't aware of what was happening, even after I and several others told them that this girl was having a hard time. This should have been avoided by all means. The truth is that those remarks made at Eve contributed to her growing state of confusion, and she picked up on all remarks hinted at her.

In her state it was impractical to let Eve go inside the care space where some of the other guests were sleeping, as she would have greatly disturbed the peace inside. At the same time, walking away alone with her didn't seem like a solution, as I would be by myself if the situation developed into an even harder experience. It was only afterwards that I realised how this decision turned out to be a really wise one. It became increasingly difficult reasoning with Eve. She was wondering what she did wrong, why people were reacting as they were to her. For me, it was clear that she was heading towards a total psychological collapse, so I asked some other care givers to come help me and sit near by just in case. By now, an hour had passed. After all this time, she still was going in and out of sanity, being a happy little creature one second and the saddest person alive the next.

I will try to give a description of one example of how this translated into behaviours in Eve, recounting her words, describing the expressions on her face and the intonations that went hand-in-hand with them. Eve was talking in two different languages, jumping from one to another, speaking in English and in her mother tongue, a language of which I couldn't understand a word. I can only say I was happy at the time to have someone in the vicinity who could translate part of what she was saying. It would go slightly like this, "I have to call my mum. I have to tell her that everything is okay. Can I call my mum, Jay?" (Question directed at me, although she was confusing me with her boyfriend the whole time.) "Jay, where are you? You are so far away. Jay, please call me. I really have to call my mum right? I really have to. Jay, don't leave me, Jay... But it is late, maybe my mum is asleep. What if she is asleep? Should I call my mum, Jay?"

The intonation of her voice made it all seem even weirder. She would whisper, then scream, then whisper, and so on. She would talk with a high-pitched voice followed by a low one, sometimes switching in the same sentence. She would

and ran over to the other volunteers. Again I was amazed at how rapidly I adjusted to the situation, revived once more from my tiredness, putting on my so-called psychological battle helmet again.

By the time I arrived there, Eve was foaming from her mouth, and was frantically trying to get out of the grip of the volunteers. I stepped in and tried to subdue Eve physically, by holding one of her arms, and we managed to get a little bit of control over her largely uncontrollable physical movements. It was amazing to see how strong a person really can be physically in these sorts of situations.

To be clear, restraining Eve was only done because, at this point, she had started to physically harm herself and the people around her. Two more male volunteers came to help, and together with three female volunteers we carried Eve towards the care space. We decided as a team that it would be best to put her in the restricted space that was set up especially for cases that might disturb the others present in the main care space. This turned out to be a very good choice, and we finally got Eve to lie down in this place.

It took four people to hold her down, one on each leg and each arm. The power that came from her was unimaginable, it seemed as if the energy of a complete galaxy was rushing through her and driving her body to do physical things that were simply not possible. Eve lingered in this strange outbreak—screaming, kicking, laughing, and crying—as if all these emotions could combine into one at the same time.

It is also hard to describe how much a person changes during these experiences, concerning the appearance of their face and their body language, as I had the chance to witness with Eve. The young girl who is sitting quietly next to you in one moment, is kicking and spitting at you an hour later, eyes popping out and facial expressions totally blown out of proportion. Remaining calm was the only thing we could do, especially for Eve's sake.

After following her for another hour, I asked someone to take over because I was getting too tired. Soon I was relieved from my duty and I could finally go to sleep. I had a very good rest because I was really exhausted. After I woke up, the first thing I did was walk out to the care space, because I was wondering about Eve's follow-up. It turned out she came to her senses, only four hours after I left. I got to hear a wonderful story from my fellow volunteers about how, in the end, she started to say she was Shiva and all was love, falling asleep afterwards. In the morning she was totally fine, apart from being shaken up from the psychological ride, which is to be expected after an experience of this magnitude.

come back. By that time I had noticed somewhat paranoid behaviour, and in our conversation he had mentioned that he had heard a talk the evening before about how MDMA was used to heal in a psychological setting and he had intended to do something like that with his trip. I anticipated something might come up, and told the other volunteers I would return later.

Uri and I walked off to the waterside, sitting down. After a short conversation he asked me how long the come on should take and if there was any way he could make it come on easier; whilst he asked this, he seemed rather tense. I replied that it would probably pass more easily if he let go a bit and allow the experience to enter at its own pace. I used an analogy of a hot bath, as one doesn't jump into a hot bath all at once. You first enter a little bit with your foot and as your body adjusts itself you enter more and more until you are submerged.

After that we both sat upright for a while, our feet tucked under us, and we stared at the lake and the small waves that were slowly sloshing onto the shore. For a while, we exchanged glances and drank water often.

At some point he expressed his gratitude for this opportunity and we started to talk again. His talk basically revolved around paranoia, and in the conversation that ensued, it came up that I'd had paranoia as well at one point in my life. We talked about this and he asked how I had overcome it. I explained that I had allowed all of my paranoid energy to symbolically flow into a rock, and then I cast that rock into a lake. After that moment, I could always refer any paranoid idea to that rock at the bottom of the lake and overwrite it with a positive and healing thought instead. On one hand, you recognise it as something real; but on the other hand you, have chosen not to stay with that paranoia and you choose healing instead.

He decided to do the same, and even picked up a marker to write "paranoia" on a stone. I feel I must state at this point that I never suggested he would or could do anything during this conversation. I continuously allowed him to speak his mind and only elaborated on my own thoughts when he asked for conversation. He sat with the stone in his hands for a while and talked. By this time I noticed that I was pretty much out of the conversation mode, as if I had taken a back-seat in his mind and we were not really having a dialogue. His words seemed more a manifestation of thought than an attempt to relay thoughts from one human to another. Perhaps he was addressing his paranoia directly? I have no idea and no way of knowing.

IMPRESSIONS

Early in the night, a nineteen-year-old girl (“Gabrielle”) and her eighteen-year-old friend (“Kate”)—high on LSD (150 micrograms each)—were brought in by the paramedics. The two girls, who had taken LSD for the first time, weren’t really aware that the paramedics (all male in this situation) were friendly professionals, so they kept thinking that the paramedics would harm them in some way. Possibly experiencing fears of rape (something that can occur within an psychoactive crisis experience), they were very scared in the beginning, asking many questions; we reassured them they were in a safe space where nothing bad was going to happen. The team on that shift decided that only female care givers should take care of the girls, in order to hopefully decrease their delusional thoughts and paranoia.

Gabrielle’s physical condition was stable but she was feeling somewhat lost and hypothermic, switching between passively lying down and suddenly going outside to smoke or to see the stars. She was having intense visions and her eyes looked spaced-out whilst she was shifting between total focus (especially when we asked questions) and detaching all of a sudden, not really listening to anything any more. She was so awe-struck with the experience that she couldn’t put it all into words; at the same time, she wanted to pay attention to her friend who was slightly younger. One could see they had a strong bond, so the best option for this sitting experience was to have a female care giver work with the two of them.

Another care giver and I did the girls’ intake. They ate some apples and lay down together in sleeping bags; and when the girls had proper shelter and seemed more grounded, they were left with just one care giver who sat with both of them. One could notice how Kate was caressing her friend’s face with the tip of her fingers in a very delicate manner and both girls seemed to derive great pleasure from this. Later on, their symbiotic bond allowed them to sleep together coiled with each other in foetal positions, an image that was like a soothing portrait. The care service is not only a container for people ridden with despair, anxiety, fear, and feelings of hopelessness, but also a warm, peaceful “womb” where guests can really feel safe and nurtured.

Once their basic needs were met (warmth, food, water, and toilet), we opted to give the girls enough space to explore their sensations, whilst simultaneously keeping an eye on them. During a sitting experience it’s important to pay attention to issues of personal boundaries, as the guest often feels rather sensitive with every move and might need very little interaction with the care giver, without any dialogue.

disturbances. He didn't speak at all and he was grimacing in a spectacular way, moving all his facial muscles at an incredible pace. He was in a very weak condition, had a fever, and had been experiencing vomiting and diarrhoea for a couple of days.

KEY ISSUE: *In the course of providing care, what turned out to be the core condition or challenge that had to be handled?*

The guest probably had a bipolar condition and was in the middle of a manic phase. On top of this, there was a suspicion that he had taken some psychoactive substance and that he had dropped his prescription treatment.

PSYCHOACTIVES INVOLVED: *What substances (if any) relevant to the incident had the guest consumed?*

Nobody really knew for sure, but there was a suspicion that the guest had taken some psychoactive substance, whilst having dropped his treatment with a prescription psychiatric drug.

MEDICAL CARE: *Was there a need for medical intervention (that is, any treatment beyond interaction with a care service volunteer)?*

This guest had to be treated by the psychiatrist in the care service.

TIME IN CARE: *How much time did the guest spend in the care service?*

The guest came in the evening and left the next day, but later on he was brought back again to the care service.

FINAL OUTCOME: *What was the condition of the guest upon discharge from the care service?*

After sleeping a few hours the guest left, but he had taken one of the care givers' bags and disappeared. On the following day he caused some serious trouble around the event and security services brought him back to the care space. The event was over and the installations were being dismantled, so there was no choice but to evacuate the guest to the closest hospital in the area with a psychiatric ward.

NOTABLE POINTS/LESSONS LEARNED: *What was done well, and what could have been improved upon or done differently? Are there any other notable points from this case?*

With the guest being evacuated to a psychiatric hospital ward, in certain ways it was a sad ending, but the case also showed that although psychiatric patients have a right to go

She was going through an intense trip, confused and lost. She would sit down for a minute, then jump up trying to walk towards somewhere, then forget her intention and collapse back on the floor! She appreciated the grounding effect of my touch and started following simple instructions like, "Stay with us!" I was assisting her with another of our care givers.

Within five minutes she started speaking in a very British accent, her words emphatic and dramatic with long spaces in between, sometimes striving to place more than three words together in a sentence. She would say things like, "Embarrassment, cold, confusion, so strong, is it really me? Acceptance, safety, trust, why everything?" Her emotions were changing quickly; she was struggling to make sense of her surroundings and attempting to regain her identity.



A "Starlight Kush" cannabis clone displayed by Oaksterdam University's booth at the 2009 Harmony Festival in Santa Rosa, California. Photo by Erowid.

She was verbal, attempting to answer questions like, “What is your name?”, “Where you are from?” and trying to explain her situation without any success for a good whole hour. Then, she managed to put some clothes from our stock on by herself but needed assistance with her socks. During her moments of restlessness and agitation, shame or insecurity, she really appreciated my hand supporting her back and shoulders, a friendly pat on the shoulders and a quick back rub to shake off that chilly feeling.

Her Kundalini was travelling wildly up and down her spine, to a point she felt so relaxed and excited she started touching me in intimate spots in a very sensual way. I had to gently remove her hand, reflecting that the “brotherly or fatherly” approach would be more ethical for all of us. Flashes of heat would make her take some clothes off again but the bitter cold around her was forcing her to get dressed and wrapped in one of our sleeping bags. After a while she felt more secure—calm and appreciative of our company—and started saying longer phrases, still struggling to put events in order.

Within half an hour more she could say her name with certainty, and she would ask ours and remember where we all came from. She started getting concerned about her looks, feeling the mess on her hair and trying to pull out the thorns and plants, but she would try to pull her hair out many times and we had to gently persuade her to stop. By now, three hours had passed and we had gathered interesting facts together, as she had confirmed them enough times to be confident that she was telling the truth. She was a sixteen-year-old girl on her birthday night, and this was her first psychedelic experience; she was on a red micro-star LSD trip of 130–150 micrograms, a large dose especially for such a young person.¹

The few of us who were with her sang her happy birthday, and for the first time we saw sincere happiness shining in her eyes! I was glad to see how she was checking and evaluating her looks. We also offered her a cup of tea. “I

1 Compare with 16.3, “A Rollercoaster of Emotions—From Hell and Back”, above. In that Impression the author describes 100 micrograms of LSD as a *light* dose, whilst here, 130–150 micrograms is labelled *large*. These discrepancies illustrate how different individuals are affected by psychoactives in varying ways, yet also how different people—including experienced psychonauts—conceive of similar doses differently. Be wary of jumping to the conclusion that a certain dose will be light, medium or strong for a particular person, especially someone you’ve never met before. As always, remember that *set* and *setting*, as well as *dose*, each play a fundamental role in determining the strength and quality of a psychedelic experience.

would love a cup of Earl Grey”, she said. But we only had camomile, and she gratefully accepted that. Just the fact that she could remember that she loves Earl Grey made me feel confident that she was returning at a steady pace.

By this point she was accurately reflecting upon the events of the night in perfect chronological order, feeling a bit guilty that she had caused such a mobilisation. Now that she was so present—aware and enjoying, letting long breaths flow from her lungs and lowering her stressed-out shoulders—we gave her a short massage. Her body had been so tense since those poses on the dance floor and now she was coming all the way from a hazy, abstract, and “melted space”, back into touch with reality and connecting to the sensations of her body, regaining her sense of identity. She seemed really focused on planning her next moves whilst she was empathising with the worries of her friends who must be missing her; yet she also blamed them for letting her down.

It was 4:30 am, dark and cold. She felt like going outside the care space to enjoy the rest of her night but she could also feel the need to rest. The acid was still giving her uncomfortable boosts of energy whilst she was struggling to stay in



A soft reassuring voice and gentle touch can help mellow out an anxious tripper, encouraging a longer stay at the care space if needed.

spitting all the time. He kept sliding his hands away from the grip of the belts tied up around him, and he tried to pull off his penis three or four times more. We kept on tying him back and placing the pillows tightly against his thighs and stomach so he couldn't reach his centre line, and we kept on readjusting the belts to have the maximum hold possible without suffocating him.

Suddenly, he bit the water bottle again! Every time he would cover his face with snot and spit, I had to take a big thick diaper, reach his face, and wipe him clean without giving him a chance to bite me (although he tried many times). After a good hour had passed, it came a point when I started losing my patience with him, as all our approaches were useless: talking calmly and brotherly wasn't helping, joking around didn't come through, begging him for his cooperation was not giving results, and now was the time for a harsher approach. I screamed something like, **"Stop treating me as if I was security! I am here to help you!"** I felt as though I shocked everybody who was there; my voice was loud and angry, and my phrase clearly expressed my own experiences and projections. It was out of context and unfair to the security personnel. However, it did help to calm the guy; and by now the injection was setting in; as his muscles relaxed, his powers gave way to a struggle to find rest. He finally drank some water and started dozing off.

He had been keeping four of our people on full alert for more than two hours, during which time three or four of his friends came and went. They told us that he had been taking a lot of ketamine over the last four days, and then he took ten drops of liquid LSD, but soon after that he bit the whole bottle and apparently drank it all! His friends, who were each starting to trip on two drops of LSD just as the security had earlier intervened, wanted to stay there, but their friend was going to be sleeping for some hours, so they had better things to do. They promised to drop by many times and to be there when he woke up. I must have slept like a rock after that, yet I woke up still full of adrenalin. Back at the care space, I was told that the guy we treated had left with friends, and that he was calm, sweet, and very thankful—an amazing difference.

I saw him at a crossroads at the festival and he truly was thankful. He even fell on his knees when I told him we had a plastic bag with his mobile phone and dirty clothes. It was wonderful to see him so different and happy! I wish I could see him again and chat more.

It was a tough job with a pleasant ending, and it made me really appreciate the backup of the paramedics and security,

the need for training to deal with difficult and violent cases, and the alertness of our group. It also made me think of the dangers of the work: getting hit, contaminated with microbes from receiving bodily fluids, and potentially being bitten!

I felt so warm to receive thanks and to know that I protected him from the darker self we all hide inside. It is always amazing to see a human being like a wild dangerous beast one day, and the next day like a saint, the hope of humanity!

Water Grounds a Guest in Discomfort

INITIAL OBSERVATION: *What was the first condition that the guest presented with upon coming or being brought to the care service?*

Agitation, incoherence, and discomfort that manifested in hyper-energy.

KEY ISSUE: *In the course of providing care, what turned out to be the core condition or challenge that had to be handled?*

The key issue was that the guest needed grounding.

PSYCHOACTIVES INVOLVED: *What substances (if any) relevant to the incident had the guest consumed?*

It was unclear whether or not the guest had taken anything, and if so, whether the effects were getting stronger or weaker.

MEDICAL CARE: *Was there a need for medical intervention (that is, any treatment beyond interaction with a care service volunteer)?*

There was no need for medical intervention.

TIME IN CARE: *How much time did the guest spend in the care service?*

The guest spent about two hours at the care space.

FINAL OUTCOME: *What was the condition of the guest upon discharge from the care service?*

After sleeping, the guest woke up able to converse.

NOTABLE POINTS/LESSONS LEARNED: *What was done well, and what could have been improved upon or done differently? Are there any other notable points from this case?*

From this experience I came away with an appreciation for the grounding power of water. Although there were potential hazards involved in swimming, the benefits greatly outweighed the risks.

16.11

immediately appealed to her. We walked to the water and went in. She dove in and I dove in ahead of her. I had a short moment of hesitation, considering whether she was self-destructive. The water was a great relief to her; she was able to get out some physical energy and demonstrated that she wasn't self-destructive.

After five or ten minutes in the water I suggested we head back to the dome. When we got back, she finally relaxed and was able to lie down. I tried to project a sense of tranquillity and meditated a few feet away from her. She grew increasingly quiet, falling asleep after fifteen minutes; it was very peaceful. She was able to converse when she awoke.

From this experience, I came away with an appreciation for the grounding power of water. Though there were risks involved, I carefully considered each of them and decided that the potential benefits greatly outweighed the risks.

Over-Anxious, Overwrought, and Overwhelmed—KosmicAid, a Care Service Leader's Point of View

There are so many things to consider when managing a psychedelic support service. Over the years we have encountered many problems, with event organisers and workers not understanding what the service is about, and even with care givers thinking that volunteering at the service is just an easy way to attend an event "for free". The following is a case study that emphasises some of the problems faced by the care service leader, and how they were resolved in this particular instance.

INITIAL OBSERVATION: *What was the first condition that the guest presented with upon coming or being brought to the care service?*

The guest was a young woman about twenty-four years old; she was alone and verging on tears. She looked lost and scared.

KEY ISSUE: *In the course of providing care, what turned out to be the core condition or challenge that had to be handled?*

The woman was extremely anxious and overwhelmed by the emotions she was mentally and physically feeling. She was looping from the darkest, deepest despair to euphoria.

PSYCHOACTIVES INVOLVED: *What substances (if any) relevant to the incident had the guest consumed?*

The guest had taken hash cakes.

16.12

The following day, when the rest of the team looked to me for guidance, and all I wanted to do was sleep, I realised that the skills of leadership include the capacity to organise one's own work and that of others. This requires attending to several activities simultaneously, prioritising, and switching gears as necessary. It includes dealing with unexpected crises, obstacles, or interruptions, and effectively getting back on track, to prevent further crises.

I learned that a clear head, calm demeanour, and the ability to delegate are essential when running a successful service. *It is also essential to have a co-leader of some sort to share the workload* (one person cannot be on-call twenty-four hours a day); it also means you have assistance rather than isolation in dealing with any problems that arise. Making sure that the correct team is chosen is crucial; it is important for morale and the smooth, successful running of the care service. Members should be aware of their abilities and should be encouraged to ask for help if they need it. There are always challenges in the care service and a strong team can act as a support mechanism for all care givers, working together to improve the service. The team certainly supported me that day; the workload was organised between them, allowing me a few hours rest and recuperation.

I would like to share a quote from Silvia, which she wrote after the experience and granted permission for us to use in the Manual:

"I was severely anxious and very overwrought and very overwhelmed by the physical sensations in my body as a result of the ingestion of too much of a good thing. The anxiety was in my mind, as well as in my body. Tracey was an angel to me when I badly needed one. My mind was a very difficult place to inhabit that night and she possessed great patience and empathy, which she generously shared with me to guide me through the experience.

I was shattered for most of the festival thereafter. But one thing is certain in my mind. I truly honestly deeply do not know how I would have come safely through the experience, were it not for her guiding light."

Being part of a psychedelic support service is hard work and can be emotionally, physically, and financially draining at times, but the benefits far outweigh the down times. It enhances your life tremendously; and the satisfaction of doing something successfully that you wholeheartedly believe in is the most incredible feeling ever; it restores your faith in humanity. Just reading Silvia's email reaffirms that services such as ours, if done well, are the most valuable resource that a party, event or festival can offer their clientele.

with the people in need and, on the contrary, was talking down to them as if they were stupid. I decided to remove her from sitting, and gave her work at the kitchen, where she was in charge of making cups of tea; in this way, she was still involved with the team but not directly involved with the people in crisis.

Most times volunteers go through emotional problems themselves. This can be because they are dealing with lots of deep existential situations that the care service guests are going through, and these can act as a mirror to their own life situations; sooner or later something triggers their own fears and challenges, and they find themselves in a conflict. It is important that the care service leader be ready for this. In our experience, it happens to nearly every volunteer at least once! That's why the team must be very reliable and support each other. Nevertheless, it's the responsibility of the service leader (and also team leads) to try to resolve such issues as soon as they arise. We have had many cases like this, but I'll present an especially serious one as an example, because it also relates to the predicament of not having enough volunteers.

We had a friend of the team, a vibrant and charming person who was there to help organise the group. However, I didn't want him to sit because he was suffering from bipolar disorder and often felt depressed and helpless. Unfortunately, we didn't have enough volunteers, and one night around the fire circle he started to talk to a woman who was suffering from depression. She was self-harming and not taking care of her personal appearance. After talking to her for a short while, he realised he couldn't help her and called another colleague to step in. Whilst he was with me, reporting the case, he said, "Look at the state she is in! I think it would be better if she killed herself!" But at the same time that he made this statement, he realised that he was actually talking about himself. Immediately after he realised this, he fell into a deep depression and had suicidal thoughts that lasted for days after the event. I had to follow him very closely, talking to him every day, and a week later assisted him in entering a suicide help clinic, where he was admitted for five days until the crisis ceased. Thankfully he is still alive today.

Another problem we encounter is that many of the people inclined to do sitting work have been or currently are involved at some level with sharing or selling substances. In some ways I see this as a natural consequence of the subject, because in the best case scenario, any well-intentioned, conscious dealer of psychedelics would be there for a friend or customer if/when things go wrong, giving direct counselling or providing information about other similar reactions


his peak and come back before I could have a word with him... And even then, it wasn't possible until the next day to sit down and seriously explain how misguided their decision to smoke near the care service was. As a leader, one has to be vigilant about these issues; on occasions, I had volunteers smoking inside the tent (because it was empty), or using the privacy of our space's curtains to weigh substances (because they didn't have good lights in their own tents!). Any such inappropriate activities must be shut down as quickly and discreetly as possible.

What we have learned is that staffing a psychedelic care service is both a very demanding and a very rewarding job. It is not to be taken lightly. As a coordinator, one has to be on top of things without dominating the group. Leave space for growing. Have others to rely on. Be humane and speak up if you are tired and need support. The team becomes a family. Treat them with respect and love, and you will receive the same in return.

Good luck!



Refreshingly cool and dark during the heat of the day, this kiva/tepee structure was a more private space for psychedelic journeys at KosmiCare during the 2008 Boom Festival. Photo by Erowid.



VIBRATA CHROMODORIS • Below Zero, 2012 • digital (Adobe Illustrator)

<http://vibrata.com>

ONLINE RESOURCES AND OBTAINING ASSISTANCE

Xavier Urquiaga A.

Svea Nielsen

Annie Oak

This chapter provides Internet links to various online resources and harm-reduction organisations. Whilst fairly comprehensive, it is by no means exhaustive. The website of the [Multidisciplinary Association for Psychedelic Studies \(MAPS\)](#) also provides a list of relevant resources.

General Resources

Code of Ethics for Spiritual Guides
by the Council on Spiritual Practices (2001)
<http://csp.org/code.html>

The Code of Ethics is also reproduced in [Chapter 2](#),
“The Principles and Ethics of Psychedelic Support”.

“Psychedelic Crisis FAQ” by Erowid (2005)
http://www.erowid.org/psychoactives/faqs/psychedelic_crisis_faq.shtml

Erowid is *the* website for information on psychoactive drugs. This publication gives a good summary and provides a useful list of things that can be done to help in a psychedelic crisis.

Erowid Experience Vaults
<http://www.erowid.org/experiences/>

Over 24,000 first-person trip reports, reviewed and searchable by several criteria. The most comprehensive resource of its type in the world.

Green Dot Advanced Ranger Training Manual
by Burning Man (2012)
<http://rangers.burningman.com/wp-content/uploads/GD-manual-2012.pdf>

The training manual for the Green Dot Rangers, who provide peer-based counselling at the Burning Man Arts Festival.

DÁT2 Psy Help Manual (2013)
<http://daath.hu/dat2/psy-help/dat2-psy-help-manual-EN.pdf>

This “psy help” (that is, psychedelic/psychological/psychiatric help) manual is a practical guide to harm reduction at parties and festivals, focusing on psychedelic emergencies and spiritual crises. It draws together practical knowledge on drug-related harm reduction, discusses the requirements for the helpers as both individuals and team members, and provides practical details about the psychedelic support process, including various ethical considerations.

“Crisis Intervention in Situations Related to Unsupervised Use of Psychedelics”
by Stanislav Grof (1980)
<http://www.psychedelic-library.org/grof2.htm>

An excellent piece of writing by one of the leaders in the scientific research of psychedelics, from his classic book, *LSD Psychotherapy*. In a psychedelic crisis, we often think that the drug has created the problem. But actually, we are usually dealing with the dynamics of the unconscious.

“A Note on Adverse Effects”

by Lester Grinspoon and James B. Bakalar (1983)

<http://www.druglibrary.org/schaffer/lsd/adverse.htm>

From Grinspoon and Bakalar’s book *Psychedelic Reflections*, this chapter reviews the literature on adverse effects of psychedelic drugs. In summary, bad trips and mild flashbacks are common and even expected, but are usually considered a mere nuisance—and occasionally even an opportunity—rather than a danger. There is no good evidence of organic brain damage or genetic alterations as a result of psychedelic drug use. Bad trips usually become deterrents before they become dangerous.

“Bad Trips’ May Be the Best Trips”

by Walter Houston Clark (1976)

<http://www.druglibrary.org/schaffer/lsd/clark2.htm>

Clark’s article, which appeared in the April 1976 issue of *FATE* magazine, contains a first-person account from someone who underwent treatment in a controversial Mexican clinic that was inducing “bad” trips in their patients. Dr. Salvador Roquet deliberately disturbed his subjects to bring their worst fears and issues to the surface. He had a successful (apparently positive) outcome for nearly 3,000 patients.

How to Treat Difficult Psychedelic Experiences: A Manual

<http://www.maps.org/images/pdf/Psychedelic-Harm-Reduction-2014.pdf>

Written by a psychedelic therapist and originally posted as part of MAPS’ Rites of Passage Project, this concise article has recently been adapted as “Appendix A” within *The Zendo Project Harm Reduction Manual*. It covers the “Role of the Sitter, Facilitator”, “Varieties of Psychedelic-Induced Crises”, “Working and Being with Psychedelic Emergencies”, “Aftercare”, and “Related Readings”.

“Ethical Caring in Psychedelic Work”

by Kylea Taylor, M.S. (1997)

<http://www.maps.org/news-letters/v07n3/07326tay.html>

An article from the *MAPS Bulletin* that presents some ethical considerations for psychedelic sitters.

“Working with Difficult Psychedelic Experiences”

by Brandy Doyle (2001)

http://www.maps.org/news-letters/v11n2/v11n2_14-17.pdf

An article from the *MAPS Bulletin* that reports on a care service at a festival in Columbus, Ohio. An interesting quote: “In a sense, the young people who find themselves in a tent like a psychedelic Civil War hospital really are war victims,

“Ground Control: A Sitter’s Primer”

by The Teafærie (July 22, 2007)

https://www.erowid.org/psychoactives/guides/guides_article2.shtml

An excellent general overview of basic protocols and best practices for those who would act as sitters or “ground control” for psychedelic psychonauts. Also check out the author’s short supplementary piece, “Spiritual Emergence Kit”.

“Interview with Kosmicare UK founder Karin Silenzi de Stagni” by Robert Dickins (November 19, 2013)

<http://psypressuk.com/2013/11/19/interview-with-KosmiCare-uk-founder-karin-silenzi-de-stagni>

One of our Manual authors, Karin Silenzi de Stagni, speaks to the *Psychedelic Press UK* about her British psychedelic care service.

Videos

Working With Difficult Psychedelic Experiences: A Practical Introduction to the Principles of Psychedelic Therapy by Donna Dryer (2011)

<https://www.youtube.com/playlist?list=PLF78A33465DDA48D2>

A twenty-minute video produced by MAPS that presents information about how to take care of someone who is undergoing a difficult psychedelic experience. Good material to use for training purposes.

Psychedelics in the Psychiatric Emergency Room by Julie Holland, MD, video and transcript (2010)

<http://vimeo.com/16702478>
http://www.erowid.org/culture/characters/holland_julie/holland_julie_ps21c_presentation1.shtml

An interesting thirty-minute video (and transcript thereof). Dr. Holland shares lessons she learned in a psychiatric emergency room at Bellevue Hospital Center in New York City. She also describes the potential therapeutic use of MDMA in the treatment of schizophrenia. Holland is the editor of *Ecstasy: The Complete Guide*.

Safer Festival Intervention at O.Z.O.R.A. 2012: The Haven by Jonas Di Gregorio (August 23, 2012)

<http://www.youtube.com/watch?v=fdoPjsMct1k>

A short video by one of our Manual authors, Jonas Di Gregorio, about The Haven care space at O.Z.O.R.A. Festival in Hungary, 2012.

17.2

17.3

Discussion Forums

Bluelight's Harm Reduction Forum

<http://www.bluelight.ru/vb/forumdisplay.php?forumid=144>

Drugs-Forum

<http://www.drugs-forum.com/index.php>

The Lycaem

<http://www.lycaem.org/forums/>

The Shroomery

<http://www.shroomery.org/forums>

17.4

Some Organisations Working in Psychedelic Care and Harm Reduction

EUROPE

Agência Piaget para o Desenvolvimento (APDES)

<http://www.apdes.pt/v1/>

Alice Project

<http://www.alice-project.de>

Checkit!

<http://www.checkyourdrugs.at>

Chill out

<http://chillout-pdm.de/verein>

Correlation Network

<http://www.correlation-net.org>

Crew

<http://www.crew2000.org.uk>

DÁT2 Psy Help

<http://daath.hu/dat2/psy-help>

Democracy, Cities and Drugs Projects

<http://www.democitydrug.org>

DrogArt

<http://www.drogart.org>

Drug Scouts

<http://www.drugscouts.de>

Drugcom.de

<http://www.drugcom.de>

Drugs Just Say Know

<http://www.know-drugs.ch/home.htm>

Energy Control

<http://www.energycontrol.org>

European Cities On Drug Policy

<http://www.ecdp.net>

European Foundation of Drug Helplines (FESAT)

<http://www.fesat.org/en>

**European Monitoring Centre for Drugs
and Drugs Addiction (EMCDDA)**

<http://www.emcdda.europa.eu>

Eve & Rave

<http://www.eve-rave.net>

Fêtez Clairs (Celebrate Clear)

<http://www.fetez-clairs.org>

Jellinek

<http://www.jellinek.nl/>

KosmiCare Boom

[http://www.boomfestival.org/boom2014/
boomguide/kosmicare](http://www.boomfestival.org/boom2014/boomguide/kosmicare)

KosmicAid

<http://www.kosmicaid.org>

**Lab57 Alchemica: Laboratorio Antiproibizionista
Bologna (Alchemical Lab57: Anti-prohibitionist
Laboratory of Bologna)**

<http://lab57.indivia.net>

Modus Vivendi

<http://www.modusvivendi-be.org>

Movida Project

[http://www.comune.venezia.it/flex/cm/pages/
ServeBLOB.php/L/IT/IDPagina/58737](http://www.comune.venezia.it/flex/cm/pages/ServeBLOB.php/L/IT/IDPagina/58737)

Progetto Neutavel (Neutavel Project)

<https://www.facebook.com/Neutavel>

**Nightlife Empowerment & Well-being Network
(NEW Net) / Safer Nightlife**

<http://www.safernightlife.org>

PartyProjekt-Odyssee (Party Project Odyssey)

<http://partyprojekt-odyssee.de>

PartySmart

<http://partysmart.org/index.php?file=public/home.php>

Peer Involvement

<http://www.peerinvolvement.eu>

Progetto Nautilus (Nautilus Project)

<http://www.progettonautilus.it>

Psicologi Senza Frontiere (Psychologists Without Borders)

<http://www.psicologisenzafrontiere.org>

Q de festa (Q Festival)

<http://www.qdefesta.cat>

Quality Nights


<http://www.qualitynights.be>

Safer Clubbing

<http://www.saferclubbing.ch>

Safer Party

<http://www.saferparty.ch>



DanceSafe information booth at the 2011 International Drug Policy Reform Conference. Photo by Erowid.

Spora

<http://www.spora.ws/en>

Techno+

<http://www.technoplus.org>

THE UNITED STATES

(see also Chapter 1, “A History of Psychedelic Care Services”)

Burning Man Emergency Services Department (ESD) & the Green Dot Rangers

<http://www.bracesd.org>

<http://rangers.burningman.com/ranger-teams>

The Burning Man Emergency Services Department (ESD) and the Green Dot Rangers both provide services to participants at the annual Burning Man Festival in Nevada. The Burning Man ESD runs a Mental Health Branch that provides psychiatric services for distressed participants at the event’s Sanctuary space, and the Green Dot Rangers provide peer counselling at this location.

DanceSafe

<http://www.dancesafe.org>

DanceSafe provides harm reduction and peer-based educational programmes to reduce negative drug experiences and empower young people to make healthy, informed choices. DanceSafe is known for bringing pill-testing services to the rave and nightlife communities in the United States, where their volunteers staff harm-reduction booths at raves, nightclubs, and other dance events.


The Rainbow Family of Living Light

The Rainbow Gathering has assembled each year since 1972 on National Forest land in the United States and is coordinated by a loose affiliation of people called the Rainbow Family of Living Light. The Gathering offers health services run by a group of volunteers called the Center for Alternative Living Medicine (CALM). Psychedelic care services are provided by Brew HaHa, a CALM subcamp.

Rock Med

<http://www.rockmed.org>

Rock Med was created in 1973 to serve participants at large concerts in the San Francisco Bay Area. Since then, it has branched out to provide care at sporting events, marches, fairs, circuses, and other large gatherings. The group now has about 1,200 volunteer doctors, nurses, and CPR-certified care givers, and serves at more than 700 events a year in Northern California.



LUKE GRAY • *Fountain of Youth*, 2013 • Staedtler Triplus Fineliner and watercolour
<http://www.lukegray.net>

FINAL WORDS

Psychedelic care services—in their modern form—have been around since the 1960s, yet it appears that a new era is underway, characterised by more care spaces than ever before, and increasingly organised, professional, and well-trained care service teams (that we hope will only continue and expand). There are many reasons for this growing trend; they include the gradual revival and re-legitimation of psychoactive drug research around the globe; the fact that large music festivals are now being regularly held and run in a competent and responsible manner; the shifting of focus and attitudes of some national policy makers (in Europe especially) from prohibition to harm reduction; and the emerging availability of a great number of novel psychoactive substances for which there is little research or experiential knowledge. Importantly, the most significant efforts at setting up and running new care services are coming largely from within the “psychedelic community” itself; brave initiatives by men and women who are personally familiar with the psychedelic space, generally love music festivals, and have identified a pressing need for care work. They are well-aware that such care spaces can and do bring light to guests in their darkest hours of need, and may make the difference between a horrific, scarring experience, and a difficult yet ultimately radiant and liberating one.



MARK HENSON • *Illusion of Reality*, 1993 • oil on canvas
<http://markhensonart.com/all-art-gallery-shop/illusion-of-reality>

*Most of us who were raised in the '60s and '70s have "been there"/"done that",
or knew someone who had "been there"/"done that"
We may have visited someone like this poor soul...*

In a shabby room, in any big city, a broken man lies dead or near death. From his pipe, a vision of what all of humanity seeks wafts towards the ceiling. Paradise, the face of a woman, brotherhood, harmony with nature and spirit, the heart of human existence is but a vision. His table is filled with a cornucopia of escape mechanisms, anything to quash the pain of existence. A nuclear bomb goes off on the TV set, as the newspaper proclaims the next war. The toxic environment was not the drug of his choice. The room overlooks a desolate urban nightmare. Pollution hangs over a garish street scene. Ladies of the night stand on the corner; cops roust folks on the opposite street as Krishna devotees sing their mantras hoping to bring a bit of divinity to the situation. In the hotel across the way, an artist peers through his window. In rooms nearby, various people escape in their own ways from their collective self-created miseries.

It's our war on us.

– Commentary by Monti Moore

STREET NAMES FOR COMMONLY ENCOUNTERED PSYCHOACTIVES

Zevic Mishor

Christopher J. Ward
Daniel Leuenberger
Emma Metcalf
Igor Domsac
Isla Camille Duporge
Jacob Potkonyak
João Gonçalves
Kai Schulze
Karin Silenzi de Stagni
Kim Penders
Marc B. Aixalà
Maria Carmo Carvalho
Natacha Ribeiro
Snu Voogelbreinder

The following lists are intended as a quick reference: an alphabetically ordered guide for “translating” street names of commonly encountered psychoactives into their more standard versions (for example, cannabis, cocaine, LSD, and so forth). In this first edition of the Manual, we present names in six languages: Dutch, English, French, German, Portuguese, and Spanish. Where possible, we have tried to preserve region-specific information (for example, usage of a term in Australian- versus American-English, or European- versus Mexican-Spanish). Botanical names are given, as per standard practice, in *italics* (for example, *Salvia divinorum*); however, more commonly used terms are written normally (for example, cannabis, psilocybin-containing mushrooms, and so forth).

These lists must be considered a work in progress; indeed, the very knowledge they are attempting to capture is constantly changing due to the nature of day-to-day spoken language. We welcome any additions or feedback, which can be provided to us at <http://www.psychsitter.com>.

DUTCH

STREET NAME	PSYCHOACTIVE
ACID	LSD
BALLON	NITROUS OXIDE
BLOW	COCAINE
BRUINE	HEROIN
CHRYSTALLEN	MDMA
COKE	COCAINE
EEN BLOWTJE	CANNABIS
GRAS	CANNABIS
HASJ	HASHISH
KET	KETAMINE
LIQUID	GHB
M	MDMA
MAGIC TRUFFELS	PSILOCYBIN-CONTAINING MUSHROOM SCLEROTIA
MD	MDMA
MOLLY	MDMA
PADDOS	PSILOCYBIN-CONTAINING MUSHROOMS
PEP	AMPHETAMINE
PHILOSOPHER'S STONES	PSILOCYBIN-CONTAINING MUSHROOM SCLEROTIA
SHIT	HASHISH
SKUNK	CANNABIS
SMACK	HEROIN
SNELLE	AMPHETAMINE
SPECIAL K	KETAMINE
SPEED	AMPHETAMINE
STOELTJES	PSILOCYBIN-CONTAINING MUSHROOMS
STUFF	HASHISH
TRIPCACTUS	MESCALINE-CONTAINING CACTI
TRIPS	LSD
TRUFFEL	PSILOCYBIN-CONTAINING MUSHROOM SCLEROTIA
VLOEIBARE	GHB
VLOEIBARE XTC	GHB
WEED	CANNABIS
WIET	CANNABIS
WITTE	COCAINE
ZEGELS	LSD



MDMA may be sold pressed into pills (as shown here from the 2010 Boom Festival), or it may be available as crystalline chunks or powder. Photo by Erowid.


Commonly described by dealers at the 2008 Boom Festival as being “mescaline”, these very tiny stars were actually LSD microdots. Photo by Erowid.



The “Fly Agaric” (*Amanita muscaria*) contains the psychoactive chemicals ibotenic acid and muscimol. Due to their sometimes-less-than-pleasant effects, other mushrooms—those that contain the psychedelics psilocybin and psilocin—are much more popular among festival attendees. Photo by Jon Hanna, 2009.

ENGLISH

STREET NAME	PSYCHOACTIVE
5-MEO	5-METHOXY-DIMETHYLTRYPTAMINE
ACID	LSD
ADDERALL	SALTS OF RACEMIC AMPHETAMINE AND DEXTROAMPHETAMINE (PRESCRIPTION DRUG)
ANGEL DUST	PHENCYCLIDINE (PCP)
ANGEL'S TRUMPET	<i>BRUGMANSIA</i> AND <i>DATURA</i> SPECIES (CONTAIN TROPANE ALKALOIDS)
BASE	COCAINE FREEBASE (USA AND UK) — OR — METHAMPHETAMINE (IN IMPURE FORM; AUSTRALIA)
BICCIE	MDMA (PILL, OFTEN CONTAINING ADULTERANTS; AUSTRALIA)
BISCUIT	MDMA (PILL, OFTEN CONTAINING ADULTERANTS; AUSTRALIA)
BLUE MEANIES	PSILOCYBIN-CONTAINING MUSHROOMS (<i>PANAEOLUS CYANESCENS</i> , ALTHOUGH SOMETIMES APPLIED TO ANY BLUING PSILOCYBIN MUSHROOM)
BROWN	HEROIN, USUALLY FREEBASE (UK)
BRUG	<i>BRUGMANSIA</i> SPECIES (CONTAIN TROPANE ALKALOIDS)
BUD	CANNABIS (FEMALE FLOWER CLUSTER)
BULBS	NITROUS OXIDE (WHEN IN METAL BULBS / CARTRIDGES SOLD FOR MAKING WHIPPED CREAM)
C	COCAINE
CHANGA	DMT (DIMETHYLTRYPTAMINE) MIXED WITH A HERBAL SMOKING MIXTURE THAT INCLUDES A MONO-AMINE OXIDASE INHIBITOR (MAOI)
CHARAS	CANNABIS (CONCENTRATED RESIN PREPARATION)
CHARLIE	COCAINE
CHINA WHITE	HEROIN
CHOOF	CANNABIS (AUSTRALIA)
CHRONIC	CANNABIS (NOT TO BE CONFUSED WITH SMOKING BLENDS MARKETED AS "KRONIC" THAT MAY CONTAIN SYNTHETIC CANNABIMIMETIC AGENTS)
COKE	COCAINE
CRACK	COCAINE FREEBASE — OR — METHAMPHETAMINE CRYSTALS (AUSTRALIA)
CRANK	AMPHETAMINES (GENERAL TERM)
CRYSTAL	METHAMPHETAMINE
CUBES / CUBIES	PSILOCYBIN-CONTAINING MUSHROOMS (<i>PSILOCYBE CUBENSIS</i>)



A variety of packages used to market 5 mg tablets of 2C-B (4-bromo-2,5-dimethoxyphenethylamine).
Scan by Jon Hanna, 2014.



The *Banisteriopsis caapi* vine contains monoamine oxidase inhibiting harmala alkaloids, allowing the DMT from *Psychotria viridis* to become orally active in an ayahuasca brew.
Photo from the 2006 Mind States conference in Costa Rica by Jon Hanna.

Moulded with a Mesoamerica glyph, this disc containing delicious Belgian chocolate plus 16 grams of *Psilocybe atlantis sclerotia* was the perfect vehicle for a psychedelic experience at the 2010 Boom Festival.
Photo by Erowid.



ENGLISH

CONTINUED...

STREET NAME	PSYCHOACTIVE
DATURA	<i>BRUGMANSIA</i> OR <i>DATURA</i> SPECIES (CONTAIN TROPANE ALKALOIDS)
DESOXYN	METHAMPHETAMINE (PRESCRIPTION DRUG)
DEX	AMPHETAMINES (PRESCRIPTION DRUG)
DEXEDRINE	AMPHETAMINES (PRESCRIPTION DRUG)
DEXXIES	AMPHETAMINES (PRESCRIPTION DRUG)
DIMITRI	DMT (DIMETHYLTRYPTAMINE)
DINGER	MDMA (PILL, OFTEN CONTAINING ADULTERANTS; AUSTRALIA)
DOPE	HEROIN (ALSO USED FOR CANNABIS)
DRAW	CANNABIS (UK)
ECCIES	MDMA
ECSTASY	MDMA
ELF SPICE / SPICE	DMT (DIMETHYLTRYPTAMINE)
FANTA	GHB (AUSTRALIA)
FANTASY	GHB
FLY AGARIC	<i>AMANITA MUSCARIA</i> MUSHROOMS
FOXY / FOXY METHOXY	5-METHOXY-DIPT (5-METHOXY-DI-ISOPROPYLTRYPTAMINE)
G	GHB
GANJA	CANNABIS
GAS	NITROUS OXIDE — OR — METHAMPHETAMINE IN IMPURE FORM (AUSTRALIA)
GBH	GHB
GEAR	HEROIN (AUSTRALIA AND UK)
GLASS	METHAMPHETAMINE
GOLD TOPS	PSILOCYBIN-CONTAINING MUSHROOMS
GRASS	CANNABIS
GREEN	CANNABIS
H	HEROIN
HAMMER	HEROIN
HEADS	CANNABIS (FEMALE FLOWER CLUSTERS; AUSTRALIA)
HERB	CANNABIS (ALTHOUGH COULD ALSO REFER TO ANY HERB)
HIPPY CRACK	NITROUS OXIDE
ICE	METHAMPHETAMINE
JAZZ CIGARETTE	CANNABIS CIGARETTE (ALTHOUGH THIS ONE SOUNDS LIKE AN ARCHAIC AND OBSOLETE TERM, IT IS STILL USED WITH HUMOUR TODAY)

STREET NAME	PSYCHOACTIVE
JIMSONWEED	<i>DATURA</i> SPECIES (CONTAIN TROPANE ALKALOIDS)
JUNK	HEROIN
K	KETAMINE
K BOMBS	KETAMINE (INSTEAD OF MDMA IN STREET TABLETS)
KIM	KETAMINE (INTRAMUSCULAR) [K IM]
KITTY / KIT KAT	KETAMINE
LAUGHING GAS	NITROUS OXIDE
LIBERTY CAPS	PSILOCYBIN-CONTAINING MUSHROOMS (<i>PSILOCYBE SEMILANCEATA</i>)
LIQUID	LSD IN A (USUALLY) CLEAR LIQUID CARRIER SUBSTANCE
LIQUID ECSTASY	GHB
LUCY	LSD
MAGIC MUSHROOMS	PSILOCYBIN-CONTAINING MUSHROOMS (ALTHOUGH MIGHT ALSO BE APPLIED TO <i>AMANITA MUSCARIA</i> OR <i>A. PANTHERINA</i>)
MD	MDMA
MEOW MEOW	MEPHEDRONE
MEP	MEPHEDRONE
METHEDRINE	METHAMPHETAMINE
MOLLY	MDMA
MOONFLOWER	<i>DATURA</i> SPECIES (CONTAIN TROPANE ALKALOIDS)
MUSHIES	PSILOCYBIN-CONTAINING MUSHROOMS
NANG	NITROUS OXIDE
NITROUS	NITROUS OXIDE
NOS	NITROUS OXIDE
PANTHER CAP	<i>AMANITA PANTHERINA</i> MUSHROOM
PAPER	LSD (BLOTTER PAPER)
PEP	AMPHETAMINES (GENERAL TERM)
PERUVIAN TORCH CACTUS	<i>TRICHOCEREUS PERUVIANUS</i> (CONTAINS MESCALINE)
PEYOTE CACTUS	<i>LOPHOPHORA WILLIAMSII</i> (CONTAINS MESCALINE)
PHARMAHUASCA	DMT (DIMETHYLTRYPTAMINE) + PHARMACEUTICAL MONOAMINE OXIDASE INHIBITOR (MAOI, OFTEN MOCLOBEMIDE), TAKEN ORALLY
PILL	MDMA (PILL, OFTEN CONTAINING ADULTERANTS, ALTHOUGH CAN ALSO BE USED FOR ANY TABLET)
PINGER	MDMA (PILL, OFTEN CONTAINING ADULTERANTS: AUSTRALIA)
POT	CANNABIS
PSILOS	PSILOCYBIN-CONTAINING MUSHROOMS
ROCK	COCAINE FREEBASE

ENGLISH

CONTINUED...

STREET NAME	PSYCHOACTIVE
RUSH	MEPHEDRONE
SALLY / SALLY D	<i>SALVIA DIVINORUM</i>
SAN PEDRO CACTUS	<i>TRICHOCEREUS PACHANOI</i> , AND SOMETIMES OTHER <i>TRICHOCEREUS</i> SPECIES (CONTAINS MESCALINE)
SHABS	METHAMPHETAMINE (AUSTRALIA)
SHABU	METHAMPHETAMINE (FILIPINO)
SHARDS	METHAMPHETAMINE
SHROOMS	PSILOCYBIN-CONTAINING MUSHROOMS
SID	LSD
SMACK	HEROIN
SMOKE	CANNABIS
SPECIAL K	KETAMINE
SPEED	AMPHETAMINES (GENERAL TERM)
SPEED BOMBS	METHAMPHETAMINE / AMPHETAMINE (INSTEAD OF MDMA IN STREET TABLETS)
SPLIFF	CANNABIS OR CANNABIS + TOBACCO (EITHER AS A ROLLED CIGARETTE OR AS A GENERALISED TERM)
SUBS	PSILOCYBIN-CONTAINING MUSHROOMS (<i>PSILOCYBE SUBAERUGINOSA</i>)
TABS	LSD (EITHER AS TABLETS OR ON BLOTTER PAPER)
TAR / BLACK TAR	HEROIN (AMERICA)
TREE DATURA	<i>BRUGMANSIA</i> SPECIES (CONTAIN TROPANE ALKALOIDS)
TRIP	LSD
TRIPSTACY	2C-X OR 2C-T-# (INSTEAD OF MDMA IN STREET TABLETS; AUSTRALIA)
WACKY BACCY / WACKY TOBACCY	CANNABIS
WEED	CANNABIS
WHIPPITS / WHIP-ITS	NITROUS OXIDE (WHEN IN METAL BULBS / CARTRIDGES SOLD FOR MAKING WHIPPED CREAM; DERIVED FROM THE BRAND-NAME "WHIP-IT!")
WHIZZ	METHAMPHETAMINE (IN IMPURE FORM; AUSTRALIA)
X	MDMA
YARNI	CANNABIS (AUSTRALIAN INDIGENOUS TERM)

"Angel's Trumpet", "Brug", "Datura", "Jimsonweed", and "Moonflower", are all names given to plants from the Brugmansia and Datura genera, which contain somewhat dangerous deliriant/hallucinogenic tropane alkaloids that often produce bad trips when taken recreationally. Photo from the 2006 Mind States Costa Rica conference by Jon Hanna.



One of the "Rainbow Roll" Cannabis sativa/C. indica hybrid strains from a 2011 Northern California medical marijuana garden. Photo by Erowid.

"San Pedro" (or Echinopsis pachanoi [= Trichocereus pachanoi]) cacti is a visionary sacrament used by some indigenous and mestizo shamans within South America; it contains mescaline, similar to peyote (Lophophora williamsii) used by the Native American Church in the United States and the Huichol Indians in Mexico. Due to the nausea and vomiting associated with mescaline, San Pedro is not as popular on the festival circuit as other psychedelics or empathogens, such as LSD, mushrooms, or MDMA. Photo by Jon Hanna, 2014.



FRENCH

STREET NAME	PSYCHOACTIVE
ACIDE	LSD
AMPHÉ THAI	METHAMPHETAMINE
BAT	CANNABIS (CIGARETTE; QUEBEC)
BEUH	CANNABIS
BEUHER	CANNABIS
BEURRE DE MARRAKECH	CANNABIS (DISSOLVED IN BUTTER)
BRUN	HASHISH
BUVARD	LSD (BLOTTER PAPER)
C	COCAINE
CARTONS	LSD (BLOTTER PAPER)
CHAMP	PSILOCYBIN-CONTAINING MUSHROOMS
CHAMPIGNONS MAGIQUE	PSILOCYBIN-CONTAINING MUSHROOMS
CHAMPIS	PSILOCYBIN-CONTAINING MUSHROOMS
CHICHON	HASHISH
COCO	COCAINE
COKE	COCAINE
COM	HASHISH
CÔNE	CANNABIS (CIGARETTE)
CRISTAUX	MDMA
DE BUT	CANNABIS
ECSTASY	MDMA
EXTA	MDMA
GOUTTE	LSD (DROP)
HASH	HASHISH
HERBE	CANNABIS
HERBE DES DIEUX	<i>SALVIA DIVINORUM</i>
JOINT	CANNABIS (CIGARETTE)
K	KETAMINE
KETA	KETAMINE
LIGNE	COCAINE
MAGIE-JUANA	CANNABIS
MARRON	HASHISH
MD	MDMA
MICROPOINTE	LSD (MICRODOT)
MUSH	PSILOCYBIN-CONTAINING MUSHROOMS (QUEBEC)

"Changa" smoking mixtures containing DMT and harmala alkaloids—such as this sample photographed at the 2010 Boom Festival—have become increasingly popular in recent years.
Photo by Erowid.



Known as "Laughing Gas", "Hippie Crack", "Whip-its" (a brand), "Nang", "Nos", "Bulbs" (for the small metal cartridges that it comes in when sold as a propellant for making whipped cream), or "Ballon" (in Dutch, for the balloons from which it is commonly inhaled), nitrous oxide is often a popular psychoactive at festivals.
Photo of various brands of spent nitrous cartridges by Jon Hanna, 2014.

This crystalline MDMA was being sold at the 2010 Boom Festival under the street name "Sass", a slang term that has also been used for MDA and other chemically similar empathogens. Some dealers/users claim that "Sass" is a "more natural" (or less refined) version of MDMA or MDA, due to their belief that a precursor chemical that can be used in the production of these drugs, safrole, was created out of sassafras oil obtained from the root of a tree in the Sassafras genus.
Photo by Erowid.



FRENCH

CONTINUED...

STREET NAME	PSYCHOACTIVE
OUINJ	CANNABIS (CIGARETTE)
PANO	LSD (BLOTTER PAPER)
PARACHUTE	MDMA (POWDER WRAPPED IN PAPER)
PÉTARD	CANNABIS (CIGARETTE)
PETRI	LSD
PILLS	MDMA
PILON	CANNABIS (CIGARETTE)
PILON	MDMA (SWITZERLAND)
PLOMB	MDMA
POUDRE	COCAINE
PSILO	PSILOCYBIN-CONTAINING MUSHROOMS
RABLA	HEROIN (CHEAP VARIETY)
RASHASHA	OPIUM
SALADE	CANNABIS
SALVIA	<i>SALVIA DIVINORUM</i>
SAV	HASHISH (LARGE BLOCK)
SAVONETTE	HASHISH (LARGE BLOCK)
SEUM	HASHISH
SHIT	HASHISH
SHROOM	PSILOCYBIN-CONTAINING MUSHROOMS
SPACE CAKE	CANNABIS (CAKE)
SPECIAL K	KETAMINE
SPEED	AMPHETAMINE
SPEEDBALL	HEROIN + COCAINE
SPLIF	CANNABIS OR CANNABIS + TOBACCO (CIGARETTE)
STICK	CANNABIS (CIGARETTE)
TARPÉ	CANNABIS (CIGARETTE)
TAZ	MDMA
TEUCHI	HASHISH
THC	CANNABIS
TIGE	CANNABIS (CIGARETTE)
TONCAR	LSD (BLOTTER PAPER)
TONJ'	CANNABIS
TRACE	COCAINE
TRAIT	COCAINE

STREET NAME	PSYCHOACTIVE
TRIP	LSD
TRUFFES	PSILOCYBIN-CONTAINING MUSHROOMS
UN DARD	CANNABIS (CIGARETTE)
WEED	CANNABIS (CIGARETTE)
XE	MDMA



Depicted to the left are 30 mg scored generic Adderall pills, a prescription stimulant made from a mixture of four racemic salts: amphetamine aspartate, amphetamine sulphate, dextroamphetamine saccharate, and dextroamphetamine sulphate.

On the street, various amphetamines may be known as "Crank", "Dex"/"Dexies"/"Dexxies", "Feijão Mágico", "González", "Pep", "Pepp", "Pille", "Snelle", and, most commonly, "Speed".
Photo by Jon Hanna, 2014.



Available as a prescription called Desoxyn (and formerly sold using the brand name Methedrine), methamphetamine hydrochloride is a popular stimulant on the illicit market; users may consume it orally, snorted, smoked, or injected. On the street it is known as "Crank", "Crystal", "Glass", "Ice", "Meta", "Meth", "Shabs", "Shabu", "Shards", "Speed", "Tweak"/"Tweek", "Whizz", "Yaba", "Yama", and various other names. Photo by Erowid, 2014.

GERMAN

STREET NAME	PSYCHOACTIVE
ACID	LSD
ADAM	MDMA
ANGEL DUST	PCP
BOMBE	AMPHETAMINES (PACKED INTO A CIGARETTE PAPER AND SWALLOWED)
BRAUNES	HEROIN (NOT CLEAN) — OR — HASHISH
BUFF	CANNABIS — OR — HASHISH
C	COCAINE
CANDYFLIP	MDMA + LSD
COKIE	COCAINE
COOKIE	CANNABIS COOKIES — OR — HASH COOKIES
CRYSTAL	METHAMPHETAMINE
DEEP PURPLE	LSD
DIAZ	DIAZEPAM
DOPE	HASHISH
E	ECSTASY — OR — AMPHETAMINE
ENGELSSTAUB	PCP
ETHNOFLIP	MDMA + PSILOCYBIN-CONTAINING MUSHROOMS
GANJA	CANNABIS
GRAS	CANNABIS
GRÜNES	CANNABIS
H	HEROIN
HERO	HEROIN
HOHES	COCAINE
K	KETAMINE
KOKS	COCAINE
LADY	LSD
LIQUID ECSTASY	GHB
MANDY	MDMA
NEXUS	2C-B
PAPPE	LSD (BLOTTER PAPER)
PEACE	HASHISH — OR — PCP

STREET NAME	PSYCHOACTIVE
PEPP	AMPHETAMINE
PILLE	AMPHETAMINE — OR — MDMA — OR — OTHER DRUGS IN TABLET FORM
PILZE	PSILOCYBIN-CONTAINING MUSHROOMS
POLLEN	CANNABIS
POTT	HASHISH
PSILOS	PSILOCYBIN-CONTAINING MUSHROOMS
PUDER	COCAINE
RAKETE(N)	LSD + PCP
ROTZE	COCAINE
SCHNEE	COCAINE
SCHORE	HEROIN
SHERMAN HEMSLEY	PCP
SHIT	HASHISH
SHORE	HEROIN
TICKET	LSD
TIEFES	HEROIN
WEED	CANNABIS
WEIßES	COCAINE
YABA	METHAMPHETAMINE
YAMA	METHAMPHETAMINE
ZETTEL	LSD (BLOTTER PAPER)
ZEUG	HEROIN

Four hits of the "Shiva" blotter acid that was making the rounds at the 2010 Boom Festival; each hit was reportedly quite strong.
Photo by Erowid.



PORTUGUESE

STREET NAME	PSYCHOACTIVE
ÁCIDO	LSD
ALBERTO	LSD
ALFACE	CANNABIS
BASE	COCAINE FREEBASE
BAZUCADA	COCAINE
BITOLA	ECSTASY
BRANCA	COCAINE
BRITA	COCAINE
CANHÃO	CANNABIS (CIGARETTE)
CARTOLINA	LSD (BLOTTER PAPER)
CASTANHA	HEROIN
CAVALO	HEROIN
CHAMON	CANNABIS (CONCENTRATED PREPARATION)
CHARRO	CANNABIS (CIGARETTE)
CHARUTOS	CANNABIS (CIGARETTE)
CHINESA	HEROIN (SMOKED)
CHINESINHA	COCAINE (SMOKED) — OR — HEROIN (SMOKED)
CHUTO	HEROIN (INJECTED) — OR — COCAINE (INJECTED)
COCA	COCAINE
COGUMELOS	PSILOCYBIN-CONTAINING MUSHROOMS (ALSO USED FOR PSYCHOACTIVE MUSHROOMS IN GENERAL)
CRACK	COCAINE FREEBASE
CRISTAL	MDMA (IN CRYSTALLINE FORM)
CUGUIS	PSILOCYBIN-CONTAINING MUSHROOMS (ALSO USED FOR PSYCHOACTIVE MUSHROOMS IN GENERAL)
DAIME	AYAHUASCA
DROP	LSD (LIQUID)
ERVA	CANNABIS
FALOPA	COCAINE
FARINHA	COCAINE
FARLOPA	COCAINE
FARLUPA	COCAINE
FEIJÃO MÁGICO	AMPHETAMINE
FUMOS	CANNABIS

STREET NAME	PSYCHOACTIVE
GANZA	CANNABIS
GELATINA	LSD
GONZÁLEZ	AMPHETAMINE
GOTA	LSD (LIQUID)
HAXE	CANNABIS (CONCENTRATED PREPARATION)
HAXIXE	CANNABIS (CONCENTRATED PREPARATION)
HOFMANN	LSD
KETA	KETAMINE
KIZA	COCAINE
KRUGUERS	PSILOCYBIN-CONTAINING MUSHROOMS (ALSO USED FOR PSYCHOACTIVE MUSHROOMS IN GENERAL)
MANUEL DAMÁSIO	MDMA
MÁRIO	MDMA
MÁRIO DIAS	MDMA
MD	MDMA
MEL	CANNABIS
MIAU-MIAU	MEPHEDRONE
MICRO	LSD (MICRODOT)
MUSHYS	PSILOCYBIN-CONTAINING MUSHROOMS (ALSO USED FOR PSYCHOACTIVE MUSHROOMS IN GENERAL)
PAIVA	CANNABIS
PAPEL	LSD
PARPALHO	CANNABIS
PASTILHA	MDMA (PILL, OFTEN CONTAINING ADULTERANTS)
PÓ	COCAINE (COMMONLY, BUT CAN ALSO MEAN HEROIN)
POLEN	CANNABIS (CONCENTRATED PREPARATION)
POMBO	CANNABIS
PORRO	CANNABIS (CIGARETTE)
RODA	MDMA (PILL, OFTEN CONTAINING ADULTERANTS)
SELO	LSD
SPEED	AMPHETAMINE
SPEEDBALL	COCAINE + HEROIN (INJECTED)
TILHA	MDMA (PILL)
TRIP	LSD
TÚLIA	COCAINE
WELLA	CANNABIS
XITO	CANNABIS


SPANISH

STREET NAME	PSYCHOACTIVE
ABUELA	AYAHUASCA
ABUELITA	AYAHUASCA
ACEITE	HASHISH (OIL)
ÁCIDO	LSD
AJO	LSD
ALFALFA	CANNABIS
ANGOLEÑA	CANNABIS
APALEAO	HASHISH
ARIMBA	CANNABIS
AVISPA	HEROIN
AZÚCAR MARRÓN	HEROIN
BACALAO	HEROIN
BAZUCO	COCAINE FREEBASE
BELLOTA	HASHISH
BERNICE	COCAINE
BIBERÓN	GHB
BICHO	LSD (SOUTH OF SPAIN) — OR — MDMA (PILL; ARGENTINA)
BOMBETA	MDMA
BREVA	CANNABIS (CIGARETTE)
BROWN	HEROIN
BUCO	HEROIN (INJECTED)
BURRO	HEROIN
CABALLO	HEROIN
CALIFORNIANO	LSD
CALIQUEÑO	CANNABIS (CIGARETTE)
CAMERUSA	COCAINE
CAMISA	COCAINE — OR — HEROIN
CANDELO	CANNABIS (CIGARETTE)
CANUTO	CANNABIS (CIGARETTE)
CHAMPIS	PSILOCYBIN-CONTAINING MUSHROOMS
CHICLE	HASHISH
CHINA	HASHISH
CHINO	HEROIN (SMOKED)



The humble poppy seed pod (*Papaver somniferum*), source of painkilling opiates such as morphine and codeine, and inspiration for semi-synthetic opioids such as heroin and oxycontin.
Photo by Jon Hanna, 2009.

The *Erythroxylum coca* plant is celebrated in Bolivia, where it is commonly chewed, brewed as tea (shown here), and incorporated into various foods, including candies and an energy drink launched in 2010 called Coca Colla. Such uses do not seem to be as problematic as the pure alkaloid cocaine can sometimes be.
Photo by Jon Hanna, 2014.



Alcohol remains one of the most popular psychoactives at many festivals, as this wall of beer available at the 2008 Boom Festival attests to.
Photo by Erowid.

SPANISH CONTINUED...

STREET NAME	PSYCHOACTIVE
CHIPITURCA	CANNABIS
CHIRI	CANNABIS (CIGARETTE)
CHIVA	HEROIN
CHIVO	HEROIN (MEXICO)
CHOCOLATE	HASHISH
CHUFLA	MDMA PILL
CHURRO	CANNABIS (CIGARETTE)
CHUTE	HEROIN
COCA	COCAINE
COCA COLA	COCAINE
COIS	COCAINE (MEXICO)
CONO	LSD
COPOS	COCAINE
COSTO	HASHISH
CRISTAL	MDMA — OR — COCAINE FREEBASE (MEXICO)
DIMITRI	DMT (DIMETHYLTRYPTAMINE)
DULCE	COCAINE
EME	MDMA
ESTRELLA	LSD
ÉXTASIS	MDMA
ÉXTASIS LÍQUIDO	GHB
FARLA	COCAINE
FARLOPA	COCAINE
FASO	CANNABIS (CIGARETTE)
FILETE DE MERLUZA	COCAINE
FINA	COCAINE
FLAI	CANNABIS (CIGARETTE)
FLAN	COCAINE
FLY	CANNABIS (CIGARETTE)
FUEL	HASHISH
FUL	HASHISH
GALLO	CANNABIS (CIGARETTE)
GAMBA	COCAINE
GENA	HASHISH
GOMA	HASHISH

STREET NAME	PSYCHOACTIVE
GOTA	LSD
GRIFA	CANNABIS
H	HEROIN
HENNA	HASHISH
HONGOS	PSILOCYBIN-CONTAINING MUSHROOMS (ALTHOUGH THIS IS ALSO THE COMMON WORD FOR MUSHROOMS IN GENERAL; MEXICO & SPAIN)
HUEVO	HASHISH
JACO	HEROIN
JAIMITO	LSD
JALI	HASHISH
JAMILA	CANNABIS
K	KETAMINE
KETA	KETAMINE
KIT KAT	KETAMINE
LENTEJA	LSD
M	MDMA
MACOÑA	CANNABIS
MAI	CANNABIS (CIGARETTE)
MAMUCO	CANNABIS (CIGARETTE)
MANDANGA	CANNABIS — OR — COCAINE
MANTECA	HEROIN
MANZANERO	AMPHETAMINE
MARCHOSA	COCAINE
MARIACHI	CANNABIS + HASHISH
MEFE	MEPHEDRONE
MERCA	COCAINE
META	METHAMPHETAMINE — OR — METHADONE
MIAU	MEPHEDRONE
MICROPUNTO	LSD (MICRODOT)
MOIS	CANNABIS (MEXICO)
MONGUIS	PSILOCYBIN-CONTAINING MUSHROOMS
MOTA	CANNABIS
NENA	MDMA (PILL)
NEVADITO	TOBACCO OR CANNABIS CIGARETTE, MIXED WITH COCAINE
NEVADO	TOBACCO OR CANNABIS CIGARETTE, MIXED WITH COCAINE

SPANISH CONTINUED...

STREET NAME	PSYCHOACTIVE
NEXUS	2C-B
NIEVE	COCAINE
ORANGE	LSD
PAJA	CANNABIS (CIGARETTE)
PALA	COCAINE
PASTI	MDMA (PILL)
PASTILLA	MDMA (PILL)
PEPAS	MDMA (PILL)
PERICO	COCAINE
PETA	CANNABIS (CIGARETTE)
PETARDO	CANNABIS (CIGARETTE)
PICHU	AMPHETAMINE
PICO	HEROIN
PIEDRA	HASHISH
PIRULAS	MDMA (PILLS)
PITO	CANNABIS (CIGARETTE)
PITXU	AMPHETAMINE
PLATA	HEROIN (SMOKED)
POLEN	HASHISH
PORRO	CANNABIS (CIGARETTE)
POSTRE	COCAINE
POSTURA	HASHISH
POTE	GHB
POTRO	HEROIN
PRIVA	ALCOHOL
REINA	HEROIN
ROSAMARÍA	CANNABIS
RULA	MDMA (PILL)
SALTAPERICO	LSD
SECANTE	LSD
SELLO	LSD
SPECIAL K	KETAMINE
SPEED	AMPHETAMINE
SPEED BALL	HEROIN + COCAINE
TACHA	MDMA (PILL)


STREET NAME	PSYCHOACTIVE
TAILANDESA	HEROIN
TATANO	HEROIN
TATE	HASHISH
TOBOGÁN	HEROIN (SMOKED)
TOQUE	CANNABIS (CIGARETTE)
TOSTIS	MDMA (PILLS)
TRINQUI	ALCOHOL
TRIPA	LSD
TRIFI	LSD
TRÓCOLO	CANNABIS (CIGARETTE)
TROMPETA	CANNABIS (CIGARETTE)
TRONCHO	CANNABIS (CIGARETTE)
TURRÓN	HEROIN
VITAMINA K	KETAMINE
VOLCÁN	LSD
YERBA	CANNABIS
YOE	CANNABIS (CIGARETTE)
ZARPA	COCAINE



A few different brands of injectable ketamine. On the festival market, ketamine is more frequently sold as a powder, which is taken intra-nasally. Photo by Jon Hanna, 1999.

In recent years, several powerful psychedelics, such as bromo-dragonfly (shown left), DOI (shown right), and some NBOMe compounds (not depicted), have begun to appear on blotter. These drugs have a different risk profile associated with each of them, as compared to LSD, and unfortunately they are sometimes misrepresented or mistaken for LSD. BDF and DOI blotters shown are from the 2008 Boom Festival. Photo by Erowid.





GWYLLM LLWYDD • *Event Horizon*, 2014 • India ink, digital corrections
<http://www.gwyllm-art.com>

MONITORING, EVALUATING AND RESEARCHING— RECOMMENDATIONS FROM AN ACADEMIC PERSPECTIVE FOR AN EVIDENCE-BASED APPROACH TO PSYCHOACTIVE CRISIS INTERVENTION

Maria Carmo Carvalho

Mariana Pinto de Sousa

Implementing a successful care service doesn't solely depend on your capacity to guarantee a skilled and trained team, appropriate intervention strategies, or adequate resources. Furthermore, an appraisal of these factors frequently isn't really formed until well after work in the field has commenced. This seems to be the case with all interventions occurring where guidelines and experiences haven't been systematically reported and documented, as often occurs in the case of psychedelic support. It is every intervention agent's responsibility to contribute in order to change this scenario.

The only way of doing so is to *monitor* your activity, making sure you have accomplished your intervention goals, and to share the product of your work with your colleagues. This is the kind of approach that will allow you to grow from spontaneous and informal action into an evidence-based care service. Please note that some topics in this Appendix are also covered in [Chapters 10, "Running the Service"](#) and [15, "Risk Management and Performance Improvement"](#).

Finally, where legal considerations do not preclude the ability to do so, you may wish to consider using your care service for scientific research purposes. Care services for psychedelic support at recreational settings present unique opportunities to get in touch with research subjects who can be difficult to sample elsewhere. Data regarding their personal backgrounds and experiences is a potentially precious contribution to scientific knowledge in many diverse domains (including pharmacology, health studies, psychology, anthropology, sociology, criminology, and more) and research themes (risk behaviour, drug use patterns, life trajectories, transpersonal experiences, psychopathology, and so forth). Implementing research is a demanding task, and it is clearly not an essential requirement for the effective facilitation of a psychedelic care service. So our purpose here is simply to present examples of what *could* be achieved, should you have the required resources and skills, and decide to go ahead with conducting some manner of scientific study. We develop this approach under “Research” below.

1. Feedback and Monitoring

Gathering basic information about your guests and their experiences at the care service ensures you get feedback about what is happening, allowing you to monitor your interventions in the field. That information is useful for clinical purposes, since it provides you with an opportunity to get to know your guests and decide how to best respond to their needs. In the field you will encounter a diversity of individuals presenting varying requests, symptoms, and predicaments. It is often the case that you will expect some of these situations, whilst others may catch you off-guard. During care work you will also find the need to pass along information from a guest to a colleague or team lead who replaces you in the next shift, or to medical personnel who become involved with a guest’s care. There is much variation between care services in terms of event type, number of care team members, and complexity of team management. As an event and its corresponding care service increase in size, the challenges posed to gathering data about guests are also expected to increase.

Below we outline some of critical aspects you should consider regarding data collection. When building your data collection forms, you should endeavour to use easily manageable formats that facilitate consultation of the information whilst in the field (when you need it), and provide a structure for future data analysis (if applicable). We will present suggestions on how to do this, along with practical examples.

VISITOR DEMOGRAPHICS

1. Name:	
2. Age: <input type="checkbox"/> Actual <input type="checkbox"/> Estimated	3. Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female
4. Nationality and language(s) spoken:	
5. Number of times at the service: <input type="checkbox"/> One <input type="checkbox"/> Two or more	6. Number of times at the event: <input type="checkbox"/> One <input type="checkbox"/> Two or more

People who first encounter a guest in trouble are the ones who are often most able to offer details that will help in understanding the guest’s needs, particularly in situations where the individual isn’t communicating verbally. At large-scale events, a guest might be brought in by other event services in the field (including medical and security services), by other staff at the event, by care service staff, by friends, or by a well-meaning passer-by. If the guest has lost consciousness at any point or if they have trouble recalling what happened prior to the admission, they will probably ask you about the circumstances that brought them to the service once they become more coherent. To be able to offer this feedback is frequently reassuring for the individual. In cases where the guest was brought in by friends, it is very important to keep track of and stay in touch with these people—they are the ones most likely to provide relevant information such as which substances were consumed, their quantities, the time(s) of ingestion, combinations, and any details on medical and/or psychiatric history. Most of all, friends may be able to offer reassurance and grounding for the guest who is likely to be suffering from all the insecurities that an unexpected and painful experience usually brings up.

The date and time of a guest’s arrival have implications for team organisation that surpass the mere identification of the situation attended. From our experience evaluating a care service, these data have helped us realise that the care service was receiving more guests on specific days of the event, which was a large scale festival that lasted for a total of eight days. In our example of Boom 2010, these were the days immediately following the beginning and immediately preceding the end of the event. Data on times that guests were received furthermore allowed us to understand that the number of guests at the care space peaked during the afternoon (15:00 to 23:00) (Carvalho et al. 2011). Future editions of the same intervention at the same event might take advantage of this information to improve human resource management.

Information regarding *substance use* is central at this point and you should allocate specific attention to a number of details including not only the substance names, but also quantities, timing of ingestions, the setting/context of

FIGURE 1:
Data Collection
Regarding Guests’
Identification

**People
who first
encountered a
guest in trouble
are the ones
who are often
most able to
offer details
that will help in
understanding
the guest’s needs,
particularly
in situations
where the
individual isn’t
communicating
verbally.**

ARRIVAL					
7. Date:		8. Time:		9. Care Giver #1:	
				10. Care giver #2:	
11. Guest was brought in by: <input type="checkbox"/> Him-/herself <input type="checkbox"/> Friend <input type="checkbox"/> Paramedics <input type="checkbox"/> Care giver <input type="checkbox"/> Other					
12. If brought in by friends, did they stay with the guest?					
13. Describe the guest's physical condition					
14. Describe the guest's psychological condition					
15. Describe presented symptoms and their severity					
16. Describe relevant physical or mental health history					
17. Regarding guest's psychoactive substance uses, describe each product, quantity of ingestions, ingestion day(s), ingestion time(s), ingestion context (where, with whom), and ingestion method (oral, smoked, injected, other)					
Product		Quantity	Day	Time	Context
17-a.					
17-b.					
17-c.					
17-d.					
17-e.					
18. This guest was brought in because he/she was:				18-a. Any additional notes related to question #18:	
<input type="checkbox"/> having an intentional but difficult experience related to PAS <input type="checkbox"/> having an accidental experience related to PAS <input type="checkbox"/> having a personal crisis not related to PAS <input type="checkbox"/> having a mental crisis concurrent with PAS use <input type="checkbox"/> having a mental crisis without any PAS use <input type="checkbox"/> not having any sort of crisis (explain reason in 18-a)					

FIGURE 2:
Data Collection
on Arrival Related
to the Use of any
PsychoActive
Substances (PAS)

**...some substances
are being used
in such high
prevalence that
their consumption
is frequently
under-reported.**

ingestions (where, with whom), method of ingestions (how), and if interaction with alcohol existed. From our experience, some substances are being used in such high prevalence that their consumption is frequently under-reported. This happens because guests tend to consider their common use as normalised behaviour that, in their perception, seems less relevant. This is the case primarily with alcohol and cannabis. Knowledge of these, however, is important for intervention; for example, a guest may have been ingesting stimulants (such as amphetamine or cocaine) alongside alcohol (a depressant), which can affect treatment choice. Our documentation has found substance use to be the most common source of symptoms presented by guests, even though other factors, including contextual emotional effects and health or psychiatric history, may also be of prime importance.

A final aspect to consider at the initial stage is a summary description of *symptoms* presented and an evaluation of the *type of crisis situation*. Symptoms and their evolution during intervention will also be part of a distinct section of the record that is solely dedicated to intervention. However, a summary of the most visible signs of distress

presented by the guest upon arrival will allow for a quick overview of the situation and aid initial decision-making. From our experience, you can expect a wide variety of crisis situations that present for assistance. At Boom Festival 2010, from an approximate total of 120 guests who visited the care service, we noted that 76% presented situations related to difficult intentional experiences with a psychoactive substance (PAS); 8.3% were mental crises that also involved the use of a PAS; 7.4% of situations didn't correspond to any sort of psychological crisis (for example, information and first aid requests); 5% related to mental (psychiatric) crisis without PAS use; 2.5% related to accidental experiences with a PAS; and 0.8% had to do with personal crisis (due to emotional and contextual factors) not related to a PAS (Carvalho et al. 2011). Knowledge of this breakdown helps you better prepare the team in terms of training emphasis.

In our experience, psychiatric situations, whether involving PAS use or not, tend to be the most demanding on a care service's resources, and are the ones you will probably feel least prepared to deal with. They are also the ones with higher probability for unsuccessful intervention, occasionally even resulting in the transfer of the guest to a medical/psychiatric facility. These guests are more likely to arrive earlier in the event, and they tend to stay for longer periods of time. They are also more likely to require prescription drugs. Despite these challenges, and provided that there is appropriate medical/psychiatric assessment and supervision, in our opinion the care service remains the most suitable place to attend to these individuals' needs at an event. To better respond to these situations, the help of qualified staff is essential. The skills required have to do not only with adequate medical and psychiatric training, but also with a good understanding of the dynamics of recreational drug settings and substance-using communities.

INTERVENTION PROCESS DESCRIPTION

This is perhaps the richest section of your data collection, since it provides feedback on clinical decisions, contains detailed qualitative content to evaluate the success of the intervention, and gathers knowledge about your guests and their PAS experiences for research purposes.

We suggest you gather information on a number of general topics that summarise your guest's episode, and then simply record in the most systematic way possible what happens, following a timeline of the guest's stay at the care space (see Figure 3, "Description of Intervention Process").

*We suggest
you gather
information on
a number of
general topics
that summarise
your guest's
episode, and
then simply
record in
the most
systematic way
possible
what happens,
following a
timeline of
the guest's stay
at the
care space...*

INTERVENTION		
19. Summarise the psychological issues that the guest was dealing with during the intervention:		
20. Describe the guest's primary emotional states during the intervention in chronological order (for example: hyper alert, anxious, calm, etc.):		
21. Summarise therapeutic strategies used with guest that seemed to help most (for example: listening; sitting with quietly; talking; music therapy; walking around; holding; wanted to be left alone, etc.). Also describe strategies used that were less helpful:		
Date:	Time:	Care giver:
Date:	Time:	Care giver:

FIGURE 3:
Description of
Intervention Process

**Take notice of
two aspects:
the date
and time
the guest left,
and how
the guest left.**

Whilst previous sections should be completed at the moment of arrival, the intervention section should be filled out during the course of care, and completed just after the guest's situation has resolved and the guest has left the care space. In this process you should register information that tells a "story", with a clear time sequence of major events, guest reactions, and care givers' decisions and their impact on the guest.

As for general topics, we suggest you try to start with a short summary of the psychological issues the guest was dealing with when intervention began, the guest's primary emotional states, and how these developed. Also include a short summary of any therapeutic strategies to which the guest responded positively. After this, simply register all major reactions, events, therapeutic decisions and strategies, and their impact on the guest, along a timeline.

INFORMATION ABOUT DEPARTURE

Your basic records for Feedback and Monitoring of intervention should conclude at the time your guest leaves the care service. Take notice of two aspects: the *date and time* the guest left, and *how* the guest left. Date and time allow you to know how many hours were spent in the care space, and thus the average length of intervention per guest or type of situation—for the care service as a whole—may eventually be calculated. For example, at KosmiCare's intervention at the 2010 Boom Festival we concluded that 52% of all guests attending the care service stayed for between one and five hours. This means that all remaining guests (48%) stayed at the care service for a minimum of six hours, which represents a considerably more lengthy intervention (Carvalho et al. 2011).

INFORMED CONSENT

All of the guest data collected at this care service is kept 100% confidential.

Within that framework of confidentiality, we are conducting scientific research that will help us increase and share knowledge regarding the use of psychoactive substances within a variety of social environments, and the unique—and sometimes challenging—mental spaces that can be inspired by the consumption of psychedelics. Information concerning your experience whilst at the care service is of great importance for us. We would very much appreciate if you agreed to allow us to use—within an entirely anonymous context—the data collected during your stay for research purposes. Please indicate your preference and sign below:

- YES** I have been informed about the objectives of this research project, and **I agree to the anonymous use of information** collected during my stay at the care service.
- NO** I have been informed about the objectives of this research project, and **I DO NOT agree to the anonymous use of information** collected during my stay at the care service.

If you agree to participate, we would be interested in checking back in with you in a few months.
If that would be okay, please neatly print your email address below.

EMAIL: _____

SIGNATURE: _____ DATE: _____

FIGURE 5:
Example of an Informed
Consent Form

You should expect a range of different reactions when an informed consent request is presented.

read and sign a document; or it may be that the guest totally rejects (and sometimes regards with intense suspicion) the idea of his/her information being used in the future. From our experience, verbal consent can be considered valuable for our purposes—if this is the case, register what occurred so you will know later why the document wasn't properly signed. If you find yourself in the scenario where a guest totally refuses to cooperate, we recommend that you destroy all personal information (for example name, age, nationality, and any notes that contain information referencing personal data, such as the names and phone numbers of friends), but retain a global record of the situation so that you can still use it as a simple indicator of the project's activity.

See [Chapter 3, "Legal Considerations"](#), for a further discussion regarding consent and record keeping. *Please note that informed consent documentation may not be deemed valid and/or legally binding when signed by an individual in any altered/intoxicated state.*

2. Evaluation

Data collection suggestions presented above for Feedback and Monitoring purposes already constitute a valuable contribution to your intervention evaluation. In the following, however, we will give a broader overview on what may be accomplished through evaluation, the questions you can expect to answer, and further indicators you may want to consider. We'll start with a short introduction to the origins of evaluation practice and what its general goals are.

Systematic empirical methodologies for intervention evaluation began to appear in the 1950s, mostly in the fields of

education and human resources (Illback, Zins, Maher & Greenberg 1990). Flaherty and Morell (1978; cited in Illback et al. 1990) refer to a number of factors that led to the increased concern for evaluating interventions, such as: guaranteeing that public funding would be distributed according to worthy criteria; researchers' increased concern for public matters; limited resources available for social sciences; and the need to improve methodologies available for evaluation itself. These factors combined have been contributing to an evolution in the way that planning and evaluation of interventions has been implemented over the last few decades.

Recognition of the importance of evaluation has been followed by the understanding that this effort should not focus on the *results* alone of intervention, but also on the process through which intervention implementation occurs (Illback, Kalafat & Sanders 1997). From here, consensus arose around the idea that programme evaluation should contribute in determining intervention efficacy and the efficiency of strategies used for programme implementation. The way to achieve this should be through the gathering of systematic information on a programme's activities, characteristics, and results (Almeida & Mourão 2010).

The purpose of evaluation should therefore be, on the one hand, to determine whether goals and expected results have been achieved, and on the other hand, to gain insight into how the programme could be improved (Almeida & Mourão 2010).

Regarding methodology for developing such evaluation, the literature suggests a combination of qualitative and quantitative approaches. There is, however, a growing trend to favour qualitative methodologies. In our own work we have been placing increasing emphasis on strategies such as observation, in-depth interviewing, focus-groups, and content analysis, since these methods seem to provide rich and detailed information concerning process and programme implementation (Illback et al. 1997).

The three main stages for evaluating an intervention programme consist of *Programme Planning*, *Process Evaluation*, and *Outcome Evaluation*. For each of these stages we will provide examples of our own approach employed in the evaluation of KosmiCare at the Boom Festival in 2010 (Carvalho et al. 2011). That evaluation will serve as an example to help you visualise each of the steps involved; however, it does not constitute a one-size-fits-all evaluation plan, as each evaluation effort must be designed according to a particular project's characteristics and context.

The purpose of evaluation should therefore be, on the one hand, to determine whether goals and expected results have been achieved, and on the other hand, to gain insight into how the programme could be improved.

The research assistants had no involvement with actual intervention care. Additionally, a group of four external evaluators was present during all intervention stages, assisting in adjusting the process and making on-site decisions about evaluation methods.

PROGRAMME PLANNING

Every programme should begin with thorough planning of the intervention being implemented. This means that the first task has to do with clearly stating intervention goals and strategies. However, these are not always easily definable; therefore, we suggest you reflect on what your intervention problem is, and who your target group is. We commonly refer to this stage as *evaluation of needs and available resources*.

At this stage you should consider who will conduct evaluation. There are two alternatives: evaluation conducted by an external agent, meaning a person who isn't involved in the intervention itself (as a care giver, for example); or evaluation conducted by a person who *is* responsible for some aspect of the intervention, and assumes an additional evaluation coordination role. The people responsible for evaluation will be in charge of collecting information alongside the team responsible for implementation (care givers) and the target group (guests). This can happen through in-depth interviewing, observation, questionnaires, checklists, written reports, or a combination of several strategies.

At our project we decided that evaluation was to be managed by a leadership team member. This person had the primary responsibility of organising the intervention team and care space. Occasionally this individual would also be involved in assistance with guests as needs required. This person supervised data collection, which was performed by a group of three research assistants, who took turns in eight-hour shifts. During this period they helped care givers collect information about guest identification, arrival details, intervention specifics, and departure. At the moment a guest was about to leave, and provided that informed consent had been granted, they would also conduct a small interview assessing guest satisfaction with the intervention. The research assistants had no involvement with actual intervention care. Additionally, a group of four external evaluators was present during all intervention stages, assisting in adjusting the process and making on-site decisions about evaluation methods. These consultants also had no involvement with intervention care. After the event, they produced a comprehensive report, which contained valuable insights about the care service's intervention.

Another requirement is that you *characterise your intervention problem and develop a conceptual framework*. This means you should describe the nature, scope, and localisation of the intervention problem you'll focus on (Kröger, Winter & Shaw 1998). National or local surveys and scientific publications are useful resources to consult when structuring your framework.

and a number of non-governmental organisations assisted us with pro bono consultancy and harm reduction services that complimented and enhanced our interventions. With this support, the care team itself was able to concentrate on logistics, assembling the care space, and ensuring that it was ready on schedule for the event opening.

After you plan your intervention methods, we suggest you focus on your *target group*. Characterise the demographics of the target involved as thoroughly as you can. Think about the scope of the problem that involves them and what led you to choose that particular group or context. Think about the numbers you expect to cover; think about how you plan to contact, recruit, and motivate volunteers and other partners such as event organisers or public entities (Kröger et al. 1998). Also consider whether intervention has support from any potential intermediate or indirect target-groups; these are the groups or persons that, even though not directly served by intervention, may also benefit from it.

At our project we could predict the major demographics of our target group due to past similar interventions. In those previous events, even though no planned evaluation had been implemented, there were efforts to monitor and collect feedback about operations. That data proved valuable, as it allowed us to anticipate various factors such as age, gender, nationality, PAS-use patterns, and other considerations that influenced our intervention strategies (Nielsen & Bettencourt 2008; Ventura 2008). As the intervention unfolded, we noticed that our work wasn't solely benefiting guests in crisis, but also event staff members who became increasingly aware of PAS-related issues. They brought guests to our care service and wanted to know more about how to respond when finding someone in difficulty.

Keep in mind that *evaluation of needs* means that you are already aware of the dimension of your intervention problem and whether that dimension justifies the intervention and resources you plan to allocate to it. Consider such things as an estimation of how many people are affected, and present arguments in favour of your particular intervention to the relevant bodies. Questions you should be answering at this stage include: (1) How many people are affected by this problem? (2) How many new situations are expected and how frequently do they come up? (prevalence and survey data); (3) What is the result of the "status quo" of not providing any intervention? (4) How can the need for intervention be described? (5) Are there different opinions about the need for intervention? (6) How has the need for intervention been assessed? (7) Is there knowledge regarding other related interventions in the field? And if so, can benefit be obtained by following their efforts? (Kröger et al. 1998). The main points presented under "Programme Planning" above have been summarised in Figure 6, "Tasks for Programme Planning".

**As the
intervention
unfolded we
noticed that our
work wasn't
benefiting guests
in crisis alone,
but also event
staff members
who became
more aware of
PAS-related
issues.**

PROGRAMME PLANNING CHECKLIST	
<input type="checkbox"/> 1. Characterise intervention problem	<input type="checkbox"/> 4. Decide on intervention methods
<input type="checkbox"/> 2. Clearly state goals and objectives	<input type="checkbox"/> 5. Characterise target-groups
<input type="checkbox"/> 3. Decide who does evaluation	<input type="checkbox"/> 6. Assess and guarantee resources

FIGURE 6:
Tasks for Programme
Planning

At our process evaluation of a care service at a large scale event, we decided to gather information on our implementation through multiple approaches...

Process Evaluation

The central purpose of process evaluation is to determine whether intervention produced the expected results. Through this we promote process improvement, as areas in need of development are identified. Moreover, we can identify difficulties in procedures, and obstacles that emerged during programme implementation. We also document strengths and aspects in which the programme was effective. When we perform process evaluation, our trust in perceived benefits is increased because we are confident that results are directly associated with interventions that were implemented and not with random happenstance (Illback et al. 1997).

In developing process evaluation, one follows a planned methodology. This consists of obtaining answers to several questions: (1) Which variables and indicators will offer us useful information on intervention implementation? And what kind of information (qualitative and/or quantitative) do we intend to collect? (2) What methods and instruments will we use to collect that data (interviews, questionnaires, observation checklists, and so forth)? (3) Where, when, and for how long will we collect data regarding the intervention process? (4) Who will provide this data? (5) How will data be analysed?

These concerns strongly resemble the questions any scientist asks when planning a research project. What is particular here is that you will be planning research that has a specific intention: to know more about how intervention is occurring and how it can be improved in the future. Whilst scientific research has a global audience and community composed of every person studying the same problem or its analogue (academically or for intervention purposes), evaluation research is primarily aimed at a more restricted audience of programme coordinators, partners, and the team itself, as these stakeholders will benefit most from its results in the future.

At our process evaluation of a care service at a large-scale event, we decided to gather information on our implementation through multiple approaches, and through a combined use of qualitative and quantitative indicators. Observation checklists were created that allowed close monitoring of the intervention received by each guest. Even though it was the care givers' responsibility to provide this input, research assistants frequently assumed the lead in soliciting, documenting,

GUEST SATISFACTION QUESTIONNAIRE					
	Totally agree	Agree	Don't know / Can't tell	Disagree	Totally disagree
26. I consider I have been helped by the care services					
27. I consider the care space had all the appropriate conditions to satisfy my needs during my stay					
28. I consider the care services had well-prepared, efficient staff to help me deal with my situation					
29. I consider care givers were helpful, caring, and available to satisfy my needs during my stay					
30. Please feel free to comment below on any aspect(s) related to your experience at the care service					

FIGURE 7:
Guest Satisfaction
Questionnaire

and maintaining information for all guests at the care space. Additionally, our implementation was retrospectively evaluated through care team feedback subsequent to the interventions.

When you plan *process evaluation for implementation monitoring*, consider including information about indicators such as: (1) Intervention strategies; (2) The target group (how many and their demographics); (3) The target group's exposure to intervention (intervention duration and number of activities/interventions delivered) (Kröger et al. 1998). At our project, these indicators were approximately the same as we described above under "Feedback and Monitoring".

Process evaluation also contributes to *assessing programme efficacy*. This is obtained through the measurement (quantitative or qualitative) of the reaction of the subjects and their attitudes towards the programme: Did they accept intervention? Did they identify with the goals of the programme? Did they obtain benefit from intervention? These are just some examples of questions you can attempt to answer to help assess efficacy through process evaluation (Kröger et al. 1998). Consider what indicators you need in order to answer these questions, and how to collect this data.

**Did they accept
intervention?
Did they identify
with the goals
of the programme?
Did they obtain
benefit from
intervention?**

FIGURE 8:
Care Giver's
Assessment of
Treatment Outcome

DEPARTURE				
31. Do you consider that this guest was helped by the care service?				
Yes, much	Yes, a little	Don't know / Can't tell	No, not much	No, not at all
32. Please include other comments below (for example, guest's verbalisations regarding his/her experience at the care service)				

CARE TEAM SATISFACTION QUESTIONNAIRE					
	Totally agree	Agree	Don't know / Can't tell	Disagree	Totally disagree
1. Care service training was of an appropriate duration					
2. Care service training had well-prepared sessions					
3. Care service training content was relevant					
4. The content of the care service training contributed to my preparation for intervention					
5. Care service training was well organised					
6. Care service physical work conditions (lighting, temperature, comfort, etc.) were appropriate					
7. Guests' acceptance of intervention was positive					
8. Intervention met its purposes effectively					
9. Care givers' work was effective.					
10. Organisational support to the care service was effective.					
11. Care service implementation levels were high.					
12. The climate and cooperation in the care service team was very positive.					
13. Working conditions were appropriate.					
14. Care space capacity was appropriate for intervention's needs.					

FIGURE 10:
Care Team Satisfaction
Questionnaire

At our project, each care team member was invited to express their thoughts about the project by filling in a form that allowed for both "closed" (Figure 10) and "open" (Figure 11) responses.

FIGURE 11:
Care Team Satisfaction
through S.W.O.T. Analysis

CARE TEAM SATISFACTION / S.W.O.T. ANALYSIS					
Please fill in the following table referring to Strengths (S), Weaknesses (W), Opportunities (O), and Threats (T) of given topics.					
	Training	Team	Work conditions	Organisers	Implementation
Strengths					
Weaknesses					
Opportunities					
Threats					

PROCESS EVALUATION CHECKLIST	
<input type="checkbox"/> 1. Plan process evaluation (as you would prepare scientific research)	<input type="checkbox"/> 4. Include team satisfaction assessment
<input type="checkbox"/> 2. Include implementation monitoring indicators	<input type="checkbox"/> 5. Consider measuring side-effects and discrepancy
<input type="checkbox"/> 3. Include programme efficacy indicators	<input type="checkbox"/> 6. Discuss results

FIGURE 12:
Tasks for Process
Evaluation

The central purpose of outcome evaluation is to determine to what level the original goals for intervention were attained. An essential requirement is to ensure that your goals and objectives have been stated clearly from the start of the programme.

Figure 12, “Tasks for Process Evaluation” lists some of the main points discussed above under “Process Evaluation”. To end, we suggest that when you report and discuss process evaluation results you focus on the following (Kröger et al. 1998):

- Compare intervention plan, intervention implementation, and evaluation results.
- Reflect on any discrepancies and their impact on the intervention.
- Identify the intervention’s strengths and weaknesses and compare it with other interventions you have researched.
- Formulate suggestions for any future intervention and for future process evaluation approaches to the same intervention.

Outcome Evaluation

The central purpose of outcome evaluation is to determine to what level the original goals for intervention were attained. An essential requirement is to ensure that your goals and objectives have been stated clearly from the start of the programme. According to Illback, Kallafat, and Sanders (1997), however, the success of an intervention should be determined more by the subjects’ perception of intervention efficacy than by the measurement of goals achieved. For this reason, it is also crucial to consider guest satisfaction for the purpose of outcome evaluation. We have presented a number of items above referring to guest satisfaction that may be used simultaneously as process and outcome measures.


Whilst *planning* for outcome evaluation, contemplate the following questions: (1) What do you consider to be the intervention’s result indicators and how do you plan to measure them (through which instruments)? (2) What type of data (quantitative or qualitative, or both) do you intend to analyse? (3) What guarantees exist regarding the quality of those instruments (for example, if you use standardised instruments, are they objective, reliable, and trustworthy?) (4) Where, when, and how do you plan to collect those data? (5) How do you plan to analyse the results? (Kröger et al. 1998).

At our evaluation of a care service at a large-scale festival, we intended to measure if our goal of contributing to diminished mental health risk following a psychoactive substance-related crisis had been achieved. We determined that to accomplish this we could obtain a quantitative and standardised measure of guests' mental state through a symptom checklist on arrival at the care space and again on departure. Even though we had other more qualitative and indirect measures for intervention outcome (such as care giver perception and guest satisfaction, already presented above), we wanted to complement these with more direct and quantitative measures of our intervention.

Whilst performing a mental state exam (through instruments such as the *Mini-Mental State*,¹ for example) our attention should focus on the presence of symptoms and signs, and not so much on formally diagnosed "syndromes". Consequently, this exam consists of a discrete "instantaneous" assessment of an individual's operative functioning (Fugas 2011; Baños & Perpiñá 2002) which, unlike formally diagnosed "syndromes", might suffer alterations at any moment. Traditionally, a mental state exam is performed by a psychotherapist who observes a patient whilst conducting a clinical interview (Trzepacz & Baker 2001). But in our case, we had some challenges to overcome. Considering PAS produce modified states of mind that can have an impact on speech, data collection through an interview could be extremely challenging or not even possible. Another aspect was the immediate nature of the crisis intervention setting; this meant that all data had to be collected during the guests' time at the care space, as there was no expectation of further contact after their departure. Finally, we had to recognise that using standardised instruments was usually an impossible request for guests undergoing the often mentally distorting effects of PAS.

So we decided to build a new instrument—the *Mental State Exam Checklist (MSEC)* (Carvalho, Carvalho, Frango, Dias, Veríssimo, & Llandrich 2010)—consisting of 74 items that were evaluated by a trained observer (the care giver assigned to the guest). The 74 items were organised into eight sub-scales of dimensions: (1) Appearance, attitude; (2) Psychomotor behaviour; (3) Consciousness, alertness, attention, and orientation; (4) Language and speech; (5) Thought process; (6) Self-awareness; (7) Affect and emotions; (8) Physiological functioning. In this way we could ensure an unobtrusive

1 The *Mini-Mental State* exam was developed in 1975 (Folstein, Folstein & McHugh 1975), and it has been used as an auxiliary to the diagnosis of cognitive functioning problems. It consists of a series of requests and tasks that subjects must solve. Performance on these tasks can be quantified, yielding a final score.




Wind Oracle by Vibrata Chromodoris and David Shamanik had four rotating cubes suspended by a fifteen-foot steel tripod. The cubes featured mystical symbols that aligned according to the wind patterns in order to answer one's questions. Photographed on the playa at the 2003 Burning Man Festival by Vibrata Chromodoris.

4. References

- Almeida, D., and Mourão, B. (2010). "Avaliação de Programas de Prevenção das Toxicodependências" ["Evaluation of Addiction Prevention Programmes"]. *Revista Toxicodependências [Addictions Magazine]* 16(3): 79–88. Accessed Nov. 20, 2014, from <http://tinyurl.com/qjl7h66>
- Balsa, C. (2008). *Inquérito Nacional ao Consumo de Substâncias Psicoativas na População Geral, Portugal 2007 [National Survey on the Use of Psychoactive Substances in the General Population, Portugal 2007]*. Lisboa: Instituto da Droga e da Toxicodependência [Lisbon: Institute for Drugs and Drug Addiction]. Accessed Nov. 20, 2014, from <http://tinyurl.com/njgztq3>
- Baños, R.M., and Perpiñá, C. (2002). *Exploración Psicopatológica [Psychopathological Examination]*. Madrid: Editorial Síntesis.
- Carvalho, M.C., Carvalho, J., Frango, P., Dias, P., Veríssimo, L., and Llandrich, J. (2010). *Mental State Exam Checklist (MSEC)*. Porto: Faculdade de Educação e Psicologia da Universidade Católica Portuguesa, não publicado [Porto: Faculty of Education and Psychology, Catholic University of Portugal, unpublished].
- Carvalho, M.C., Pinto de Sousa, M., Frango, P., Carvalho, J., Dias, P., and Veríssimo, L. (2011). *Crisis Intervention in Recreational Settings—Data From Kosmicare/Boom Festival 2010, Process Evaluation*. Porto: Faculdade de Educação e Psicologia da Universidade Católica Portuguesa [Porto: Faculty of Education and Psychology, Catholic University of Portugal]. Accessed Nov. 20, 2014, from <http://tinyurl.com/khdhlp> (see also <http://tinyurl.com/lv3m6wj>).
- EMCDDA (2006). *Annual Report 2006, Selected Issues—Developments in Drug Use Within Recreational Settings*. European Monitoring Centre for Drugs and Drug Addiction. Accessed Nov. 20, 2014, from <http://www.emcdda.europa.eu/html.cfm/index34883EN.html>

- EMCDDA (2009). *Selected Issues 2009—Polydrug Use: Patterns and Responses*. European Monitoring Centre for Drugs and Drug Addiction. Accessed Nov. 20, 2014, from http://www.emcdda.europa.eu/attachements.cfm/att_93217_EN_EMCDDA_S109_poldrug%20use.pdf
- Folstein, M.F., Folstein, S.E., and McHugh, P.R. (1975). "‘Mini-Mental State’: A Practical Method for Grading the Cognitive State of Patients for the Clinician". *Journal of Psychiatric Research* 12: 189–198. Accessed Nov. 20, 2014, from <http://tinyurl.com/q45wpmv>
- Fugas, J.N. (2011). *Mental State Exam Checklist: Contributo para a Validação de um Instrumento de Avaliação do Estado Mental*. [Mental State Exam Checklist: A Contribution for the Validation of a Mental State Evaluation Instrument]. Porto: Faculdade de Educação e Psicologia da Universidade Católica Portuguesa, não publicado [Porto: Faculty of Education and Psychology, Catholic University of Portugal, unpublished Masters dissertation].
- Grof, S. (2008). "Crisis Intervention in Situations Related to Unsupervised Use of Psychedelics". *LSD Psychotherapy*, fourth edition (pages 308–319). Santa Cruz, California: Multidisciplinary Association for Psychedelic Studies.
- Hedrich, D. (2005). "...Putting Harm Reduction on the Map". Accessed Nov. 20, 2014, from <http://tinyurl.com/p3tppl6>
- Hoff, L.A., and Adamowski, K. (1998). *Creating Excellence in Crisis Care: A Guide to Effective Training and Program Designs*. San Francisco, CA: Jossey-Bass Publishers.
- Illback, R.J., Kalafat, J., and Sanders, D. (1997). "Evaluating Integrated Service Programs". In R.J. Illback, C.T. Cobb, and H.M. Joseph, *Integrated Services for Children and Families: Opportunities for Psychological Practice* (pages 323–346). Washington, DC: American Psychological Association.
- Illback, R.J., Zins, J.E., Maher, C.A., and Greenberg, R. (1990). "An Overview of Principles and Procedures of Program Planning and Evaluation". In T.B. Gutkin and C.R. Reynolds *The Handbook of School Psychology*, second edition (pages 799–820). New York: Wiley.
- Kanel, K. (2003). *Manual to Accompany A Guide to Crisis Intervention*. California: Brooks/Cole.
- Kröger, C., Winter, H., and Shaw, R. (1998). *Guidelines for the Evaluation of Drug Prevention: A Manual for Programme-Planners and Evaluators*. European Monitoring Centre for Drugs and Drug Addiction. Accessed Nov. 20, 2014, from http://www.emcdda.europa.eu/attachements.cfm/att_78087_EN_manual1.pdf
- Marlatt, G.A. (1998). *Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors*. New York: Guilford Press.
- Nielsen, S., and Bettencourt, C. (2008). "Kosmi-Care: Creating Safe Spaces for Difficult Psychedelic Experiences". *MAPS Bulletin* 18(3): 39–44. Nov. 20, 2014, from <https://www.maps.org/news-letters/v18n3/v18n3-39to44.pdf>
- Parker, H.J., Aldridge, J., and Measham, F. (1998). *Illegal Leisure: The Normalization of Adolescent Recreational Drug Use*. London: Routledge.
- Parker, H., Williams, L., and Aldridge, J. (2002). "The Normalization of ‘Sensible’ Recreational Drug Use: Further Evidence from the North West England Longitudinal Study". *Sociology* 36(4): 941–964. Accessed Nov. 20, 2014, from <http://www.brown.uk.com/brownlibrary/parker.pdf>
- Trzepacz, P.T., and Baker, R.W. (2001). *Exame Psiquiátrico do Estado Mental* [Psychiatric Mental State Examination]. Lisboa: Climepsi Editores.
- Ventura, M. (2008). "Energy Control: Harm Reduction with Drug Analysis at Boom Festival". *MAPS Bulletin* 18(3): 45–47. Nov. 20, 2014, from <http://www.maps.org/news-letters/v18n3/v18n3-45to47.pdf>



JON HANNA • *Sasha Presenting the Quantitative Scale of Potency*, 2016 • digital (Adobe Photoshop)
<http://www.mindstates.org>

GUIDE TO DRUG EFFECTS AND INTERACTIONS

Timothy Bakas

Vince Cakic

Zevic Mishor

Christopher J. Ward

Gastone Zanette

Jon Hanna

This Guide summarises notable interactions that may be life-threatening or highly dangerous between different classes of psychoactive drugs. It also provides a quick reference index to those substances commonly encountered at music festivals and similar events. Although coverage of every drug used in these contexts is out of scope, we have included the major classes in such a way that the Guide should be able to provide a basic level of information regarding most substances.

For each chemical or botanical, the alphabetically ordered drug index entries include data on nomenclature, appearance, mechanism of action, psychoactive effects, pharmacokinetics, adverse reactions, contraindications, interactions, overdose, and harm minimisation. Where relevant, additional information on related compounds is included.

The information supplied in each entry is two-tiered. First, we present a practical overview regarding dose, duration, psychoactive effects, adverse effects, and harm reduction. Second, we provide technical data regarding relevant mechanisms, pharmacokinetics, and contraindications; this is information that medical staff working with a care service may find useful for their assessments. In addition to the practical and the technical, with each entry we have also included a bit of historical data and/or cultural context related to the featured drug.

Our research sources have been extensive, ranging from the latest studies published in medical journals, to first-hand accounts. Much of our information was obtained from standard texts and peer-reviewed sources. However, given the role of the Internet in disseminating information—and shaping drug trends themselves—several reliable online resources, including Erowid and Drugs-Forum, have been of invaluable assistance for preparing content, particularly with regard to subjective descriptions of the drugs' effects and with dose information.

The material contained in this Guide is intended to promote the reduction of suffering and the minimisation of harm in the context of drug usage in festival and other environments. Although keenly aware of the importance of accuracy to the integrity of this document, we also know that to err is to be human. In the same spirit of collaboration with which this Manual was written, we invite you to alert us to any errors or omissions that you may identify. Please contact the editors if you spot any mistakes.

While we have taken great care to provide accurate and relevant information, we do not accept liability for any errors or omissions; please refer to the disclaimer at the beginning of this Manual. One sentence from that disclaimer is reiterated here: *The editors and authors are not responsible for any specific health needs that may require medical supervision and shall not be held liable for any damages or negative consequences from any treatment, action, application, or preparation undertaken by and/or provided to any person reading or following the information in this book.*

This Guide aims to provide a rich source of information on many psychoactive agents, information rarely found in such a comprehensive yet concise format. We welcome you to use it to aid in providing assistance and information while working at a drug care service, as well as in any other setting for which it may prove valuable.

DRUG INTERACTIONS

Regardless of whether they are illegal, prescription, or over-the-counter (OTC), and whether used for medical, recreational, or spiritual/contemplative purposes, adverse drug reactions may arise from

the combination of a variety of specific drugs. As such, a great number of possible drug interactions involving recreational (and other) drugs exist; covering every one of them is beyond the scope of this Guide.

Our focus is on dangerous and life-threatening interactions. These tend to be clustered around a particular few drug classes, namely CNS depressants (particularly alcohol and GHB) and monoamine oxidase inhibitors (MAOIs). Combinations of many recreational agents with these drugs may cause life-threatening or serious adverse consequences.

The Table of High-Risk Drug Interactions below summarises which common psychoactive drugs and other pharmaceutical drug classes constitute a potentially life-threatening interaction when mixed with alcohol, GHB, or MAOIs. In order to aid the reader in assessing for such interactions, also included is a list of the most commonly used medication names from within each pharmaceutical drug class as found in the table.

Further information on both harm minimisation and other potential drug interactions specific to many recreational agents can be found at the end of this Guide, in the Index of Drug Effects.

High-Risk Interactions

The three drugs/classes appearing at the top of the table—alcohol, GHB, and MAOIs—are those with potential for life-threatening interactions; the commonly found drugs that constitute such interactions are listed beneath each heading. Medical assistance should be sought immediately upon encountering adverse consequences from such combinations.

TABLE OF HIGH-RISK DRUG INTERACTIONS		
CNS DEPRESSANTS		MAOIs
ALCOHOL	GHB	
<i>combined with:</i> First Generation Antihistamines Barbiturates Benzodiazepines GHB Heroin Ketamine	<i>combined with:</i> First Generation Antihistamines Alcohol Barbiturates Benzodiazepines Heroin	<i>combined with:</i> 2C-x Amphetamine Antihistamines Cocaine DOx MDxx MDPV / α -PVP Mephedrone, etc. Methamphetamine SSRIs

Alcohol

Alcohol is a widely consumed agent that interacts with many other drugs and substances. As a general rule, CNS depressants should not be combined with one another. These depressants include alcohol, general anaesthetic agents, barbiturates, benzodiazepines, and GHB (γ -hydroxybutyrate). In addition, the concomitant use of these drugs with opiates/opioids, ketamine, nitrous oxide, or sedating antihistamines may result in serious adverse consequences. Symptoms of overdose include pronounced sedation, decreased heart rate and hypotension, motor incoordination, slurred speech, respiratory depression, coma, and death. Please see the Alcohol entry in the index below for further information.

GHB (γ -hydroxybutyrate)

GHB has synergistic effects with other CNS depressants such as alcohol, benzodiazepines, barbiturates, and opiates/opioids, and most GHB-related deaths have been associated with these sorts of co-ingestions. GHB overdose can result in life-threatening CNS and respiratory depression, and requires immediate medical attention. Symptoms of overdose include drowsiness, respiratory depression, nausea, vomiting, confusion, tremors and twitching, rapid pulse, unconsciousness, and rarely, seizures. Please see the GHB entry in the index for further information.

Monoamine Oxidase Inhibitors (MAOIs)

Monoamine oxidase inhibitors (MAOIs) are a class of compounds, often used as antidepressants, which reduce the metabolising actions of the enzyme monoamine oxidase (MAO) on neurotransmitters, particularly serotonin and dopamine.

Consumption of recreational drugs that enhance the actions of monoamines, and concomitant use of MAOIs should therefore be strictly avoided. Monoamine-enhancing drugs include psychostimulants, such as amphetamines, cocaine, methamphetamine, and MDMA (and related compounds), as well as other antidepressants like SSRIs.

The risk of these interactions is serotonin toxicity (serotonin syndrome), a life-threatening condition characterised by excessive levels of serotonergic activation in neurons and muscles. Symptoms

include agitation, sweating, tremors and hyperreflexia (overactive reflexes), muscle rigidity, twitching, and hyperthermia. Further, hypertensive symptoms may also arise, such as severe headache, rapid heart rate, and rises in blood pressure. Extreme symptoms include intracranial haemorrhage and acute cardiac failure.

MAOIs obtained from plant sources include Syrian rue (*Peganum harmala*), and the ayahuasca vine (*Banisteriopsis caapi*), both of which contain harmala alkaloids. In some instances, tryptamines such as DMT or psilocybin-containing mushrooms may be combined with these MAOIs to activate or potentiate the tryptamines' effects. These tryptamines have few direct actions on monoamine concentrations. As such, the risk of serotonin toxicity resulting from their concomitant use with reversible MAOIs (such as harmala alkaloids) is much lower than that seen between MAOIs and other psychoactive agents, for example stimulants such as the amphetamines or cocaine, empathogens such as MDMA or methylone, or psychedelic phenethylamines such as those in the DOx and 2C-x series of compounds, all of which should be strictly avoided with MAO inhibitors.

Identifying Prescription and Over-The-Counter Drugs with High-Risk Interactions

This section provides information to assist in determining which drug class a particular medication fits into. The drug classes that we have focused on are those with major interactions, as presented in the Table of High-Risk Drug Interactions above, such as: barbiturates, benzodiazepines, opiates/opioids, antihistamines, MAOIs, SSRIs, and stimulants.

In the listings below, the generic names (proprietary names in brackets) for the most commonly used drugs in each class are given. Some proprietary products may contain other drugs in addition to the main compound described by the generic name; in most cases we have not listed those other drugs. Please note that this list of drug names is far from complete, and does not identify many proprietary names. As such, additional resources may be required to identify particular prescription drugs, which class they belong to, and whether they possess potential for harmful interactions with particular commonly used recreational agents.

Use the lists below to determine the class—such as barbiturate, MAOI, and so forth—that the common prescription or OTC drug in question belongs to. Then use the Table of High-Risk Drug Interactions above to determine the potential consequences of drug combinations. Once again, the lists below are incomplete and provided for information purposes only. A medic should always be consulted when any dangerous drug combination is suspected.

Barbiturates

allobarbitol (Cibalgin, Dial-Ciba); amobarbital (Amytal); aprobarbital/aprobarbitone (Allonal, Oramon, Somnifaine); barbital/barbitone (Medinal, Veronal); butalbital (Axocet, Axoxtal, Esgic, Fioricet, Fioricet#3 [with codeine]); mephobarbital (Mebaral); pentobarbital/pentobarbitone (Nembutal); phenobarbital/phentobarbitone (Luminal); secobarbital (Seconal); sodium thiopental/thiopental/thiopentone (Trapanal)

Benzodiazepines/Hypnotics

alprazolam (Xanax); chlordiazepoxide hydrochloride (Librium, Librax); clobazam (Onfi); clonazepam (Klonopin); chlorazepate (Tranxene); diazepam (Valium); estazolam (Prosom, Eurodin); lorazepam (Ativan); midazolam (Dormitol, Dormicum, Versed); oxazepam (Alepan, Bonare, Serax); temazepam (Restoril, Normison); triazolam (Halcion); zopiclone (Imovane, Zimovane), zolpidem (Ambien, Stilnox, Zolpimist)

Opiates/Opioids

buprenorphine (Buprenex, Butrans, Cizdol, Subutex, Temgesic); codeine (Paveral); diacetylmorphine/diamorphine (Heroin); ethylmorphine (Codethylene, Cosylan); fentanyl/fentanil (Actiq, Duragesic; Sublimaze); hydrocodone/dihydrocodeinone (Norco, Lortab, Vicodin, Vicoprofen); methadone (Dolophine); morphine (Avinza, Dolcontin, Kadian, MS Contin); oxycodone (OxyContin, Percocet, Percodan); oxymorphone (Opana, Numorphan, Numorphone); tramadol (Ultram, Zytram)

First Generation Antihistamines

brompheniramine (Dimetapp); chlorphenamine/chlorpheniramine (Allerest, Codral, Demazin); clemastine/meclastin (Tavist); cyclizine (Marezine); cyproheptadine (Peritol); dexbrompheniramine (Drixoral); dexchlorpheniramine (Polaramine); diphenhydramine (Benadryl, Dramamine,

Sominex, Unisom SleepMelts, Unisom SleepGels); doxylamine (Dozile; Sleep Aid, Unisom Sleep-Tabs); embramine (Mebryl); fexofenadine (Allegra, Mucinex); hydroxyzine (Vistaril); loratadine (Claritin); pheniramine (Avil); phenyltoloxamine (Duraxin); promethazine (Phenergan); rupatadine (Rupafin); triprolidine (Actifed, Zymine)

SSRIs/SNRIs

bupropion (Wellbutrin, Zyban); citalopram (Celexa); desvenlafaxine (Pristiq); duloxetine (Cymbalta); escitalopram (Lexapro); fluoxetine (Prozac); fluvoxamine (Luvox); levomilnacipran (Fetzima); milnacipran (Ixel, Savella); paroxetine (Paxil, Pexeva); sertraline (Zoloft); tofenacin (Elamol, Tofacine); vilazodone (Viibryd); venlafaxine (Effexor)

MAOIs

moclobemide (Aurorix, Manerix); bifemelane (Alnert); brofaramine (Consonar); toloxatone (Humoryl); harmaline; selegiline (Eldepryl, Zelapar); pargyline (Eutonyl); tranylcypromine (Parnate); phenelzine (Nardil); isocarboxazid (Marplan); procarbazine (Matulane, Natulan); St. John's wort (*Hypericum perforatum*) [Note: St. John's wort is an extremely weak MAOI, and no "adverse MAOI effects" have been reported that we're aware of. However, since it increases serotonin levels, it should not be taken with SSRIs or other drugs that strongly boost serotonin, like MDMA, MDA, etc. Additionally, St. John's wort contains compounds known to activate cytochrome P450 enzymes, which the body uses to metabolize many drugs; concurrent use may therefore reduce the effectiveness of whatever other drug has been taken if that drug is metabolized by CYP450.]

Prescription Psychostimulants

amphetamine/dextroamphetamine (Adderall, Dexedrine); fenfluramine (Adifax); methylphenidate (Ritalin, Concerta); methamphetamine (Desoxyn); lisdexamfetamine (Vyvanse); phentermine (Adipex-P, Duromine); phendimetrazine (Appacon, Bontril)



INDEX OF DRUG EFFECTS

Each drug entry in this index contains a brief introduction, relevant names, drug class, appearance, mechanisms of action, psychoactive effects, dosing approaches and the pharmacokinetics for different routes of administration, adverse reactions, contraindications, drug interactions, harm minimisation strategies, overdose descriptions, and related compounds.

DRUG NAME	PAGE
2C-B (2C-x, DOx)	336
Alcohol	338
Amphetamine (and Methamphetamine)	341
Cannabis	344
Cocaine	347
DMT (Dimethyltryptamine)	349
GHB (γ -hydroxybutyrate)	351
Heroin	353
Ketamine	355
LSD	357
MDMA (MDA and PMA)	359
MDPV	362
Mephedrone	364
25I-NBOMe (and other related compounds)	366
Nitrous Oxide	367
Psilocybin	369
<i>Salvia divinorum</i>	372
Scopolamine	375

2C-B

A psychedelic phenethylamine first synthesised by Alexander Shulgin in 1974. It possesses visionary and empathogenic properties, with putative aphrodisiac qualities, and has seen use as an adjunct to psychotherapy. 2C-B has a relatively shorter onset and duration than other hallucinogens. It gained popularity in the rave subculture in the late 1980s as a legal alternative to MDMA, later being scheduled by the United Nations' Convention on Psychotropic Substances in 2001.

Chemical Name:

2-(4-bromo-2,5-dimethoxyphenyl)ethanamine;

- OR -

4-bromo-2,5-dimethoxyphenethylamine;

- OR -

2,5-dimethoxy-4-bromophenethylamine

Synonyms:

Nexus; B; bees; CB; bromo-mescaline; Venus; Erox; Ubalawu Nomothotholo

Class:

Serotonergic hallucinogen; psychedelic phenethylamine

Appearance:


Usually presents as a white powder, in gelatine capsules, or in tablet form.

Mechanism:

Partial serotonin agonist at 5-HT_{2A} and 5-HT_{2C} receptors. There is evidence of antagonism at 5HT_{2A} receptors. Additionally, affinity to various other serotonergic and adrenergic receptor subtypes has been shown.

Psychoactive Effects:

Characterised by visual effects akin to but milder than LSD, while also exhibiting empathogenic properties reminiscent of MDMA, with a lower propensity for stimulant effects. Alters perceptual processes, with visual patterning, auditory, olfactory, and tactile sensations reported. Changes in mental processes may include feelings of insight, closeness to self and others, emotional introspection, anxiety, and confusion. It is often described as possessing more euphoric effects than other psychedelic phenethylamines.



Pharmacokinetics:

Oral: 10–50 mg, with 15–30 mg as commonly used active doses. Onset 20–90 minutes, duration 3–5 hours, and after-effects lasting 2–4 hours.

Intranasal: 5–15 mg as commonly reported doses, and has a shorter onset and duration of action than oral ingestion. Disorientation following insufflation of higher doses is often self-reported. Increases in the prevalence and duration of side-effects have been self-reported with this administration route.

Rectal: 7–40 mg as commonly reported doses. Similar durations as per oral have been reported.

Injection: 1–3 mg reported doses, however this route of administration is rarely reported in surveys of users (<1%). It seems likely that the duration profile will be more rapid.

Note: A wide range of doses has been described for this drug, suggesting individual sensitivities to 2C-B.

Adverse Reactions:

Common: Decreased appetite; insomnia; increased blood pressure; increased heart rate; nausea.

Severe pain and irritation in the nasal cavity is often reported upon insufflation.

Less Common: Vomiting; anxiety; confusion; changes in body temperature; muscle twitches; excessive mucous production

Rare: Seizures

Life-threatening: None reported

Contraindications:

Psychiatric illness, particularly schizophrenia and related psychotic disorders; any medical condition where hypertension would be hazardous, for example cardiovascular disease.

Interactions:

None reported. Given that MAO-A and MAO-B are enzymes involved in the metabolism of 2C-B, the use of any MAO inhibitor may potentiate the risk of adverse effects including hypertensive crisis. With SSRIs, such risks are lower, where rather than a potentiation, additive effects have been noted with agents such as 2C-B. It is suspected that use with other stimulants will compound hypertensive effects. Co-usage of MDMA has been reported; information regarding potentially enhanced toxicity, however, is lacking. Synergistic effects have been reported with concomitant hallucinogen use.

Harm Minimisation:

Standard precautions as per all hallucinogens.

Overdose:

LD₅₀ is unknown. Despite high oral doses of over 75 mg having been reported without harm, individual sensitivities to a wide range of doses have been reported, meaning that in some individuals, lower doses may carry greater risk.

Related Compounds:

2C-x

The halogen in 2C-B—namely the bromine moiety at the carbon 4-position—has been replaced with other halogens such as chlorine, fluorine, and iodine, to give rise to the compounds 2C-C, 2C-F, and 2C-I. In addition to halogen substitution, other substituents at this position include alkyl chains,

O-methyl, and S-alkyl groups. Collectively these are often referred to as the “2C-x series”, with over twenty-five different substances that have been synthesised. A few *N*-benzyl-oxy-methyl (“NBOMe”) analogues of 2C-x compounds have also been synthesised and marketed, including 25B-NBOMe (or “25B”), 25C-NBOMe (or “25C”), 25D-NBOMe (or “25D”), and others. For more info on these, see the 25I-NBOMe listing.

It should be noted that these agents have extremely varied onsets, durations of action, and importantly varied intra-subjective effects. Some of the 2C-x series require over three hours before any initial effects are felt; because they take so long to come on, users anticipating an earlier onset may believe the agent that they took must have been adulterated, causing them to underdose. So they decide to “top up” and take more. This may lead to difficult experiences for some users. Potencies also vary substantially amongst the different 2C-x compounds; however, oral dosages are usually in the order of >10 mg, with the important exception of the extremely potent 25x-NBOMe (aka 2C-x-NBOMe) compounds, which are active at sub-milligram doses and sometimes sold on blotter paper misrepresented as LSD.

DOx

If there is an α -methyl substituent added to 2C-B then this will give rise to the amphetamine analogue DOB. Similar with the 2C-x series, subsequent alteration of the 4-bromo moiety gives rise to the DOx series. It includes DOB, DOI, DOM, and DOB-Dragonfly. Generally, these agents carry a greater risk for adverse sympathomimetic effects and are also noted to have very long durations, in some cases greater than thirty hours. The potency of these agents is also much greater than the 2C-x series, by about a factor of ten. With active doses ranging 1–3 mg, correct dosing can be difficult. In recent years, the challenge of properly measuring-out dose units has sometimes been addressed by soaking these compounds into perforated sheets of blotter paper.

For the four decades following the late 1960s, blotter paper was used almost exclusively as a delivery method to distribute a single drug: LSD. But in the mid-2000s, blotter began to increasingly appear that had been dosed with psychedelic compounds other than LSD. As vendors of

research chemicals have expanded their offerings in the years since then, the trend of using blotter as distribution method for a widening variety of extremely potent drugs has increased. By 2017, the assortment of lysergamides, phenethylamines, tryptamines, and other compounds that have been distributed on blotter includes the drugs: 1P-LSD (1-propionyl-lysergic acid diethylamide), 5-MeO- α MT, 25I-NBF, 25I-NBOH, 25C-NBOH, 25B-NBOMe, 25C-NBOMe, 25I-NBOMe, 25N-NBOMe, AL-LAD (6-allyl-6-nor-lysergic acid diethylamide), bromo-dragonfly, 2C-C, 2C-E, 2C-I, DMA, DOB, DOC, DOI, DOM, lamid (methyl-isopropyllysergamide), LSZ (lysergic acid 2,4-dimethylazetide), along with the benzodiazapines etizolam, pyrazolam, diclazepam, and the powerful stimulant 3,4-dichloromethylphenidate.

Due to the popularity (and sometimes low availability) of LSD, and the high potency of these

other "LSD-like" compounds, unscrupulous or uninformed dealers may misrepresent them as LSD. Some users who unknowingly take DOx or 25x-NBOMe instead of LSD, may experience anxiety from still being high for so long after they had anticipated the effects to subside. Additionally, while LSD is essentially non-toxic (overdose deaths due solely to adverse physiological responses are unheard of), a few fatalities have been associated with several of these other compounds.

Sasha Shulgin, pioneering creator of 2C-x and DOx compounds, held six psychedelic phenethylamines in such high regard that he referred to them as "the magical half-dozen". Joining the naturally inspiring compound mescaline, the five additional Shulgin synthetics he considered top shelf are: 2C-B, 2C-E, 2C-T-2, 2C-T-7, and DOM. It is therefore not surprising that these have been among the most commonly seen on the street.

ALCOHOL

Alcohol is a widely used intoxicant found in beer, wine, spirits, and other beverages, which has a long history of human use. The psychoactive effects of alcohol are generally biphasic, such that low doses tend to produce a disinhibited state, whilst depressant effects are seen with larger doses. Alcohol is commonly obtained via fermentation, a process where sugars undergo metabolism by yeasts.

Chemical Names:

Ethanol;
- OR -
ethyl alcohol

Synonyms:


Grog; booze; liquor; alky; spirits; hooch

Class:

Depressant

Appearance:

A colourless volatile liquid



Mechanism:

Ethanol acts as a positive allosteric modulator of synaptic and extra synaptic GABA_A receptors. At higher dosages, ethanol acts as a negative allosteric modulator at glutamatergic NMDA receptors. Ethanol also exerts actions upon other targets, including nicotinic receptors, AMPA and Kainate receptors, and L-type calcium channels, amongst others.

Psychoactive Effects:

Different concentrations of alcohol in the human

body have different effects on the consumer. The following table lists the common effects produced at increasing levels of blood alcohol content (BAC). Please note, however, that both tolerance and responses to alcohol can vary considerably between individuals.

BAC has traditionally been determined either as a percentage based on a mass of alcohol per volume of blood, or as percentage based on a mass of alcohol per mass of blood. BAC expressed in terms of weight-per-volume (% w/v) is not equivalent

across-the-board to BAC expressed in terms of weight-per-weight (% w/w). For example, a BAC of 5.00 grams of alcohol per litre of blood is equivalent to a BAC of 4.71 grams of alcohol per kilogram of blood. Complicating things further, different countries employ varying units of measurement to report BAC: micrograms per litre ($\mu\text{g}/\text{litre}$), milligram per 100 millilitres ($\text{mg}/100\text{ ml}$), milligrams per decilitre (mg/dl), and grams per litre (g/l), are all in use. In the chart below, ranges are expressed using BAC (% w/v) figures.

BAC (% w/v) 0.03%–0.12%	BAC (% w/v) 0.09%–0.25%	BAC (% w/v) 0.18%–0.30%	BAC (% w/v) 0.25%–0.40%	BAC (% w/v) 0.35%–0.50%
Elevated mood	Lethargy	Profound confusion	Stupor	Coma
Euphoria	Sedation	Emotional lability	Severe ataxia	Depressed reflexes (for example, pupillary responses to light)
Increased confidence	Impaired memory	Impaired sensory perception	Lapses of consciousness	Marked life-threatening respiratory depression
Enhanced sociability	Delayed reactions	Analgesia	Anterograde amnesia	Markedly decreased heart rate and hypotension
Decreased attention	Ataxia, or unbalanced walk	Advanced ataxia	Vomiting (death may occur due to inhalation of vomit while unconscious)	
Flushed appearance	Blurred vision	Impaired speech	Respiratory depression	
Impaired judgment	Other sensory impairments	Dizziness	Decreased heart rate	
Impaired fine muscle coordination		Nausea	Urinary incontinence	
		Vomiting		

Pharmacokinetics:

Ethanol is metabolised by the body, as an energy-providing nutrient, into acetyl coenzyme A (acetyl-CoA), an intermediate that can be used for energy in the citric acid cycle. Ethanol largely gets converted by liver enzymes into acetaldehyde, followed by acetic acid, which subsequently gets converted into acetyl-CoA. Those with acquired alcohol tolerance have a greater quantity of these enzymes, and metabolise ethanol more rapidly. Differences in the rates of alcohol-converting enzymes may produce a build-up of acetaldehyde and mild toxic effects in some individuals. Alcohol clearance follows zero-order kinetics and is excreted at a constant rate of approximately ten grams per hour, although this can vary between individuals.

Adverse Reactions:

Common: Sedation; loss of motor coordination; delayed reactions; impaired memory and comprehension; impaired speech; blurred vision; aggression; impulsivity. Hang-over effects are characterised by intense headache, nausea, shakiness, and sometimes vomiting.

Less Common: Profound confusion; emotional lability; analgesia; dizziness; nausea; vomiting

Rare: Severe ataxia; loss of consciousness; anterograde amnesia; respiratory depression; decreased heart rate; urinary incontinence

Life-threatening: Unconsciousness; depressed reflexes; respiratory depression; bradycardia and hypotension; aspiration of vomit

Contraindications:

Severe mental disturbances; hepatic diseases

Interactions:

Alcohol interacts with many drugs and substances; as a general rule, all CNS depressants should be avoided. Drugs with actions on GABA receptors should be avoided, including: barbiturates,

general anaesthetic agents, benzodiazepines, and GHB (γ -hydroxybutyrate). Opiates/opioids, ketamine, nitrous oxide, and antihistamines should also be avoided with alcohol. These interactions may enhance the dangerous effects of alcohol including, sedation, motor incoordination, unconsciousness, and respiratory depression. Mixing antibiotics and alcohol should be avoided, particularly metronidazole, tinidazole, and trimethoprim/sulfamethoxazole where disulfiram-like reactions of increased sensitivity to alcohol may occur and precipitate breathlessness, headaches, skin flushing, irregular heartbeat, light-headedness, and vomiting.

Harm Minimisation:

Alcoholism is a contributing factor to morbidity and mortality worldwide. In 2004, 3.8% of all global deaths were attributable to alcohol. Men are several times more likely to die from alcohol than women. Globally, the harmful use of alcohol is the leading risk factor for death in men aged 15–59 (WHO 2011). Alcohol is widely used in social contexts for its mood-enhancing, euphoric, and relaxant effects, and the maintenance of these effects requires a continuous consumption of the drug to be employed. The potential for harm in such cases may be minimised by monitoring levels of consumption and impairment to ensure an appropriate BAC. Some methods for modulating BAC include drinking water between alcoholic beverages and also eating food to delay absorption.

BAC of $> 0.08\%$ is associated with confusion and impaired senses, which enhance the propensity for risk-taking behaviours and poor judgement. Injury may result from impaired motor coordination. The active avoidance of potentially dangerous situations when inebriated is good practice. Driving whilst on alcohol is the largest criminal cause of death and injury in the Western world. As such, planning to not drive by designating a sober driver is the best practice. Whilst zero tolerance is practiced in some countries, most Western countries have legal limits of 0.02% – 0.08% BAC.

Overdose:

Death is often due to coma and respiratory depression; however, overdose may lead to aspiration of vomit or severe bradycardia. Such effects may occur when the BAC is greater than 0.4% .

AMPHETAMINE

Amphetamine was first manufactured in 1887 by the Romanian chemist Lazar Edeleanu, who synthesised it from ephedrine, a naturally occurring compound within the Ma-Huang plant (*Ephedra sinica*). Amphetamine is a stimulant with euphoric, anorectic, and sympathomimetic actions. It is a prototypic member and serves as a common structural template for other psychostimulants, but also for hallucinogens including the DOx and TMA series of amphetamines. It is used medically in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, and obesity.

Nomenclature:

Alpha-methylphenethylamine (amphetamine); α -methylbenzeneethanamine; 1-phenyl-2-amino-propane; phenylisopropylamine

Synonyms:

Hundreds of synonyms and proprietary names exist. Common proprietary names include: Adderall; Benzedrine; Dexedrine; Dextrostat; Evekeo and ProCentra. Street-names include: bennies; crank; dex; dexies; dexy; go-ey; speed; tweak.

Class:


Stimulant

Appearance:

Amphetamine usually presents as the salt form (often as the sulphate). Colour ranges from a white to brown powder sometimes with traces of grey, red, green, and other colours, which are often impurities remaining from its synthesis. As a pharmaceutical preparation, it comes as several different tablets and capsules; however, it is often encountered in various dosages (usually 5–30 mg) as small white tablets with a split in the middle.

Mechanism:

Amphetamine is an indirect sympathomimetic, with chemical structure similar to dopamine (DA), noradrenaline (NA), and also other endogenous trace amines. It essentially acts by releasing monoamines from within neurons into the synapse, particularly dopamine and noradrenaline. Specifically, amphetamine acts as a substrate for DA



and NA reuptake transporters whereby it may be taken up into neurons. Within the neuron, amphetamine acts as a substrate for neuronal vesicle monoamine transporters (VMAT2), thus being taken up into vesicles and displacing monoamines and increasing cytosolic concentrations of DA and NA. Further actions include as a potent full agonist on trace amine receptors (TAAR1), which enables the efflux of dopamine and noradrenaline out of the cell and into the synapse.

Amphetamine is composed of two stereoisomers at the α -carbon, namely the *levo* and *dextro* forms. These isomers display similar actions but with different potencies on the varying sites they act upon. Dextroamphetamine is a more potent TAAR1 agonist and four-fold more potent at releasing DA, whilst the *levo* form is more potent as a releaser of NA. Moreover the *dextro* isomer has greater CNS psychostimulant effects, whilst the *levo* form is associated with greater cardiovascular and peripheral effects.

Psychoactive Effects:

Increased alertness; increased concentration and motivation; mood elevation; euphoria; emotional lability; heightened physical energy; prolonged stamina and reduced fatigue; enhanced tactility; aphrodisiac effects; decreased appetite

Pharmacokinetics:

Oral: 5–40 mg, with 5–30 mg as commonly reported active doses. Onset is typically 30–40 minutes, with a duration of 4–8 hours, and after-effects for 5–24 hours.

Intranasal: 5–30 mg, with 5–20 mg as commonly reported active doses. Onset is typically 1–5 minutes, with a duration of 3–6 hours, and after-effects for 5–24 hours. Insufflation of amphetamine tablets containing binders and fillers can be a very painful experience and is advised against.

Rectally: 5–30 mg as commonly reported active doses. Onset is typically 10–20 minutes, with a duration of 3–8 hours, and after-effects for 5–24 hours.

Intravenous: 2.5–30 mg as reported active doses. Onset is typically within seconds, with a duration of 3–6 hours, and after-effects for 5–24 hours. Amphetamine tablets contain both water-soluble and insoluble binders and fillers, whilst illicitly manufactured amphetamines regularly contain synthesis impurities and cutting compounds; for these reasons, the injection of amphetamine is strongly advised against.

Note: The dosages above are for pharmaceutical grade dexamphetamine in individuals with little to no tolerance. Tolerance develops rapidly to amphetamine, and dosages can be 2–3 times higher during periods of extended use. In people with diagnoses of narcolepsy, oral dosages are titrated up to a maximum of 60 mg/day over a

number of weeks. Street speed is usually a mixture of 50% levo and 50% dextro isomers, and is commonly cut with glucose, other sugars, and caffeine. Because the purity varies, active dosages of street speed will vary from those presented above, requiring titration.

Adverse Reactions:

Common: Anxiety; grandiosity; restlessness; insomnia; agitation; increased body temperature; increased heart rate; increased blood pressure; bruxism (teeth grinding); heart palpitations; tremor; dry mouth; loss of appetite; temporary erectile dysfunction; hyperthermia; stereotypy (repeated behaviours such as grooming or scratching)

Less Common: Aggression; paranoia; panic attack; bruxism leading to damage to the teeth; difficulty urinating; tics; hyperthermia

Rare: Psychosis; mania; aggression; confusion and delirium in susceptible individuals or with prolonged usage

Life-threatening: Cardiac arrest or seizures; sudden death in individuals with structural heart defects and other serious heart problems; suicidal ideation in susceptible individuals; cerebral haemorrhage; rhabdomyolysis and kidney failure; sympathomimetic toxidrome; seizures

Contraindications:

Cardiac arrhythmia; history of symptomatic cardiovascular disease; arteriosclerosis; hypertension; hyperthyroidism; seizure disorders; glau-

coma; motor tics and Tourette syndrome; severe depression; anorexia nervosa; psychotic symptoms; suicidal tendencies; impaired renal function; psychotic disorders such as schizophrenia or bipolar disorder.

Interactions:

There are a great many agents with potential for drug-interactions with amphetamine. Whilst describing all these is beyond the scope of this Guide, important drug-interactions are described below. Under no circumstances should amphetamine be combined with a monoamine oxidase inhibitor (MAOI), as this can lead to serious hypertensive crises. Further, concomitant use of tricyclic antidepressants and amphetamine may also enhance the risk of hypertension. The concomitant use of amphetamine with other psychostimulants such as cathinones, MDxx, cocaine, as well as prescription stimulants including fenfluramine, phentermine, and methylphenidate may enhance the risk of dangerous hypertensive responses. Additionally, amphetamines may antagonize the hypotensive effects of antihypertensive medications. The effects and toxicity of amphetamines may be enhanced by CYP2D6 inhibitors; these include the SSRIs fluoxetine (Prozac) and paroxetine (Paxil), and also the antiretroviral protease inhibitor, ritonavir.

Harm Minimisation:

Amphetamine can be a highly habit-forming substance with repeated exposures. Insufflated and intravenous administration display an enhanced propensity for addiction, which has a characteristic withdrawal syndrome that increases in severity with both age and extent of usage. Repeated dosing with amphetamines results in greatly diminished psychoactive effects, requiring larger dosages with increases in adverse physiological effects and is advised against. Heavy comedown effects may ensue with such practices, which include cognitive fatigue, depression, anxiety, irritability, suppressed motivation, and sleep paralysis. Any individual intent on injecting drugs should be advised that even in clinical settings this form of administration carries inherent risks. Such discussion is beyond the scope of this Guide. However, users should be confident and aware of safe injecting practices, and know the risks involved from a lack of adherence to these.

Overdose:

Individual response to amphetamines varies widely. As such, doses of 30 mg can produce severe reactions; however, high dosages of over 300 mg are not necessarily fatal. Emergency medical treatment must be sought immediately if over-dosage is suspected. Monitoring of vitals and emergency stabilisation is required to manage those suffering seizure, cardiac arrest, or the acute consequences of arteriospasm or rupture such as stroke. It is extremely important to keep the individual hydrated. External cold packs may be applied to help bring the body temperature down and reduce sweating, in order to reduce hyperthermia, and the risks of rhabdomyolysis and kidney failure.

Related Compounds:

Below is a stub entry for methamphetamine, a structurally analogous and commonly encountered stimulant compound similar in effect to amphetamine. More importantly many of the mechanisms, effects, adverse reactions, risks, and harms as described above for amphetamine also apply to methamphetamine; as such, points of difference with other similar compounds are considered below.

METHAMPHETAMINE

Methamphetamine (MA) is a psychostimulant with euphoriant and aphrodisiac properties. Medical indications for MA (proprietary name: Desoxyn) include ADHD and obesity. It is commonly encountered as the hydrochloride salt, which can be smoked/vaporized without being converted to the freebase form first. (Many people incorrectly presume that smokable methamphetamine comes in freebase form due to this being the case with cocaine.) Slang names include: meth, crank, crystal, ice, shabs, tweak, and glass. MA crystals range from colourless to white in colour, with colourations indicating impurities. Dosages are similar to those reported for amphetamine. Like amphetamine, tolerance develops rapidly with repeated exposure, in these cases dosages may be higher than stated above. Insufflating MA results in great pain in the nasal cavity. When smoked or vaporised, amounts of 5–50 mg are commonly reported active doses. Onset is within minutes, with a duration of 1–4 hours, and after-effects for up to 24 hours. MA has a high addiction

potential, particularly when smoked or injected. MA displays dopaminergic and serotonergic neurotoxicity in humans, which—with chronic use—is associated with post-acute withdrawals persisting for many months.

Other Analogues:

There are a great many analogues of amphetamine, with a variety of effects ranging from stimulant, to empathogenic/entactogenic, to psychedelic. Pharmacologically, these effects occur due to differences in the actions of the analogue at varying targets, which may result in different ratios and amounts of monoamines being released from presynaptic terminals, whilst psychedelic amphetamines usually exert additional direct effects on serotonin receptors. Always be aware of the active dose ranges, durations of action, and effects associated with such analogues.


Analogues of amphetamine used in medicine include fenfluramine (a weight loss agent); with substituent additions made to the 3-position on the phenyl ring and an ethyl group added to the amine of amphetamine, it acts as a stimulant at lower doses and a psychedelic when dosage is escalated. Phentermine is an appetite suppressant with stimulant effects; it has an additional methyl group added to the α -carbon of amphetamine and as such lacks the stereoisomers of amphetamine. Analogues of phentermine for medical use (containing chloro substituents added to varying positions of the phenyl ring), include 4-chloro-

phentermine and 2-chloro-phentermine. Further addition of a keto group at the carbon gives rise to the cathinones (see the Mephedrone and MDPV index entries).

Other changes to amphetamine include halogens (bromo-, chloro-, iodo-) and methyl groups added to the 2-, 3-, or 4-position of the phenyl ring or combinations thereof; these generally appear to retain monoamine reuptake activity and have stimulant and anorectant properties. When 3,4-methylenedioxy- substituents are added to amphetamine, serotonin release is enhanced and empathogenic effects are observed; these include MDxx compounds (see MDMA entry). Addition of a methoxy group to the 4-position gives rise to *para*-methoxyamphetamine (PMA), a potent serotonin-releasing agent with a low therapeutic window for adverse effects. Further addition of three methoxy groups in varying combinations to the phenyl group gives rise to the trimethoxyamphetamines (TMAs), referred to as mescalamphetamine. Many compounds in this series have psychedelic properties. Further, the addition of halogens to the 4-position of the phenyl ring of 2,5-dimethoxy-amphetamine gives rise to a potent series of long-acting psychedelics, namely the DOx series developed by Sasha Shulgin, with actions as partial agonists at varying serotonin receptors (see 2C-B entry). As such amphetamine is a prototypic compound with many analogues in its class that produce a wide variety of psychoactive effects.

CANNABIS

Originating in Central Asia, cannabis is a plant with a long history of human use. Its stalks have been employed as a fibre source in textiles, candle wicks, rope, paper production, as a component in composite panels made for the automotive industry, and even used as insulation in home construction. Its nutritious seeds have been included in birdfeed and human food. They've been made into oil used in the production of paints and varnishes, incorporated into massage oils and various other body products, formed into biodegradable plastics, and used as a biofuel for



diesel engines. With the vast array of chemical compounds it produces (over a hundred cannabinoids have been isolated from the plant), it is not surprising that cannabis has been used medicinally for over 3,400 years, employed for wide diversity of therapeutic applications including the treatment of pain, nausea, insomnia, epileptic seizure, Parkinsonism, cancer, and many others. Archaeological finds of cannabis suggest that its ritual use as a spiritual sacrament goes back at least 2,500 years. Such entheogenic use continues today, sometimes comingling with less formal hedonistic–recreational approaches.

The twenty-first century has seen a shift in social and legal positions on cannabis, and a growing acceptance not only of the important medical applications of the plant, but also of the rights of individuals to consume it at their leisure without the threat of arrest and imprisonment looming as an ever-present concern.

Botanical Names:

Cannabis sativa; *Cannabis indica*; *Cannabis ruderalis*

Active Chemicals:

Δ -9-tetrahydrocannabinol (THC); cannabidiol (CBD); cannabichromene (CBC); tetrahydrocannabinavarin (THCV); and numerous other cannabinoids

Synonyms:

Bhang; buds; charas; dabs; dagga; ganja; grass; hashish; hemp; kif; marijuana; Mary Jane; pot; shatter; weed; and many more. Often names are for specific commercially developed strains, such as AK-47, Blueberry, Bubblegum, Chocolope, Chronic, Dog Shit, Girl Scout Cookies, Granddaddy Purple, Green Crack, Neighbour Kid, Northern Lights, OG Kush, Sour Diesel, White Widow, etc.

Class:

Cannabinoid

Appearance:

Dried flowering tops or leaves (marijuana); solid, darkly coloured brown to black resin (hashish);

solid, yellowish to dark amber-coloured butane- or CO₂-extracted resins (highly potent); edibles, such as cookies and cakes; oils and other extracts of varying consistency and colour.

Mechanism:

Over a hundred cannabinoids have been isolated from the cannabis plant, of which the major inebriating compound is Δ -9-tetrahydrocannabinol (THC). THC is a partial agonist of the cannabinoid receptors CB₁ and CB₂. Cannabidiol (CBD), a major non-psychoactive component of cannabis, is a neutralising modulator at cannabinoid receptors. In addition, CBD has a multitude of medicinal applications including as an anti-anxiety agent, a neuropathic pain reliever, an anti-psychotic, and an antiepileptic. Recently, CBD been shown to act on ligand-gated ion channels including GABA and glycine receptors, as well as having actions on many other targets.

Psychoactive Effects:

Euphoria; modified body-feeling (heaviness or buzz); altered perception of time; increased associative thinking; increased creativity; psychological confusion; anxiety; paranoia; increased pulse rate; perceptive changes; dry mouth; red eyes; drowsiness. Larger doses may produce hilarity and laughter, visual and auditory hallucinations, and sedation.

Pharmacokinetics:

In the plant, THC is present as the non-inebriating THC acid, which requires heating in order to be decarboxylated into the psychoactive THC. For this reason, cannabis is usually smoked or cooked into edibles.

Smoking: Standard dose is 0.3 grams cannabis in a joint, and less, about 0.1 grams, in a water pipe. Depending on individual tolerance levels and other factors, acute effects may be experienced from a single inhalation. Onset is 20–90 seconds, duration lasts 2–4 hours, and after-effects may continue for another 2–4 hours.

Vaporisation: Similar effects, duration, and dosage as per smoking. Increasingly, purified gooey extracts of high THC content called “dabs” or “shatter” are vaporised in a process called “dabbing”. Such extracts are very potent and should only be used by regular consumers of cannabis, otherwise adverse reactions may be experienced.

Oral: Onset of effects from edibles, such as cookies, cakes, etc., is 30–90 minutes. After onset, peak effects last for an hour, with a plateau phase of up to 5 hours. Comedown and hangover effects may extend to twelve hours or more after ingestion. When cannabis is used in edibles, often it has been pre-heated before being incorporated into the baked good, since such an approach helps maximize the decarboxylation of THC-acid into THC.

Adverse Reactions:

Common: Dry mouth; red eyes; increased pulse rate; lowered blood pressure

Less Common: Nausea; vomiting; dizziness; drowsiness

Rare: Severe adverse psychological reactions; sedation; vasodepressor syncope (fainting); risk of psychosis in susceptible individuals

Life-threatening: None reported

Contraindications:

Psychiatric illness, particularly schizophrenia and related psychotic disorders; cardiovascular diseases and arrhythmias.

Interactions:

No known dangerous interactions. Combining alcohol with cannabis may increase “negative” effects, including nausea, vomiting, drowsiness, anterograde amnesia, and reduction of psychophysical performance. In an individual who is already moderately intoxicated with alcohol (for example), smoking a joint is likely to elicit predictably adverse effects, including nausea, vomiting, dizziness, general weakness, and a disturbed psychological state.

Harm Minimisation:

While having the potential to cause an adverse psychological experience (particularly in the naïve user), the ingestion of cannabis—even in high doses—very rarely presents any physiological danger.

Overdose:

None reported. The LD₅₀ of cannabis is given by some sources as being in the order of 20,000 to 40,000 times the amount contained in a single average-sized joint.

Related Compounds:

Most synthetic cannabimimetics are unrelated structurally to the phyto-cannabinoids. Being structurally novel, the cannabimimetics may exert actions at a vast array of additional physiological targets alongside actions at cannabinoid receptors. Adverse reactions that may result from use of synthetic cannabimimetics include seizures, severe withdrawals, and other mentally and physically unpleasant effects. As there is no way for the average consumer to be certain of the identity of the synthetic cannabimimetic(s) in most products on the market, such products are best avoided.

COCAINE

A psychostimulant and local anaesthetic obtained from the *Erythroxylum coca* plant. The drug was first isolated in 1859 by the German chemist Albert Niemann. Modern recreational use was popularised in the 1970s, although its consumption through the chewing of coca leaf is a practice that is thought to date back thousands of years. In its salt form cocaine is typically consumed intranasally, while its freebase preparation, crack cocaine, is more readily smoked. Cocaine possesses considerable addiction liability, particularly in smoked form.

Chemical Name:

Ecgonine methyl ester benzoate;

- OR -

benzoylmethylecgonine

Synonyms:

Coke; blow; Charlie; C; crack; big C; biscuits; caine; chalk; coca; snow; yayo; and numerous others

Class:


Stimulant; tropane alkaloid

Appearance:

In its hydrochloride salt form, cocaine usually presents as a white or off-white powder. In its freebase form the drug may appear as a white, yellowish-white, or light brown powder or in larger crystals ("rocks"), often composed of varying textures.

Mechanism:

Cocaine acts on monoamine reuptake transporters to inhibit the reuptake of dopamine, serotonin, and noradrenaline, resulting in increased synaptic concentrations and enhanced monoamine neurotransmission. Additionally, cocaine acts as a non-selective monoamine oxidase (MAO) inhibitor, a sigma-1 (σ_1) non-opioid receptor agonist and upon serotonin-2 and -3 receptor subtypes. Local anaesthesia is mediated via the blockade of sodium (Na^+) on cell membranes, preventing the conduction of nerve impulses (that is, action potentials).



Psychoactive Effects:

Cocaine acts as an indirect sympathomimetic, producing stimulant, euphoriant, and anorectic effects. Typical dose-dependent effects may include increased alertness; mood elevation; euphoria; emotional lability; reduced fatigue; sexual arousal; decreased appetite; irritability; insomnia; and restlessness. Cocaine carries a high potential for addiction.

Pharmacokinetics:

Oral: 50–200 mg as commonly used active dosages. Onset is within 30–40 minutes, with a duration of 60 minutes, and peak subjective effects 20 minutes after onset.

Intranasal: 30–100 mg as commonly used active dosages. Onset is within minutes or even faster, with a duration of 40–60 minutes, and peak subjective effects 15 minutes after onset.

Rectal: 20–100 mg as commonly reported doses. Onset is within 10 minutes; otherwise similar durations as per oral have been reported.

Injection: 10–25 mg as commonly reported active dosages. Onset is within seconds, with a duration of 5–10 minutes, and peak subjective effects 3 minutes after onset.

Inhalational: 15–30 mg as commonly reported active dosages. Onset is within seconds, with a duration of 5–15 minutes, and peak subjective effects are within 2 minutes of onset.

Note: Significant tolerance to the psychostimulant effects of cocaine occurs with chronic use and active doses may be greater in certain users.

Adverse Reactions:

Common: Anxiety; agitation; paranoia and fear; headache

Less Common: Hypertension; tremors; gastrointestinal complications such as abdominal pain and nausea

Rare: Acute psychosis; rapid breathing; hyperthermia; hyperreflexia; chest pain

Life-threatening: Cardiac arrhythmia; heart attack; respiratory failure; stroke; convulsions

Contraindications:

History of cardiac disease; acute myocardial infarction; coronary artery disease; cardiac arrhythmias; hypertension; seizure disorder; hyperthyroidism; Tourette syndrome; cerebrovascular disease; pregnancy

Interactions:

Additive effects and increased toxicity may be observed when cocaine is combined with other stimulants. Cannabis may have additive effects on hypertension, tachycardia, and possibly cardiotoxicity. Alcohol consumption will result in

the formation of cocaethylene, a metabolite more toxic than cocaine. MAO inhibitors and tricyclic antidepressants enhance the risk of hypertension with cocaine. Citalopram (SSRI) and cocaine may enhance the risk of a subarachnoid haemorrhage (bleeding in brain). Cardiac glycosides, for example digoxin, enhance the risk of cardiac arrhythmias, increased heart rate, and hypertension. Medications that decrease the seizure threshold are contraindicated, for example tramadol (opioid analgesic) and bupropion (noradrenaline–dopamine reuptake inhibitors). Co-administration of cocaine and opiates/opioids increases the risk of both nonfatal and fatal overdose.

Harm Minimisation:

Cocaine has a short half-life, commonly leading to repeated dosing in order to maintain effects. Such consumption patterns enhance the risk for potentially dangerous dose escalations to occur. When the effective dose is escalated, greater euphoria may result; however the incidence of toxic and unpleasant effects rises as well. Avoidance of “binge” consumption is recommended, and taking care to note both cumulative dosage and time between administrations is a good practice to minimise these risks. Whilst dosage levels may vary depending on administration method, one should be confident that the psychoactive effects of previous administrations have largely subsided before re-dosing.

The use of alcohol and cocaine results in the formation of the cocaethylene, a metabolite with significant cardiotoxicity. The co-administration of both alcohol and cocaine is associated with a more than twenty-fold increase in the risk of fatal overdose. Cocaine is commonly of low purity with adulterants added, including other local anaesthetics, ephedrine, and other stimulants. In recent years, levamisole has often been used as a cutting agent; it has been reported as a component in over 80% of cocaine seizures. Levamisole suppresses the immune system and can greatly increase the risk of infection, as well as being associated with autoimmune disorders such as vasculitis.

Physical side-effects specific to the route of administration include nosebleeds and intranasal perforations from insufflation, as well as coughs, laboured breathing, and sore throat from smoking freebase cocaine. Importantly, if taken via injec-

tion, the harm-minimisation practice of employing standard safe needle protocols should always be maintained. Cocaine possesses a large addiction liability and chronic usage is associated with many long-term adverse effects. These range from persisting neurological effects, such as motivational and other psychiatric disorders, cognitive deficits, cardiovascular toxicity, haemorrhages, and blood clots.

Overdose:

Cocaine is associated with a large number of overdoses worldwide. Toxicity is characterised by hyperthermia, hypertension, chest pain, anxiety, and agitation. Whilst the majority of cocaine-

induced deaths are due to hyperthermia, overdose may manifest as hypertension, convulsions, stroke, cardiac arrhythmias or ischemia, respiratory failure, and muscle overactivity leading to rhabdomyolysis and subsequent kidney dysfunction.

Related Compounds:

Compounds that act as serotonin-noradrenaline-dopamine reuptake inhibitors (SNDRIs) include other stimulants such as methylphenidate (Ritalin). Many analogues of cocaine exist, having been designed in an attempt to isolate/modify actions on sodium channel blockade or on dopamine reuptake inhibition. Some of these analogues include troparil, 2'-hydroxycocaine, and cocaethylene.

DMT

DMT is a powerful psychedelic tryptamine found in many plants, and contained endogenously in all mammals studied to date. DMT is naturally present in the human body. When DMT is consumed (for example, by smoking), radical changes in consciousness are experienced. Some indigenous groups in South America make use of various DMT-containing preparations. For such groups, the visionary experience is usually situated at the heart of their cosmology and cultural practices. The ayahuasca brew represents a remarkable technology, wherein, out of many thousands of available plant species, a precise concoction was found that combined leaves from a DMT-containing plant (such as *Psychotria viridis*) with a monoamine oxidase inhibitor-containing species (such as the *Banisteriopsis caapi* vine), thereby rendering the DMT orally active.

Chemical Name:


N,N-dimethyltryptamine

Synonyms:

D; Dimitri; elf spice; spice; ayahuasca and changa (when DMT is used with a monoamine oxidase inhibitor)

Class:

Serotonergic hallucinogen



Appearance:

Pure DMT is a white crystalline solid, and is usually in the freebase form to facilitate smoking. Crystalline DMT extracted from plants may have different colours and textures, often in yellow/orange/red tones, depending on impurities present.

Mechanism:

Similarly to other classic hallucinogens, DMT is a serotonin receptor agonist, considered to primarily act on the 5-HT_{2A} receptor, but it has also been found act as an agonist on 5-HT_{2C}, 5-HT_{1A}, 5-HT_{1D}, and 5-HT₇ receptors. Other, non-serotonergic activity for DMT has also been demonstrated, as

an agonist at G protein-coupled trace amine (TA) receptors, and as a possible endogenous agonist for the sigma-1 receptor.

Psychoactive Effects:

The experience of injected or smoked DMT has been described as a radical shift in the user's reality. The drug facilitates powerful changes in awareness, perceptions, emotions, and cognition. At appropriate doses these changes manifest as visionary experiences, often featuring distinct phenomena arising in open- and closed-eye visuals. These visual may consist of phosphenes, form constants, animated geometries and folding manifolds, through to complex immersive experiences of imagery and scenes, strange creatures, foreign otherworldly environments, and humanoid entities in various forms. As the phenomenology of DMT can be overwhelming, rapid, alien and intense, deep fear may arise, sometimes resulting in difficult experiences.

Pharmacokinetics:

Inhalational: Active at doses of 5–50 mg, with commonly used dosages of 15–30 mg. Onset of effects within 5–30 seconds, with a duration of 3–15 minutes, and come down around 5 minutes. Total duration of effects is up to 20 minutes.

Intranasal: Active at doses of 5–50 mg. Onset of effects within 5 minutes, with a duration of 15–30 minutes, and come down around 10 minutes. Total duration of effects lasts up to 45 minutes.

Injection: For intravenous injection, 0.2 mg drug/kg of bodyweight typically marks the psychedelic threshold, while 0.4 mg/kg and above may be considered a "high" dose. Time of onset is seconds, peaking at 2–5 minutes. Intramuscular injections take 2–3 minutes for onset, peaking in 10 minutes, and are over in under an hour.

Oral: DMT is inactive when consumed orally unless a MAOI is taken concurrently. Ayahuasca made from the

Amazonian DMT-containing plant *Psychotria viridis* and the MAOI-containing vine *Banisteriopsis caapi* is a traditional orally active preparation. But ayahuasca analogues, or anahuasca, can be brewed from non-Amazonian plants, such as certain DMT-containing *Acacia* species or *Mimosa tenuiflora* and the MAOI-containing plant *Peganum harmala* (Syrian rue). And some folks prefer to take their oral DMT via a pharma-huasca preparation that combines pure DMT with a pharmaceutical MAOI such as moclobimide. An approximate per person dose for ayahuasca includes 50–100 grams of *B. caapi* vine with 50–100 grams of *P. viridis* leaves, prepared in water as a tea and cooked for many hours. If *P. harmala* is used as the MAOI source instead of *B. caapi*, only 3–4 grams of ground seeds are needed. Alternatively, active doses of purified plant extracts have been reported from the combination of 35–150 mg of DMT, with 35–50 mg being an oft-recommended range, taken with 100–250 mg of harmala alkaloids. Onset is usually 20–60 minutes, with a plateau phase of 1–3 hours, and after-effects that may continue for up to eight hours.

Adverse Reactions:

Common: Anxiety; the sensation that the user is no longer breathing or is dying; dilated pupils; heightened blood pressure; increased pulse; hyperthermia

Less Common: Overwhelming fear; nausea; vomiting (usually associated with high doses); lung irritation; diarrhoea; highly disorientating experiences (usually associated with high doses)

Rare: Psychosis in susceptible individuals

Life-threatening: None reported

Contraindications:

Mental illness, particularly schizophrenia and other disorders characterised by periods of psychosis; hypertension; cardiovascular disease

Interactions:

None reported for DMT. Using DMT in combination with other hallucinogens may increase the effects and the likelihood of adverse reactions. If taken orally with a MAOI, standard precautions for consumption of a MAOI should be followed (see beginning of this Guide).

Harm Minimisation:

Standard precautions as per all hallucinogens. Guests are highly unlikely to present to a care service whilst undergoing a DMT experience, unless it is in the form of an ayahuasca trip. Guests may seek assistance after a DMT experience; this will usually involve debriefing, discussion, and psychological support.

Overdose:


No known fatal overdose has been reported solely from DMT consumption.

Related Compounds:

5-methoxy-*N,N*-dimethyltryptamine (5-MeO-DMT) is also found in a wide variety of plant species and in the Sonoran Desert toad, *Incilius alvarius* (*Bufo alvarius*). It is more potent than DMT and may have a slightly longer duration in some users. When vaporized, a 5–20 mg dose range is commonly used. Although the effects produced by 5-MeO-DMT are similar in some ways to those produced by DMT, there are some notable differences. Whilst fractal-like, kaleidoscopic imagery may be experienced at the onset of the 5-MeO-DMT experience, it is generally less visual and less colourful than DMT. Powerful and often difficult experiences—characterised by ego-dissolution and what is described as “merging with light”—have been reported by 5-MeO-DMT users. Many people have little desire to repeat the experience once they’ve taken an immersive dose of 5-MeO-DMT. Some users will combine DMT with 5-MeO-DMT at a ratio of around 5:1 (due to the higher potency of the later), in order to achieve an experience that blends the effects of both compounds; this combination has been referred to by the name “the Mayan twins”.

GHB

GHB, or gamma-hydroxybutyrate is a CNS depressant commonly consumed as a recreational drug or as a sleep aid. Its effects most closely resemble those of alcohol and its steep dose-response curve and synergistic effect with other depressants significantly increases risks of overdose. Found endogenously, research into GHB commenced in the 1960s and its role in growth-hormone production made it popular amongst bodybuilders in the 1980s. Increased recreational use and its characterisation as a date-rape drug by the media ultimately prompted prohibition worldwide by the early 2000s. Under the name sodium oxybate, GHB is approved for prescription use treating the sleep-related disorder narcolepsy.

**Chemical Name:**

γ-hydroxybutyrate;
- OR -
sodium oxybate;
- OR -
sodium 4-hydroxybutyrate;
- OR -
4-hydroxybutanoic acid

Synonyms:

Liquid E; fantasy; G; GBH; liquid X, Xyrem®

Class:

Depressant

Appearance:

Generally presents as a clear, odourless salty-tasting liquid, or less commonly as a white powder.

Mechanism:

Full agonist of the GHB receptor, weak partial agonist of the GABA_B receptor, and an agonist of extrasynaptic GABA_A receptors.

Psychoactive Effects:

The effects of GHB are reminiscent of alcohol. Users report that it induces a pleasant state of relaxation and tranquillity, and at higher doses it can be helpful as a sleep aid.

Pharmacokinetics:

Oral: Moderate dose is 2–3 grams (28–43 mg/kg in a 70-kg person). Onset within 10–20 minutes, with a duration of 1–3 hours, and after-effects lasting 2–4 hours. Absorption is reduced and delayed by food; metabolism is delayed by liver impairment.

Adverse Reactions:

Common: Headache; nausea; vomiting; dizziness; unconsciousness

Less common: Confusion; irrational behaviour; slurred speech; urinary incontinence

Rare: Very low breathing; twitching or convulsions; slowed heart rate; fixed pupils; sleepwalking

Life-threatening: Higher doses of GHB may cause both unconsciousness and vomiting, which can lead to aspiration of vomit and damage to the lungs or suffocation.

Contraindications:

Compromised liver function, e.g., cirrhosis; impaired respiratory drive, e.g., sleep apnoea; depression or suicidal ideation; succinic semialdehyde dehydrogenase deficiency (SSADHD)

Interactions:

Cumulative effects observed when mixed with other depressants as well as an increase in negative side-effects. Mixing GHB with alcohol causes cumulative depressive effects as well as increased nausea and vomiting. Avoid mixing with alcohol, opiates/opioids, ketamine, or other depressants.

Harm Minimisation:

Given its steep dose–response curve, individuals usually start with a low dose, and increase the dose incrementally, especially with a batch of unknown concentration. Accidental or surreptitious administration of GHB may be prevented by dying preparations with blue food colouring. Mixing with alcohol or other depressants is extremely dangerous and implicated in over one-third of GHB-related deaths. Whenever reasonably possible, GHB users should inform others about what they have taken. There are numerous stories of GHB users who have woken up in a hospital, having been taken there by friends or strangers who were concerned because they had become unconscious and were unrousable.

Overdose:

Oral doses of 50 to 63 mg/kg are associated with loss of consciousness and profound coma. Until they regain consciousness, persons who are unconscious should be turned on their side in the recovery position—particularly if they are actively vomiting—so that their airway is kept clear and they don't aspirate or choke on vomit. The oral LD₅₀ in rats is 9,690 mg/kg.

Related Compounds:

Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-B) are both pro-drugs of GHB, and are converted to GHB in vivo. Although it can be somewhat difficult to readily distinguish GBL from GHB, 1,4-B has a freezing point of 20.1°C and in its pure form will solidify at around room temperature (or if refrigerated).

HEROIN

Heroin is a semi-synthetic opiate derived from morphine, which is present in the opium poppy. It was first synthesized in 1874 by the English chemist C.R. Adler Wright. It was rediscovered by the German pharmaceutical company Bayer in 1897, and by 1898 Bayer was marketing it to physicians under the name of Heroin. Described as “the sedative for coughs”, it was purported to be a non-addictive alternative to morphine. Its addictive properties became readily apparent in the years to follow, and in 1913 Bayer decided to cease production. The addition of two acetyl groups to morphine forms heroin, or diacetylmorphine. Heroin crosses the blood-brain barrier readily, where it is metabolised to morphine before exerting actions on opioid receptors. Heroin’s effects are characterised by euphoric indifference, relaxation, sedation, and analgesia. Heroin possesses a high potential for addiction, and is associated with significant morbidity and mortality, particularly when injected intravenously.

Chemical Name:

3,6-diacetylmorphine;

- OR -

diamorphine

Synonyms:

Dragon; gear; H; Harry; horse; junk; scag; smack

Class:


Opiate

Appearance:

Heroin may present as a freebase or salt form, and usually ranges from a crushed powder or granules through to crystalline rocks of varying composition. Colours of crystallised heroin include white to off-white, beige, tan, brown and even black. Unrefined black or brown heroin may indicate the presence of mono-acetylated morphine derivatives.

Mechanism:

The primary mechanism of action is as a μ -opioid receptor agonist. Heroin acts as a pro-drug of morphine; the presence of the two acetyl groups make heroin more lipophilic than morphine,



allowing it to more readily cross the blood-brain barrier. Once in the brain, heroin undergoes additional metabolism and is de-acetylated into morphine, which has actions as an agonist at μ_1 - and μ_2 -opioid receptors. Further, a major active metabolite of morphine, morphine-6-glucuronide, by adopting a unique folded conformation, also crosses the blood-brain barrier with surprising efficiency, where it significantly contributes to the analgesic effects by virtue of its activity at μ -opioid receptors. This G protein-coupled receptor system undergoes pronounced regulatory changes upon repeated exposure to opiates/opioids, and tolerance can develop. These mechanisms are also associated with withdrawal phenomena.

Psychoactive Effects:

Administration by intravenous injection is typically characterised by a rapid onset of euphoria and causes a “rush” phenomena lasting for a few minutes, followed by sedation lasting a few hours. When injected intramuscularly or snorted, there is a slower onset and less intense effects. The effects of heroin are dependent on the dose administered and vary based on the quality of material, the route of administration, and the set and setting. These effects include feelings of euphoria, well-being, ataraxia, relaxation, sedation, and analgesia.

Pharmacokinetics:

Oral: Approximately 50–70 mg. Onset of 20 minutes, peak with 30 minutes, total duration of 5 hours or more. Heroin possesses considerably better bioavailability than orally administered morphine.

Intranasal: Approximately 5–40 mg. Onset of minutes, peak within 10 to 20 minutes, with a peak duration of up to 15 minutes, and a total duration of 3 hours.

Smoked: Approximately 15–25 mg. Onset of 10 seconds, peak onset within 10 minutes, with a peak duration of 5 minutes, and a total duration of 3–4 hours.

Injection: Approximately 5–10 mg intravenous for non-tolerant user. Onset is within 15 seconds, and a duration of 4–5 hours.

Adverse Reactions:

Common: Nausea and vomiting; constipation; pruritus (itching) due to histamine release; tolerance; addiction

Less Common: Loss of consciousness may occur with higher doses.

Rare: Anaphylaxis

Life-threatening: Fatal respiratory depression

Contraindications:

Hypersensitivity to morphine or other opiates/opioids; acute respiratory depression

Interactions:

Combined use with other drugs, especially CNS depressants such as alcohol and benzodiazepines, is significant, and is a strong risk factor in both fatal and non-fatal heroin overdoses. Post-

mortem studies typically implicate depressants in approximately 40% of all heroin-related deaths. Respiratory drive is mediated by the brainstem, and densely innervated by μ -opioid receptors. As such, the inhibitory actions of heroin on respiratory drive are potentiated by the concomitant use of alcohol or benzodiazepines, and these combinations are a major cause of fatalities.

Harm Minimisation:

Heroin overdose is potentially life-threatening but easily managed with prompt care. If accessible, the overdose may be rapidly and reliably reversed by intramuscular administration of the opioid antagonist naloxone. There are also naloxone nasal sprays that can be used to similar effect. Although not ubiquitous, peer-based access to naloxone is legal in a number of countries worldwide, including much of North America, Europe, and Australia. Harm-minimisation policies, including ready access to naloxone, have been shown to reduce the risk of death from aspiration of vomit.

The prevalence of blood-borne viruses, particularly Hepatitis C, is exceptionally high among intravenous drug using populations. In countries where needle exchange programs are widespread, for example Australia, rates of infection are approximately 50%, while rates of 90% are seen in many parts of the United States and Europe. Under no circumstances should needles or other injecting paraphernalia (such as tourniquets or spoons) be shared or re-used.

Any individual intent on administering drugs intravenously should be advised that even in clinical settings this form of administration carries inherent risks. Such discussion is beyond the scope of this Guide; however, users should be aware of safe injecting practices, and know the risks involved from a lack of adherence to such practices. Whenever possible, heroin should not be consumed alone, nor should its purity be assumed based on prior purchases. Analysis of drug seizures indicates considerable variability in heroin purity, including unanticipated increases in purity, which can contribute to the likelihood of an overdose.

Overdose:

Despite possessing linear dose-dependent effects, heroin poses considerable risk of overdose, particularly when used intravenously. Furthermore,

tolerance develops with repeated administrations, and tolerant users may inject doses up to twice the amounts reported above. Changes in a particular intravenous drug user's tolerance to heroin following abstinence, and/or increases in anticipated purity based on prior purchases, are major contributing factors in fatal and non-fatal overdoses.

Related Compounds:

There are several structurally related analogues of morphine that are effective analgesics when used in the clinical management of pain. Pre-

scription opioids include oxycodone (Oxycontin; Endone), hydrocodone (Vicodin, Norco), fentanyl (Duragesic), and several others. These drugs are widely abused, with significant morbidity. They vary in potencies, active doses, durations, effects profiles, therapeutic windows, and propensities for overdose. While the inclusion of detailed specifics for each of the available prescription opioids is beyond the scope of this Guide, much of the information provided above for heroin is generally applicable to any opiate/opioid drug.

KETAMINE

A dissociative used primarily in anaesthesiology, with psychedelic effects at sub-anaesthetic doses. Ketamine has also shown promise in the treatment of depression and alcoholism. Effects from sub-anaesthetic doses include sensory distortions, confusion, motor incoordination, hallucinations, and deeply dissociated states, often referred to by recreational ketamine users as a "K-holes".

Chemical Name:

2-(2-chlorophenyl)-2-(methylamino)cyclohexanone

Synonyms:

K; Ketalar; Ketaset; Ketavet; kit-kat; special K; vitamin K

Class:


Dissociative hallucinogen; arylcyclohexylamine

Appearance:

Sometimes diverted from veterinary settings and may present in its original vial as a solution for injection. However, ketamine is more commonly encountered in powder or tablet form.

Mechanism:

Ketamine's dissociative properties are primarily exerted via NMDA receptor antagonism. Ketamine has a complex pharmacology, however, and acts upon numerous targets in the central nervous system.



Psychoactive Effects:

Dissociation characterised by loss of pain sensation, motor incoordination, and feelings of detachment from the external world. When sufficiently high doses are administered, a state referred to as the "K-hole" is reached, whose phenomenology may be reminiscent of out-of-body experiences (OBEs), near-death experiences (NDEs), and lucid dreaming.

Pharmacokinetics:

Oral: Active doses range 0.5–8 mg/kg, with approximately 6–8 mg/kg required to reach the K-hole. Onset up to 20 minutes, with a duration of 90 minutes, and hangover effects lasting 4–8 hours.

Intranasal: Active doses range 0.2–2 mg/kg, with approximately 2 mg/kg required to reach the K-hole. Onset within 5–15 minutes, with a duration of 45–60 minutes, and hangover effects lasting 1–3 hours.

Rectal: Active doses range 0.5–5 mg/kg, with approximately 6–8 mg/kg required to reach the K-hole. Onset within 5–10 minutes, with a duration of 2–3 hours, and hangover effects lasting 4–8 hours.

Injection: Active doses taken intramuscularly range 0.2–1.5 mg/kg, with approximately 1.5 mg/kg required to reach the K-hole. Onset within 5 minutes, with a duration of 30–60 minutes, and hangover effects lasting 2–4 hours. Non-medical intravenous use is uncommon.

Adverse Reactions:

Common: Loss of motor coordination; nausea; hypertension; increased heart rate; double vision

Less Common: Muscle stiffness and jerking movements sometimes resembling a seizure; hypotension; reduced heart rate; ketamine-associated ulcerative cystitis and other lower urinary tract symptoms (LUTS)

Rare: Psychosis in susceptible individuals

Life-threatening: Anaphylaxis; severe respiratory depression with high doses

Contraindications:

Psychiatric illness, particularly schizophrenia and related psychotic disorders; history of seizures; glaucoma; any medical condition where hypertension would be hazardous (for example cardiovascular disease)

Interactions:

Use of depressants such as alcohol and GHB can result in increased CNS and respiratory depression. Benzodiazepines, for example diazepam, may prolong the half-life of ketamine. Ketamine is largely metabolised by the CYP3A4 enzyme and use of CYP3A4 inhibitors (like ketoconazole, for example) may also prolong its half-life.

Harm Minimisation:

Standard precautions as per all hallucinogens; however, there is a greater risk for psychosis and delusional ideation in susceptible individuals. Injury from loss of motor coordination is possible. Importantly, if taken via injection, the harm-minimisation practice of employing standard safe needle protocols should always be maintained. Chronic use is associated with cognitive deficits; and unlike other hallucinogens, ketamine is considered to have the potential to be psychologically addictive.

Overdose:

LD₅₀ is approximately 100-fold greater than doses typically used in recreational settings. Overdose of ketamine can result in severe respiratory depression requiring medical treatment.

Related Compounds:

Other arylcyclohexylamines include methoxetamine (MXE); phencyclidine (PCP, Sernyl); eticyclidine (PCE); tiletamine (Telazol [with zolazepam]). Please be aware these agents have greatly varying durations of effects and dosages.

Additional Comments:

Although commonly used in veterinary medicine, ketamine's branding as a horse tranquilliser is a misnomer.

LSD

Lysergic acid diethylamide (LSD) is arguably the most iconic psychedelic drug. Some have described it as the “fuel” that enabled the 1960s countercultural movement. LSD is derived from alkaloids found in the ergot fungus, *Claviceps purpurea* (whose accidental ingestion was historically referred to as St. Anthony’s fire). The drug was first synthesised by Albert Hofmann in 1938 at Sandoz Laboratories in Basel, Switzerland. Its psychedelic effects were discovered by Hofmann five years later following an accidental exposure, inspiring an intentional bioassay on 19 April 1943. As the LSD began to affect Hofmann, he left the lab and struggled to ride his bicycle home. Reflecting on that fateful day, Hofmann remarked: “I suddenly became strangely inebriated. The external world became changed as in a dream...”

Chemical Name:

d-lysergic acid diethylamide;

- OR -

LSD-25 (being the 25th compound in a series of modified lysergamides that Hofmann synthesised to be investigated for potential therapeutic uses)

Synonyms:

Acid; Alice; blotter; Delysid[®]; doses; fry; gel; hits; L; Lucy; tabs; trips; uncle Sid

Class:


Serotonergic hallucinogen

Appearance:

A crystalline salt, often found as the tartrate. The drug is extremely potent, and in order to enable accurate dosing is commonly soaked into blotter paper that has been perforated into small squares (“tab”). It is also made available as a liquid, prepared by dissolving the crystal into ethanol. Other forms include pills, gelatine, and liquid dropped onto sugar cubes. LSD possesses a somewhat unstable structure, which degrades when exposed to UV light, high temperature, moisture, or chlorine.

Mechanism:

The primary mechanism associated with the psychedelic effects of LSD is its action as a partial agonist at 5-HT_{2A} receptors. In addition, LSD acts



upon 5-HT_{1A}, 5-HT_{2B}, 5-HT_{2C}, 5-HT_{5A}, and 5-HT₆ receptors. Further, LSD acts upon a large number of other G protein-coupled receptors, including dopamine and adrenergic subtypes.

Psychoactive Effects:

LSD is a classic/prototypic psychedelic; it could be said to define “psychedelic” as a descriptive class. LSD’s effects include alterations to sensory- and thought-processing, resulting in powerful changes in consciousness. These changes may manifest in associative thinking, in auditory and visual perception, as closed- and open-eye visuals, states of deep psychological reflection and introspection, spiritual experiences, mood shifts, laughter, feelings of connectedness, anomalous perception of time, synaesthesia, and unusual thoughts and speech. The LSD “trip” also has potential to produce temporary anxiety, paranoia, panic, and overwhelming feelings. These may culminate into a very difficult experience, with adverse psychological effects occasionally persisting after the acute effects of the drug have worn off, sometimes for days, or weeks, or even months longer.

Pharmacokinetics:

LSD has a wide active dose range. It is most often administered orally or sublingually. Threshold ef-

ffects are felt with as low as 25 µg, with moderate effects at 75–125 µg and pronounced psychedelic effects at 150–400 µg. Higher doses have been reported; however, larger amounts can be very difficult to handle, particularly in festival environments. Onset is within 20–60 minutes, with a plateau of 3–6 hours, and a total duration of approximately 6–12 hours. Acute administration of LSD results in rapid onset of tolerance to the drug and cross-tolerance to most other serotonergic hallucinogens (for example, psilocybin), lasting approximately 3–7 days.

Adverse Reactions:

Common: Anxiety; jaw tension; increased salivation and mucous production; overwhelming feelings; insomnia; difficulty regulating body temperature; slight increase in heart rate; difficulty focusing

Less Common: Nausea; dizziness; confusion; paranoia, fear or panic; tremors; increased blood pressure

Rare: Hyperreflexia; exacerbation of latent or existing mental disorders; flashbacks; and Hallucinogen Persisting Perception Disorder (HPPD), characterised by an ongoing awareness of sensory alterations reminiscent of those produced by LSD administration. It is a very rare condition, reported by individuals with previous exposures to hallucinogens.

Life-threatening: None reported

Contraindications:

Psychiatric illness, particularly schizophrenia and related psychotic disorders

Interactions:

Use of certain antidepressants such as lithium and tricyclic antidepressants may trigger a dissociative fugue state. There are anecdotal reports that lithium and LSD may be associated with enhanced

risk of seizures. Use of SSRI antidepressants, for example fluoxetine, has been shown to reduce the subjective effects of several serotonergic hallucinogens, including LSD.

Harm Minimisation:

Standard precautions as per all hallucinogens. Use of vehicles and other heavy machinery must be avoided.

Overdose:

No well-documented cases of pharmacologically induced deaths from overdose on LSD have been reported, and none of the scant few LSD-related deaths described in the medical literature can be unquestionably stated as having been solely caused by LSD. In rare cases, LSD may have played a role in some suicides. And some behavioural fatalities—accidental deaths related to erratic and/or incautious behaviour—may have occurred. In one instance of non-fatal LSD overdose in eight patients who were seen 15 minutes after having snorted massive doses of LSD (having mistaken it for cocaine), “Emesis and collapse occurred along with [signs] of sympathetic overactivity, hyperthermia, coma, and respiratory arrest. Mild generalized bleeding occurred in several patients and evidence of platelet dysfunction was present in all. [...] With supportive care, all patients recovered.” In recent years, with an increasing assortment of psychedelic “research chemicals” being sold on blotter (sometimes misrepresented as LSD, sometimes mistaken for LSD), there has been an increase in media reports of “LSD overdoses”, which are highly likely to have involved something *other than* LSD.

Related Compounds:

There are a number of compounds related to LSD—lysergamides, both natural and semi-synthetic—with psychedelic effects similar to LSD. Compared to LSD, some of these compounds may have enhanced risk for vasoconstriction, restricting oxygen flow to tissues and muscle. Lysergamide (aka LSA, or ergine) is a naturally occurring psychedelic found in ololiuhqui (*Turbinaria corymbosa*), baby Hawaiian woodrose (*Argyrea nervosa*), and morning glories (*Ipomoea tricolor*). LSA is less potent than LSD, with an active dose in the range of 0.5–2 mg. Semi-synthetic derivatives include ALD-52, AL-LAD, ETH-LAD, LSM-775, LSZ, 1P-LSD, PRO-LAD, and others. The doses of most

of these agents are roughly comparable to that of LSD, with LSZ and ETH-LAD (doses to 150 µg reported) being slightly more potent, whilst LSM-775 is less potent (doses up to 750 µg reported). Differences in the active dose range and duration of effects of these analogues should be noted. Further, these compounds have not been extensively used by, nor studied in humans, and data regarding toxicity and long-term effects is limited

MDMA

MDMA is a stimulant with empathogenic and euphoriant properties. The drug was first synthesised by Merck pharmaceuticals in 1912 as an intermediate in the production of hydrastinine; MDMA, however, was not assessed for activity until many years later. In 1976, Alexander Shulgin initiated some of the earliest MDMA studies in humans; two years later he co-authored a journal article with David Nichols reporting on its chemistry, dosage, and effects. By the late 1970s and early 1980s MDMA, had been brought into use as an adjunct to psychotherapy. However, its growing popularity in recreational settings led to it being scheduled in the United States in 1985. Recent research argues strongly for the utility of MDMA-assisted psychotherapy in the treatment of severe posttraumatic stress disorder.

Chemical Name:

3,4-methylenedioxymethamphetamine

Synonyms:

Adam; E; disco biscuits; ecstasy; Mandy; Molly; pingers; X; XTC. Names often also reflect the large range of imprinted logos found on tablets.


Class:

Stimulant; empathogen

Appearance:

MDMA may present as a crushed powder or crystal of varying textures and colours. Colours of crystalline or powdered MDMA may include off-white, beige, yellow, pink, brown, and may be due to the presence of non-psychoactive contaminants from its synthesis. MDMA is also commonly found in pressed pill form, exhibiting various colours and logos.

or non-existent. Sold as “research chemicals”, some of these compounds are marketed directly by the vendor having been placed onto blotter paper, and at other times they are purchased in powder form and then placed onto blotter by the customer (who may go on to misbrand the material as “LSD” in order to increase sales and/or charge more for it).



Mechanism:

MDMA acts as a releasing agent of the monoamines, namely: serotonin, noradrenaline, and dopamine. Specifically, MDMA is a substrate for monoamine reuptake transporters, and has greatest affinity for serotonin transporters, through which it may be taken up into the neuron. Once in the neuron MDMA can act upon vesicular monoamine transporter-2 (VMAT2), limiting uptake of monoamines into vesicles, and increasing monoamine concentrations in the cytosol. Further actions of MDMA cause reversal of the monoamine transporters, resulting in large effluxes of serotonin (and also dopamine and noradrenaline) into the synapse, where they can act on post-synaptic receptor densities.

MDMA also has inhibitory effects on tryptophan hydroxylase and monoamine oxidase (MAO). MDMA appears to be associated with enhanced blood oxytocin concentrations, which may be involved in its pro-social effects.

Psychoactive Effects:

Euphoria; increased desire to communicate; feelings of comfort and relaxation; belonging, closeness, and bonding with others; increased awareness of senses; heightened sensuality and/or sexuality; body “buzz”; altered sense of time; difficulty concentrating; decreased hunger

Pharmacokinetics:

Oral: 50–150 mg, depending on size and sensitivity; however, 80–125 mg as commonly used active doses. Onset is within 20–60 minutes, peak effects at 75–120 minutes, duration 3–5 hours, and after-effects for up to 24 hours.

Intranasal: 30–70 mg as commonly used active doses. Onset is 10–30 minutes, with peak effects at 45–70 minutes, a duration of 3–4 hours, and after-effects for up to 24 hours. Severe pain and irritation in the nasal cavity is often reported upon insufflation (note that oral dosing is the most common route of administration for MDMA). With insufflation, the effects generally come on somewhat quicker and also subside a little earlier. However, more intense peak effects are elicited and may result in uncomfortable experiences.

Rectal: 50–120 mg, depending on size and sensitivity; however, 70–100 mg as common active doses. Onset is within 20–40 minutes, peak effects at 60–120 minutes, duration 3–5 hours, and after-effects for up to 24 hours.

Injection: Intravenous administration of MDMA is uncommon and it is advised against due to the potential for hypertensive effects and serotonin toxicity.

Adverse Reactions:

Common: Short-term memory loss; difficulty concentrating; jaw clenching; grinding of teeth; insomnia; lack of appetite; rapid heartbeat; hot and cold flashes; nausea; vomiting; dizziness; anorgasmia; dilated pupils; eye-wiggle; fatigue and depression for a few days afterwards (referred to as the “Tuesday blues” following weekend use)

Less Common: Anxiety; blurred vision; faintness; overheating (especially combined with physical activity without sufficient hydration)

Rare: Bouts of dizziness or vertigo after frequent or heavy use

Life-threatening: Dehydration; hyperthermia; hyponatremia (through overhydration); serotonin toxicity, resulting in agitation, tremors, muscle rigidity, hyperthermia, and seizures; acute hypertensive symptoms culminating in intracranial haemorrhage or acute cardiac failure

Contraindications:

Serious heart condition or hypertension; aneurysm or stroke; glaucoma; liver and kidney disorders; hypoglycaemia

Interactions:

Use of MAOIs in conjunction with MDMA may result in serotonin syndrome, overdose, and death (see the Drug Interactions section at the front of this Guide). St. John’s wort (*Hypericum perforatum*) taken in combination with drugs that strongly boost serotonin (like MDMA, MDA, etc.) may

also present a risk of inducing serotonin syndrome. Use of SSRI antidepressants is associated with blunted subjective effects from MDMA. It has been speculated that poor cytochrome P450 2D6 (CYP2D6) metabolisers, which comprise approximately 7% of Caucasians, might be more susceptible to adverse reactions. If this is the case, then poor CYP2D6 metabolisers who are also taking CYP2D6-inhibiting drugs—such as the antiretroviral protease inhibitor, ritonavir (Norvir)—could be at even greater risk. Indeed, there has been at least one fatality involving the consumption of ritonavir and MDMA. Other commonly used CYP2D6 inhibitors include fluoxetine (Prozac) and paroxetine (Paxil). Concomitant use of psychostimulants, such as amphetamine and cocaine, may enhance the risk of dangerous hypertensive responses. MDMA has immunosuppressive effects, and co-usage with immunosuppressants including methotrexate and corticosteroids such as prednisone may result in an immune-compromised state.

Harm Minimisation:

Some users double-dose to enhance or prolong MDMA's effects. Unfortunately, this often results in uncomfortable experiences, whilst increasing the risk of adverse effects. Additionally, re-dosing when the initial effects are subsiding may lead to blunted experiences due to serotonin depletion. Many users who double-dose also report experiencing more severe hangover effects afterwards. Without testing, dosage in tablets cannot be known.

It is important to stay hydrated, particularly if dancing within a crowded, hot nightclub. However, sometimes users who feel dehydrated and drink a lot of water, end up over-hydrating. Drinking far too much water without adequate electrolytes can cause a condition called hyponatremia. Whilst good hydration is recommended, drinking excessive amounts of water has led to fatal outcomes.

Increases in temperature have also been implicated in MDMA toxicity, suggesting that one should avoid using a hot tub while on the drug. Experiments performed on rats have shown that MDMA neurotoxicity can be prevented and tolerance between doses can be lowered via the prophylactic use of antioxidant supplements such as vitamins C, E, beta-carotene, and selenium. Some MDMA

users who incorporate a nutritional approach toward minimising harm have reported fewer unwanted side-effects and less or no hangover after they began to regularly consume doses of particular vitamins or other powerful antioxidants, such as BHT, along with their MDMA.

Overdose:

Large ingestions of MDMA (>0.5g) have been reported. In many cases, minimal to moderate signs of toxicity were experienced, which included confusion, hallucinations, tachycardia, and hypertension, without hyperthermia or hyponatremia. However, severe cases of overdose can lead to coma, cerebral edema, malignant hyperthermia, seizures, serotonin syndrome, and death.

Related Compounds:

Below is a stub entry for MDA, a commonly encountered empathogenic compound similar in structure and effect to MDMA. The risks and harms as described above for MDMA also apply to compounds such as MDA; as such, it is the points of difference from MDMA that we consider below.

MDA

MDA is slightly less potent than MDMA with active dosages ranging from 50–180 mg. Onset is within 30–90 minutes, with a duration of 5–8 hours. The psychoactive effects experienced on MDA are similar to MDMA with euphoria, empathy, openness, and pleasant physical sensations experienced. However, some users describe MDA as being somewhat more psychedelic than MDMA.

This claim is seemingly verified twofold. Firstly, pharmacological studies confirm that the S-isomer of MDA (S-MDA) has appreciable affinity for serotonin receptors, including the 5HT_{2A} subtype commonly affected by psychedelics. Secondly, phenomenological studies describing psychedelic visual effects from S-MDA have also been reported. Additionally, MDA may pose greater risk of neurotoxicity than MDMA, due to enhanced dopamine release. Human fatalities have occurred at very high dosages of 800 mg; symptoms of overdose resemble acute amphetamine overdose and include: profuse sweating; hyperthermia; violent, irrational or stereotypically compulsive behaviour (picking at skin, etc.); seizure; and coma. If a combination of the above effects occurs, seek medical attention.

Other Analogues:

There are a great many MDMA analogues and each of them has different active dose ranges. It is important to avoid taking an excessive dose of any of them, in order to minimise adverse responses.

MDMA is a substituted amphetamine, with a methylenedioxy group attached to the 3,4-position of its phenyl ring. Other 3,4-substituted amphetamines may exhibit empathogenic effects similar to MDMA. These include 3,4-methylenedioxyethylamphetamine (MDEA) and 3,4-methylenedioxyamphetamine (MDA). Other serotonin-releasing agents with empathogenic properties, including a few developed by David E. Nichols for research purposes, have been found in recreational markets. These include 5-methoxy-

6-methyl-2-aminoindane (MMAI), 5,6-methylenedioxy-2-aminoindane (MDAI), and 1,3-benzodioxolylmethylbutanamine (MBDB).

Some MDMA analogues have small therapeutic windows, which means that the risk of adverse effects is enhanced with slight increases in dose. If these are mistaken for MDMA, due to either an unscrupulous or uninformed dealer, this danger may not be appreciated and overdoses may occur. Such compounds include *para*-methoxyamphetamine (PMA), 4-ethoxyamphetamine (4-ETA), *para*-methoxy-*N*-ethylamphetamine (PMEA), *para*-methoxy-*N*-methylamphetamine (PMMA). These compounds have a much higher propensity for producing serotonin syndrome with dose escalations.

MDPV

MDPV is a relatively uncommon synthetic cathinone-based stimulant that may be euphemistically sold as “bath salts” in a marketing strategy akin to the sale of synthetic cannabinoids as “incense”. Despite having been developed by the international pharmaceutical corporation Boehringer Ingelheim in 1969, reports of recreational use first emerged for MDPV in the mid-2000s. The drug’s stimulant effects are reminiscent of both amphetamine and cocaine. Use may be characterised by compulsive re-dosing, and following a rise of MDPV-related fatal and non-fatal overdoses across Europe and the United States circa 2011, by 2012 MDPV became scheduled throughout much of the world.

Chemical Name:

3,4-methylenedioxypyrovalerone

Synonyms:


MDPV; NRG-1; bath salts

Class:

Stimulant; synthetic cathinone

Appearance:

Hydrochloride salt presents as fine hygroscopic powder with a tendency to clump. Colour may range from white to yellow-tan with a fishy or bromine-like odour that increases with degradation.



Mechanism:

Predominant action is as a noradrenaline-dopamine reuptake inhibitor (NDRI), with limited activity on the serotonin transporter (SERT). Compared with cocaine, MDPV is 50-times more potent as an uptake blocker at the dopamine transporter (DAT) and 10-times more potent at the norepinephrine transporter (NET).

Psychoactive Effects:

At low doses, MDPV possesses stimulant effects that have been likened to methylphenidate (Ritalin), whilst at higher doses to agents such as

cocaine and amphetamine. Although described anecdotally as possessing aphrodisiac properties, MDPV does not appear to elicit empathogenic/entactogenic effects.

Pharmacokinetics:

Oral: Approximately 5–20 mg. Common active doses range 5–15 mg. Onset up to 15–30 minutes, with a duration of 2–7 hours, and hangover effects lasting 2–48 hours.

Intranasal: Approximately 2–15 mg. Common active doses range 2–10 mg. Onset up to 5–20 minutes, with a duration of 2–3.5 hours, and hangover effects lasting 2–48 hours.

Rectal: Approximately 4–18 mg. Common active doses range 4–12 mg. Onset up to 10–30 minutes, with a duration of 2–7 hours, and hangover effects lasting 2–48 hours.

Adverse Reactions:

Limited data is available. However as MDPV inhibits reuptake of dopamine and noradrenaline, hypertensive consequences may arise with dose escalations. The following adverse reactions have been reported anecdotally and clinically, although the frequency with which they may occur is unknown: increased heart rate; palpitations; hypertension; anxiety; acute kidney failure; tremor; agitation; aggression; insomnia; abdominal pain; rhabdomyolysis; panic reaction; self-harm; psychosis.

Contraindications:

Likely as per all other stimulants, including any medical condition where hypertension would be hazardous, for example cardiovascular disease, psychiatric illness, seizure disorders, and/or history of aneurysm or stroke. Further, given the higher risk of rhabdomyolysis from cathinone derivatives, greater caution should be exercised by with pre-existing renal impairment. Poor metabolisers of MDPV would be at enhanced risk of toxicity; these include those with altered CYP2C19 and CYP2D6 expression.

Interactions:

The concomitant use of agents, which like MDPV have effects on catecholamines, may enhance their effects and toxicity, and should be avoided. These range from psychostimulants such as cocaine and amphetamines through to pharmaceutical agents such as bupropion. Serious risks of death from combined use with monoamine oxidase inhibitors MAOIs. Furthermore, hepatic metabolism of MDPV is largely via CYP2C19, but also CYP2D6, and CYP1A2. Agents that inhibit CYP2C19 enzymes and may increase the effects and toxicity of MDPV include some SSRI antidepressants, and HIV antiretrovirals.

Harm Minimisation:

Given its potency, doses of MDPV should be measured using an accurate scale. Reports suggest MDPV is strongly habituating, and may be characterised by compulsive re-dosing. Dosing should be closely monitored to prevent cumulative toxicity resulting from prolonged use. Toxicity is exacerbated in hyperthermic conditions and high temperature environments. Given a number of fatal and non-fatal overdoses resulting from acute administration, and the absence of long-term toxicological data, abstinence from MDPV and related synthetic cathinones is strongly advised.

Overdose:

Data is scant. Several hospital admissions and deaths associated with MDPV use have been reported in the recent literature. Adverse effects typically involve cardiovascular and psychiatric symptoms. Refer to Adverse Reactions above.

Related Compounds:

MDPV is a cathinone with a pyrrolidino substitution at the amine. Related compounds include α -pyrrolidino-pentiophenone (α -PVP; Flakka; Gravel), 4-methyl- α -pyrrolidino-propiofenone (4-MePPP, MPPP), and α -pyrrolidino-propiofenone (α -PPP). Further substitutions made include the familiar methylenedioxy moiety of MDMA, at the 3,4-position of the phenyl group, and include MDPV itself, but also 3,4-methylenedioxy- α -pyrrolidinopropiofenone (MDPPP). Please note deaths have been associated with these related compounds. Further, each compound may have unique active dosages, onsets, durations, and propensities for serious adverse reactions.

MEPHEDRONE

Mephedrone is a synthetic cathinone. Cathinones, or keto-amphetamines, are a class of monoamine reuptake inhibitors based on cathinone (or α -amino-propiofenone), which is a naturally occurring stimulant present in the African shrub qat or khat (*Catha edulis*) with a history of use in the Arab Peninsula and Eastern Africa. Mephedrone possesses stimulant properties that are likened to that of cocaine and amphetamine, with additional empathogenic effects reminiscent of MDMA. Use of mephedrone gained prominence from 2007 onwards and from 2009–2013 it was implicated in fatalities in the United Kingdom and other countries. Although little is known regarding toxicity, compulsive re-dosing is commonly reported among users.

Chemical Name:

4-methyl-N-methylcathinone;

- OR -

2-methylamino-1-p-tolylpropan-1-one

Synonyms:

4-MMC; meow meow; M-CAT; MC; white magic; drone

Class:


Stimulant; synthetic cathinone

Appearance:

Most commonly presents as white powder or crystals, or less commonly in pill form. Possesses a distinctive odour that some describe as fish-like.

Mechanism:

Mephedrone (4-MMC) acts as a substrate for monoamine reuptake transporters, thereby inhibiting monoamine reuptake. 4-MMC and MDMA are equipotent in inhibiting noradrenaline reuptake. However, 4-MMC differs from MDMA in that greater potency is seen at dopamine transporters (DAT) than at serotonin transporters (SERT). Additionally, it has been suggested that 4-MMC is more potent than cathinone and methamphetamine at SERTs. Further, 4-MMC likely promotes the release of monoamines from the



presynaptic terminal into the synapse; however, in terms of dopamine release, actions at vesicular monoamine transporters (VMAT) exhibit lower potency as compared with MDMA.

Psychoactive Effects:

Stimulation; euphoria; feelings of openness; enhanced mood; mild aphrodisiac effects. Produces mild perceptual changes but not hallucinations. Consumption, especially intranasally, appears to exhibit a bingeing tendency similar to that observed with cocaine use.

Pharmacokinetics:

Oral: Approximately 100–200 mg. Onset is within 30–45 minutes, with a duration of 2–5 hours, and after-effects lasting 2–4 hours.

Intranasal: Approximately 20–80 mg. Onset is within 15 minutes, with a duration of 2–4 hours, and after-effects lasting 2–4 hours.

Note: Intravenous injection of 4-MMC is extremely dangerous, with

enhanced potential for serious dangerous adverse reactions. Further, the compulsion for re-dosing with mephedrone, could lead to dangerous dose escalations with this route of administration.

Adverse Reactions:

- Common:* Insomnia; hyperthermia; teeth-clenching
- Less common:* Nausea; dizziness; heart palpitations; racing heart; increased blood pressure; agitation
- Rare:* Rhabdomyolysis; hyponatraemia
- Life-threatening:* Cardiovascular problems and hyperthermia

Contraindications:

Likely as per all other stimulants. These include any medical condition where hypertension would be hazardous (for example, cardiovascular disease); psychiatric illness; seizure disorders; and/or history of aneurysm or stroke. As with other cathinone derivatives, higher risks of mephedrone-induced rhabdomyolysis may pose additional dangers to those with pre-existing renal impairment.

Interactions:

Likely as per other stimulants. Serious risk of death from combined MAOI use. The concomitant use of agents that have effects on catecholamines may enhance the effects and toxicity of 4-MMC and should be avoided. These include cocaine, amphetamines, MDMA, and other similar compounds. Further, it seems likely that CYP2D6 inhibitors will increase the effects and toxicity of 4-MMC; these inhibitors include antiretroviral protease inhibitors and some SSRIs.

Harm Minimisation:

As per all stimulants. Compulsive re-dosing of mephedrone is commonly reported. Dosing should be closely monitored to prevent cumulative toxicity resulting from prolonged use. There is evidence to suggest that mephedrone itself is not neurotoxic,

but that it can potentiate the neurotoxic effects of other stimulants, such as amphetamine, methamphetamine, and MDMA.

Overdose:

Overdose most commonly presents with tachycardia, hypertension, agitation, and psychosis, and is most usually treated with fluids, benzodiazepines, or antipsychotics. Mephedrone has been implicated in fatal overdoses.

Related Compounds:

N-methylcathinone was synthesized in 1928 and was used as an antidepressant in the Soviet Union during the 1930s. Further methylation of the 4-position of the phenyl group gives rise to 4-methyl-N-methylcathinone, or mephedrone, which was first synthesized in 1929 but re-emerged as a legal psychoactive in early the 2000s.

Many substituted cathinones have since been developed in clandestine labs attempting to produce novel stimulant compounds in order to circumvent current drug legislation. Common substitutions to cathinone include methyl and ethyl groups, and/or halogens at the 2,3,4-positions on the phenyl ring, or combinations thereof. In addition, extensions on both the amine group and to the methyl group of cathinone have also been produced. As such, there is potential for a great many variants on cathinone that will likely retain substantial stimulant activity.

Some 4-substituted cathinones include the N-demethylated variant, 4-methyl-cathinone (4-MC), and also 4-methylpentadron (4-MPD). Methylone is a cathinone analogue of MDMA, the 3,4-methylenedioxy analogue of methyl-cathinone. However, methylone possesses significantly lower affinity for vesicle transporters, likely to be the reason why its effects were reported by the late Alexander Shulgin as lacking "the unique magic of MDMA".

25I-NBOME

25I-NBOMe is an *N*-benzyl derivative of the psychedelic phenethylamine 2C-I. It was developed in 2003 as a molecular probe of the serotonergic system. Like the other classic psychedelics and with a potency approaching that of LSD, 25I-NBOMe acts on 5-HT_{2A} receptors, although unlike classic psychedelics, it acts as a full agonist. Troublingly, its safety profile appears less forgiving than LSD, with reports of fatal and non-fatal overdoses emerging from around 2012 and onwards. These fatalities are largely a result of 25I-NBOMe's small therapeutic window in combination with it being sold on blotter and misrepresented as LSD, one of the safest of psychoactive drugs. Hence the recent emergence of the expression, "If it's bitter it's a spitter", referring to the more strongly bitter taste of 25I-NBOMe on blotter paper (as compared to LSD), and the advice to spit the hit out.

Chemical Name:

4-iodo-2,5-dimethoxy-*N*-(2-methoxybenzyl)phenethylamine

Synonyms:

25I; 2C-I-NBOMe; N-bomb; smiles; wizard

Class:

Serotonergic hallucinogen

Appearance:


White powder soluble in water

Mechanism:

25I-NBOMe acts as a full serotonin 5-HT_{2A} receptor agonist with picomolar potency. It is some 500-fold less potent on its other targets. Those targets include 5-HT_{1A}, 5-HT_{1D}, 5-HT_{1E}, 5-HT_{2C}, 5-HT_{5A}, dopamine D₃ and D₄ receptors, α_{2C} adrenoceptor, and serotonin transporter (SERT).

Psychoactive Effects:

Characterised by visual effects akin to LSD, 25I-NBOMe alters perceptual processes, with visual patterning, auditory, olfactory, and tactile sensations reported. Changes in mental processes may include feelings of insight, emotional introspection,



and altered perception of time, but also, anxiety and confusion, emotional lability, paranoia, panic, and overwhelming feelings.

Pharmacokinetics:

Sublingual/ Active doses range 200–1000
Buccal: μg, with common active doses of 500–800 μg. Onset of effects within 15–120 minutes, with peak effects for 4–6 hours, and a total duration of 6–10 hours. Hangover effects may last 24 hours or more.

Intranasal: Active doses range 200–1000 μg, with commonly consumed doses of 500–800 μg. Onset of effects within 5–10 minutes, with peak effects for 2–4 hours, and a total duration of 4–6 hours, with hangover effects lasting 24 hours or more.

Adverse Reactions:

Data regarding the frequency of adverse reactions is limited. However adverse reactions

appear to range from tachycardia, agitation, profuse sweating, and hyperthermia, to cardiac ischemia, vasoconstrictive effects, hypertension, and seizures.

Contraindications:

Psychiatric illness, particularly schizophrenia and related psychotic disorders. Due to reports of vasoconstriction in toxicology reports, any medical condition where hypertension would be hazardous, for example, cardiovascular disease.

Interactions:

No data available. In the absence of a clear understanding of its mechanism of action and toxicity, the use of others agents—recreational, therapeutic, or herbal (particularly with serotonergic activity)—is ill advised. Combined use of a monoamine oxidase inhibitor (MAOI) may be fatal.

Harm Minimisation:

The potency of 25I-NBOMe approaches that of LSD, and dosing to any safe level of precision is not possible without an analytical scale. A number of fatalities involving 25I-NBOMe are attributable to its behavioural effect (for example, lack

of coordination resulting in falls), reiterating the importance of having a sober sitter present and available.

Overdose:

Overdose is characterised by severe agitation, confusion, and a significant stimulant effect, speculated to be a manifestation of serotonin syndrome.


Related Compounds:

As alluded to above, 25I-NBOMe is an *N*-benzyl derivative of 2C-I, with some 16-fold greater potency. Interestingly, the *N*-benzyl derivative of DOI lacks any such activity.

Other analogues include halogen substitutions made at the 4-position of the phenyl group in the phenethylamine backbone, which gives rise to the 25x-NBOMe compounds and includes bromine, and chlorine. Additional similar analogues include NBOMe-mescaline and 2C-B-Fly-NBOMe, amongst others. All of these compounds are likely to have unique active dosages, onsets, durations, and propensities for serious adverse reactions. See additional discussion under Related Compounds within the 2C-B entry above.

NITROUS OXIDE

An inhalational anaesthetic used in general and dental medicine for its anxiolytic, sedative, analgesic, and anaesthetic effects. Nitrous oxide is also used in: the production of sodium azide, which is employed as the explosive agent that inflates automotive airbags; it is used to enhance engine performance within the racing industry; and it acts as the lipophilic preservative and propellant that keeps whipped cream fresh and makes it fluffy. Commonly called laughing gas, nitrous was famously employed by William James, a turn-of-the-century Harvard professor of psychology and philosophy, considered to be one of the greatest of American thinkers. James (who in some circles became known as the “Nitrous Philosopher”) would inhale the gas to induce mystical experi-



ences, and subsequently pursue philosophical ponderings and writings.

Chemical Name:

Nitrous oxide (N_2O);

- OR -

dinitrogen monoxide

Synonyms:

Bulbs; hippy crack; laughing gas; nitrous; nos; nangs; Whip-it!

Class:

Dissociative anaesthetic

Appearance:

At room temperature nitrous oxide is a colourless non-flammable gas with a slightly sweet odour and taste. It is commonly distributed in two forms, either in a large metal pressurised-gas tank for medical or racing industry use, or it can be found in small steel “bulbs” or “chargers” (about 7 cm in length) that are used for pressurizing whipped cream dispensers. Because the whipped cream chargers are easier to obtain, they are likely the main source for nitrous oxide that is inhaled recreationally.

Mechanism:

NMDA receptor antagonism is presumed to be the primary mechanism of action for both euphoric and dissociative effects. However, nitrous oxide also interacts with a number of other ionotropic targets, acting as an antagonist on nicotinic and 5-HT₃ receptors. In contrast, nitrous oxide has enhancing effects at GABA_A and glycine receptors. The analgesic effects of the drug have not been fully explained, but are thought to involve the endogenous opioid system.

Psychoactive Effects:

Anxiolysis; analgesia; anaesthesia; euphoria; laughter; perceptual changes including sound distortions; hallucinations; feelings of detachment; dream-like state; motor incoordination; tingling sensations

Pharmacokinetics:

Unlike other drugs, gaseous agents distribute in the body according to pressure gradients between alveoli, blood, and tissues. As nitrous oxide may only be administered via inhalation, dose is usually expressed in terms of a percentage, often in terms of minimum alveolar concentrations. A 50% nitrous mix delivered via a dental gas mask usually equates to less than 10% in plasma. However, one whipped cream bulb containing approximately 8 grams of nitrous oxide is sufficient to produce immediate effects that may last for up to several minutes. Concerned about potentially serious brain damage that could be caused from hypoxia resulting from the inhalation of straight nitrous oxide, some users obtain oxygen tanks in order to blend the two gases into the safer combination preferred by dentists and anaesthesiologists.

Adverse Reactions:

- Common:* Loss of motor control; short-term impairment in mental performance
- Less Common:* Nausea; vomiting; diarrhoea; headache; amnesia; depression; fatigue; shortness of breath
- Rare:* Numbness in extremities with high dosages; long-term use of nitrous oxide may lead to permanent nerve damage, heart damage, and brain injury, and it can interfere with DNA synthesis. The mechanism for some such toxicity is likely due to an interaction between nitrous oxide and vitamin B₁₂ synthesis, which leads to reductions in the activity of the B₁₂-dependant essential enzyme methionine synthase.
- Life-threatening:* At high dosages or pure concentrations, as may occur when inhaled through a mask or in an enclosed breathing space (such as a paper bag), life-threatening loss of consciousness may ensue. An airway obstructed by vomiting adds an additional level of risk.

Contraindications:

Psychotic disorders such as schizophrenia or bipolar disorder; vitamin B₁₂ deficiency; middle ear pathologies; bowel obstruction; pneumothorax; immunosuppressed individuals; history of hypotension

Interactions:

Nitrous oxide has a reputation for combining well with other psychoactive drugs. Its co-administration with hallucinogens, cannabis, and *Salvia divinorum* may lead to very intense experiences, and care should be taken in regards to set and setting with such administrations. CNS depressants such as alcohol, barbiturates, benzodiazepines, opiates/opioids, ketamine, and dextromethorphan should be avoided, as the user may experience

severe adverse reactions including respiratory depression and asphyxiation.

Harm Minimisation:

Inhalation of nitrous oxide at > 50% concentrations results in a rapid loss of motor control. As such, do not inhale nitrous oxide while standing. Never use a mask or any other delivery mechanism for nitrous oxide that does not readily fall away, unless under medical supervision. Deaths are commonly associated with garbage bags falling over somebody's head, a mask that stays attached to the face, and other delivery methods that cause hypoxia/suffocation. Death usually occurs when users, attempting to achieve increasingly higher states of euphoria, breathe pure nitrous oxide in a confined space (such as a small room or a sealed automobile) or by placing their head inside a plastic bag. As a means toward mitigating possible nerve damage, before an extended nitrous oxide session some partake in the potentially prophylactic practice of pre-loading with 4–8 grams of methionine (sold by nutritional

supplement vendors), along with some vitamin B₁₂, and folic acid. Because normal enzyme activity takes a while to fully recover following the consumption of nitrous oxide, limiting one's sessions and spacing them out by a couple of weeks may also be prudent.

Overdose:

As discussed throughout this entry, incorrect use of nitrous oxide can result in hypoxia and death in a very short space of time. Nitrous oxide concentrations greater than 50% impose the risk of loss of consciousness and respiratory depression.


Additional Comments:

The compulsive use of nitrous oxide may lead to psychological addiction in some users. Perhaps due to nitrous oxide's short, yet intriguing and pleasurable effects, "bingeing" in the course of a single session is a common practice. For this reason the gas is sometimes referred to as "hippy crack".

PSILOCYBIN

Psilocybin is a naturally occurring tryptamine hallucinogen present in over 200 mushroom species, predominantly of the *Psilocybe* genus. Hallucinogenic mushrooms have a rich history of use, dating back thousands of years with evidence from cave paintings in Northern Algeria through to ancient temples depicting mushroom gods in Central America. In 1955, their existence and use in shamanic rituals was "rediscovered" in Mexico by the banker and amateur ethnomycologist R. Gordon Wasson.

The effects of psilocybin are prototypic of other serotonergic psychedelics, with characteristic changes in consciousness and perception. Psilocybin has been shown to reliably produce mystical and spiritual experiences. Recently, these effects have been explored for utility in treating depression and anxiety (in palliative/end-of-life scenarios), where they appear to have provided positive and sustained outcomes.



Experiments using psilocybin as an adjunct to treatment for tobacco and alcohol addiction have also shown promising results. Other recent studies have shown that psilocybin can occasion meaningful mystical experiences that result in substantial and sustained life improvement through an increase in well-being and/or life satisfaction.

Chemical Name:

[3-[2-(dimethylamino)ethyl]-1*H*-indol-4-yl] dihydrogen phosphate;

- OR -

4-phosphoryloxy-*N,N*-dimethyltryptamine;

- OR -

O-phosphoryl-4-hydroxy-*N,N*-dimethyltryptamine;

- OR -

4-HO-DMT phosphate ester

Synonyms:

CY-39; Indocybin®; psilocibin, psilocin phosphate ester; PSOP; psilocybine / cubes; hongos; magic mushrooms; mushies; mushrooms; teonanácatl; shrooms

Class:

Serotonergic hallucinogen

Appearance:

Most commonly presents as psilocybin-containing mushrooms, either fresh or dried. May be prepared as a tea, toasted and ground-up and mixed into honey or chocolate, or packed into capsules.

Mechanism:

Psilocybin itself is not psychoactive; rather, it acts as a pro-drug, which the body metabolizes by dephosphorylating it into psilocin. It is psilocin that subsequently acts as a classic hallucinogen. Psilocin (4-hydroxy-*N,N*-dimethyltryptamine) acts as a partial agonist to several receptors involved with the neurotransmission of serotonin, most notably the 5HT_{2A} receptor, but also 5-HT_{2C} and 5-HT_{1A}.

Psychoactive Effects:

As per all serotonergic hallucinogens, psilocybin's effects include alterations to sensory- and thought-processing, resulting in powerful changes to consciousness. These changes may manifest in associative thinking, deep psychological reflection and introspection, spiritual and mystical experiences, mood shifts, laughter, insights, and feelings of closeness to one's self and others. At high dosages, visual patterning is characterised by phosphenes and form constants; other auditory, olfactory, and tactile changes; anomalous perception of time; synaesthesia; yawning and sleepiness. Psilocybin also has potential to produce temporary anxiety, paranoia, panic, and overwhelming feelings.

Pharmacokinetics:

As a pure compound, active psilocybin doses range from 5–50 mg. A recent landmark study looking at psilocybin-induced mystical experiences used a high but safe dose of 30 mg psilocybin/70 kg person. The highest dose on record having been given to a human was 120 mg, and a "maximum safe dose" has been estimated at 150 mg. Pure psilocybin is virtually non-existent on the black market. For this reason, psilocybin is most often taken in the form of dried mushrooms or sclerotia (truffles).

Mushrooms of any kind should not be eaten raw. Mushrooms have very tough cell walls composed of chitin, making them practically indigestible if they are not cooked first. Employing short cooking times for fresh psilocybin-containing mushrooms or preparing dried mushrooms as a hot tea does not noticeably lower their potency, and heating the mushrooms in such manners may help prevent nausea and indigestion that raw mushrooms are more likely to produce.

The psilocybin (and psilocin) content of mushrooms varies widely depending on species, but also within species. Intraspecies variation in potency is common with natural products. For example, an analysis of fifteen specimens of cultivated *P. cubensis* showed them to contain 5.0–14.3 mg of combined psilocybin/psilocin alkaloids per gram of dried mushrooms. Generally "wood loving" mushrooms are more potent; *P. azurescens*, *P. cyanescens*, and *P. subaeruginosa* can be 2–3 times as potent as *P. cubensis* species (although exceptions exist). The more potent species require about half the doses presented below for *P. cubensis*. Mushrooms exhibit "maximum shelf life" and retain their potency for the longest time when they are kept whole, well dried, and stored in a moisture-free, cool or cold dark place. However, even when stored impeccably, mushrooms tend to drop in potency over time.

Dosages presented refer to *dried* mushrooms; as a rule of thumb, a dose of the same weight of the fresh fungus will contain ten times *less* psilocybin (although this figure can vary widely in each instance). This should be kept in mind regarding ingestion information that may be obtained from a guest in the course of a drug care scenario.

Active doses for dried *P. cubensis* range from 0.5 grams to doses of greater than 5 grams, with commonly used doses of 1–2.5 grams. Strong doses range 3–5 grams, and heavy visionary doses are greater than 5 grams. Onset in 15–60 minutes, with a duration of 3–6 hours, and afterglow effects lasting 1–3 hours.

Truffle dosages range from 10–25 grams fresh weight, depending on potency.

Adverse Reactions:

Common: Anxiety; fear; overwhelming feelings; nausea; gastrointestinal discomfort

Less Common: Dizziness; confusion; paranoia

Rare: Working memory disruption; light-headedness or fainting (in cases of lowered blood pressure); exacerbation of latent or existing mental disorders

Life-threatening: None reported

Contraindications:

Psychiatric illness, particularly schizophrenia and related psychotic disorders

Interactions:

The concomitant use of a number of SSRI antidepressants has been reported to blunt the subjective effects of psilocybin. In contrast, the use of monoamine oxidase inhibitors (MAOIs) has been said to increase their effects significantly. MAOIs obtained from plant sources such as Syrian rue have been combined with mushrooms for a potentiation of their effects. Such a combination has been called “psilohuasca” or “shroomahuasca”. A common dose is approximately 3 grams of ground Syrian rue seeds, which effectively halves the amount of mushrooms required per dose; however, the propensity for nausea is increased. The psychoactive effects of mushrooms in combination with MAOIs have generally been reported to produce a more visual and “deeper” experience. Please be aware of the potential for dangerous

adverse reactions that can result from the combination of MAOIs with some other drugs; these are summarised at the beginning of this Guide.

Harm Minimisation:

Standard precautions as per all hallucinogens. If picked from the wild, mushrooms should not be consumed unless they have been positively identified. A number of fungi are toxic, and although infrequent, deaths from the consumption of misidentified mushrooms do occur.

Overdose:

A single case appears in the medical literature where the immediate cause of death was listed as “severe pulmonary congestion” due to or as a consequence of “suspected drug intoxication (psilocin)”; this fairly well-known case documents the death of John Griggs who founded the Brotherhood of Eternal Love. Griggs appears to have consumed an unknown but presumably large amount of pure psilocybin, was having a bad reaction but refused to go to the hospital out of fear of being busted. Eventually his wife persuaded him to go, but he died just after arrival. It seems possible that the pulmonary congestion resulted from his having aspirated vomit. The lethal dose of psilocybin is unknown in humans; however, is likely to be at least several hundred-fold the active dose range. Based on LD₅₀ data for rats (280 mg/kg, intravenously), it has been estimated that for an individual who weighs 80 kilograms, 22 grams of pure psilocybin might be lethal. Such a therapeutic window would require the ingestion of an impractical amount of mushrooms: 3.5 kilos dried, or 17 kilos fresh, has been given by one estimation, or “more than a person could physically eat, even if using the most potent species known” by another individual who pointed out that an oral LD₅₀ would undoubtedly require more material than one based on intravenous administration.

Related Compounds:

Additional synthetic 4-substituted tryptamines include: 4-AcO-DMT, 4-AcO-DET, 4-OH-DALT, 4-OH-DET, 4-OH-DIPT, 4-OH-DPT, 4-OH-MIPT, amongst others. Each of these compounds has particular active dose ranges, durations, and varied subjective phenomena, which should be taken into account in a drug care scenario.


Additional Comments:

Alkaloids found in psychedelic mushrooms primarily include psilocybin and psilocin, but some species also contain other psychoactive *N*-demethylated derivatives, including baeocystin (4-phosphoryloxy-*N*-methyltryptamine) and norbaeocystin (4-phosphoryloxytryptamine). These minor components are likely to be cleaved into their 4-hydroxy analogues within the body before exerting effects, in the same way that psilocybin is metabolized

into the active compound psilocin. The tryptamines derived from the fruiting bodies of these fungi are all substituted at the 4-position of the phenyl group, which is unusual in nature. Most naturally occurring substituted tryptamines in both the plant and animal kingdoms occur at the 5-position, like serotonin (5-hydroxytryptamine), bufotenin (5-hydroxy-*N,N*-dimethyltryptamine), and 5-MeO-DMT (5-methoxy-*N,N*-dimethyltryptamine).

SALVIA DIVINORUM

Salvia divinorum is a plant-based dissociative/psychedelic, whose primary psychoactive constituent salvinorin A is an atypical and potent hallucinogenic terpenoid. Although usually smoked in dried or fortified leaf preparations, the active ingredient may also be absorbed buccally. As such, effective administrations include “quidding” by slowly chewing a wad of leaves that is retained in the mouth, or by holding a high-proof ethanol tincture in the mouth. *Salvia* can produce a short-lasting dissociative-like state, accompanied by unusual and intense somatic and visionary experiences. Traditionally used as a sacrament by the Mazatecs of Oaxaca, Mexico, *Salvia divinorum* was first collected by R. Gordon Wasson and Albert Hofmann in 1962, and identified as a new species by Carl Epling and Carlos D. Játiva-M the same year.

**Botanical Name:**

Salvia divinorum

Chemical Name:

(2*S*,4*aR*,6*aR*,7*R*,9*S*,10*aS*,10*bR*)-9-(acetyloxy)-2-(3-furanyl)dodecahydro-6*a*,10*b*-dimethyl-4,10-dioxo-2*H*-naphtho[2,1-*c*]pyran-7-carboxylic acid methyl ester;

- OR -

salvinorin A

- OR -

divinorin A

Synonyms:

Diviner’s sage; ska María Pastora; shepherd’s herbs; sadi; Sally; Sally D

Class: Dissociative hallucinogen

Appearance:

The plant usually presents as dried leaf, or as leaf fortified with extracted salvinorin A redeposited onto dried leaf to increase the material’s potency. Salvinorin A is rarely encountered in its pure crystalline form.

Mechanism:

The main psychoactive component is salvinorin A, which acts as a potent non-nitrogenous agonist of the κ -opioid receptor (KOR). In addition, salvinorin A acts as a partial dopamine agonist at the D_2 receptor. Salvinorin A elicits physiological and psychological effects at doses as low as 200 μg , making it one of the most potent naturally occurring psychoactive drugs. With vaporized salvinorin A, maximum plasma concentrations are reached at 1 and 2 minutes after dosing. Vaporized salvinorin A severely reduces external sensory perception while inducing strong alterations in audio-visual perception; it increases systolic blood pressure, as well as increasing the release of cortisol, prolactin, and—to a lesser extent—growth hormone. These perceptual, cardiovascular, and neuroendocrine effects are blocked by pre-treatment with the nonspecific opioid receptor antagonist naltrexone, with the KOR partial agonist nalmefene, or the with the opioid antagonist quadazocine. As would be expected based on its binding profile, salvinorin A's effects are not blocked from pre-treatment with the selective 5-HT_{2A} receptor antagonist ketanserin, nor with the cannabinoid antagonist rimonibant.

Psychoactive Effects:

At high doses the effects of *Salvia divinorum* are unpredictable; whilst it can facilitate transcendent psychedelic experiences, very difficult hellish experiences have also been reported. Unlike the largely positive descriptions of effects produced by the classic hallucinogens, the subjective effects of *S. divinorum* are more often described as unpleasant. This is potentially due to its action at the κ -opioid receptor, which is implicated in dysphoric states.

The *Salvia divinorum* Information and Research Center categorises the plant's effects into six possible dose-dependant levels in its SALVIA Experiential Rating Scale. We have adapted the scale to provide a concise version here:

S — SUBTLE EFFECTS:

Mild feelings of relaxation and sensual appreciation

A — ALTERED PERCEPTION:

Colours and textures are more pronounced; altered depth perception; short-term memory difficulties; music enhancement; no visuals yet

L — LIGHT VISIONARY STATE:

Closed-eye visuals composed of clear imagery; fractal patterns; vine-like and 2-D geometric patterns; visions of objects; hypnagogic-like phenomena

V — VIVID VISIONARY STATE:

Complex fantasies and three-dimensional realistic scenes; voices may be heard; encounters with other beings, and entities, sometimes involving travels to other times and places

I — IMMATERIAL EXISTENCE:

Deep dissociation; loss of contact with consensual reality; experiences of merging with god, mind, universal consciousness; bizarre fusions/mergings with objects

A — AMNESIC EFFECTS:

Unconsciousness; complete memory loss during experience; somnambulism

Pharmacokinetics:

Inhalational: 0.25–0.75 grams of leaf as commonly reported doses. Onset is 30–180 seconds, with a typical duration of 2–20 minutes.

Buccal: *Salvia divinorum* may be consumed buccally (administered via the mucosal membranes of the cheek), by means of packing quids of the plant into the mouth. Users slowly chew these quids over a 15–20 minute period, in order to aid release of the active ingredient. A light effect may be obtained from 2 grams of dried leaf (or 10 grams of fresh leaves), a heavy experience from 10 grams of dried leaf (or 50 grams of fresh

leaf). Onset is 10–20 minutes, and usually lasts for up to an hour-and-a-half.

Note: The doses listed above are for unenhanced leaf. In commercially marketed products, which are generally sold for smoking rather than for oral consumption, leaf is often fortified. The amount that it has been enhanced by is usually expressed as a figure-multiple displayed prominently upon the packaging. For example, a gram bag of a product sold as “5X” is presenting itself as having the salvinorin A content of five grams of leaf contained in one gram; a “10X” has ten grams’ worth of salvinorin A per gram of material, and so on. Historically, there have been relatively few products marketed that actually set a standard concentration of salvinorin A per gram of leaf. Doing so requires a manufacturer to make a purified extraction of salvinorin A and then redeposit a specific amount onto leaf that has previously had the salvinorin A extracted from it. Producing pure salvinorin A in order to standardize potency is more labour intensive and time consuming than simply soaking a crude extraction from four-parts of leaf material onto one part of unextracted material to create a “5X” product. Because *Salvia divinorum*, like most natural products, is highly variable with regard to potency, a non-standardized “5X” could be less potent than non-enhanced leaf in one batch, and more potent than “10X” enhanced leaf in another batch, from the same manufacturer. Therefore, unless one is using a standardized extract, knowing what an appropriate dose is can be difficult. New batches of material should be tested by using small amounts at first and working up stepwise. If using an enhanced extract buccally, remember that the above-noted doses would need to

be divided and reduced by whatever the product’s “X” number is (so if you have a 10X, you would use one-tenth as much material as suggested). In recent years, standardized extracts have become more available, although non-standardized extracts still dominate the market.

Adverse Reactions:

- Common:** Loss of motor coordination and balance; dysphoria; itching; changes in one’s sense of body, space, and physical balance
- Less Common:** Disturbed ambulatory behaviour at higher doses; headache
- Rare:** Psychosis in susceptible individuals. There has been one reported suicide with a perceived connection to *Salvia divinorum* use, although it would be difficult to say for certain that this drug was a primary causal factor in the death.

Life-threatening: None reported

Contraindications:

Psychiatric illness, particularly schizophrenia and related psychotic disorders

Interactions:

None reported; difficult experiences may ensue if combined with other hallucinogens

Harm Minimisation:

Standard precautions as per all hallucinogens. *Salvia* should be consumed whilst seated or lying down, to prevent injury from loss of motor coordination. Due to the drug’s effects on balance and motor control, and potential for producing a sort of drug-induced somnambulism, a sober sitter is strongly advised, and more thought should be given to the safety of any given setting (i.e., ground floor, away from swimming pools and busy street traffic, etc.).

Overdose:

There are no known cases of *Salvia* overdose resulting in death. An adverse reaction is likely to predominantly be psychological in nature, requiring debrief and counselling.

Related Compounds:

A few semi-synthetic spin-offs from the salvinorin A molecule have been made for use as scientific research tools within investigations of the opioid receptor system. RB-64 or 22-thiocyanatosalvinorin A is a κ -opioid receptor agonist that exhibits biased agonism (or "functional selectivity") in signal transduction in favour of G protein versus β -arrestin-2, and it produces a long-lasting analgesia-like effect without producing as many of the prototypical side-effects associated with unbiased KOR agents. Herkinorin is an opioid analgesic

analogue of salvinorin A that was discovered in 2005; and while salvinorin A is a selective κ -opioid agonist with no significant μ -opioid receptor affinity, herkinorin is a μ -opioid agonist with over 100 times higher μ -opioid affinity and a 50 times lower κ -opioid agonist affinity compared to salvinorin A. Another salvinorin A analogue is salvinorin B methoxymethyl ether, which is about five times the potency of salvinorin A and has a longer duration of 2–3 hours. But an additional analogue, salvinorin B ethoxymethyl ether, which has been given the common name "Symmetry", is even more potent! One of the pioneering individuals who first bioassayed this compound felt an "alert" of effects from 10 μ g, and several experimentalists reported undeniable psychoactive effects at the 50 μ g level.

SCOPOLAMINE

Scopolamine is a plant-based tropane alkaloid derived from members of the Solanaceae family, for example, *Brugmansia* and *Datura* species. Other such naturally occurring tropanes include atropine and hyoscyamine. Use of these agents may induce delirium, a severely confused state characterised by hallucinatory disturbances, delusions, incoherent speech, and amnesia. Anticholinergic tropanes, as found in mandrake, henbane, and nightshade, have a long history of magico-religious use in the "Old World" of Europe and Asia, and were traditionally associated with witches and faerie tales, as well as used as deadly poisons. Today, the consumption of anticholinergic tropanes often results in emergency room admissions, and overdose on these agents can be lethal.

Chemical Name:


Scopolamine; 6,7-epoxytropicine-tropate; Hyosol®

Synonyms:

burundunga; devil's breath; the devil's plant; hyoscine; scop; zombie drug; scop

Class:

Tropane alkaloid; deliriant

**Appearance:**

May appear as white tablets, often in over-the-counter travel sickness medications; found in many Solanaceous plants, including *Brugmansia* and *Datura* species.

Mechanism:

Scopolamine, atropine, and hyoscyamine are all muscarinic-acetylcholine (mACh) receptor antagonists (anticholinergic agents).

Psychoactive Effects:

Delirium; hallucinations; extreme disorientation; amnesia. Scopolamine and related tropanes are “true deliriants”, in that they may induce experiences and fantasies quite removed from consensus reality, yet experienced as absolutely real by the intoxicated individual.

Pharmacokinetics:

There is no way to accurately gauge a safe dose from plant sources. This is because tropane concentrations vary widely between different individual plants of the same species and within any single individual plant at different stages of the plant’s development. Since the potency of the plant material is highly variable, and considering the small therapeutic window between an active dose and a lethal one, ingestion of plants containing anticholinergics is strongly discouraged. It should be noted, however, that small amounts of tropane-containing Solanaceous species are sometimes included within indigenous preparations of ayahuasca in South America.

Travel sickness tablets commonly contain 0.3–0.4 mg of scopolamine hydrobromide, with active dosages of 0.6–0.8 mg, and toxic effects reported with dosages as little as 2 mg. Effects consist of an onset of 20–120 minutes, with a duration of up to 15 hours, and after-effects of up to a day. As such, the total duration of effects may be nearly two days. This extended timeframe can be somewhat attributed to delayed absorption, due to reduced gastrointestinal immobility.

Adverse Reactions:

- Common:* Mydriasis (pupil dilation); dry mouth; delirium; flushed dry skin; dizziness; incoordination of movement; tachycardia; urinary retention; cycloplegia (paralysis of the ciliary muscle of the eye, disrupting focus on near objects); gastrointestinal immobility
- Less Common:* Hyperthermia; myclonus (muscle jerking); respiratory depression
- Rare:* Seizures (increased risk in combination with other anticholinergics, tricyclic antidepressants, and antihistamines)

Life-threatening: Coma; respiratory failure; cardiovascular collapse

Contraindications:

Mechanical stenoses of the gastrointestinal tract; achalasia; paralytic ileus; intestinal atony; prostatic hypertrophy with urinary retention; myasthenia gravis; glaucoma; pathological tachyarrhythmias; megacolon

Interactions:

Scopolamine has interactions with drugs that possess anticholinergic properties, such as tricyclic antidepressants, MAO inhibitors, and antihistamines. Antipsychotics may also potentiate the effects of scopolamine. Enhanced cardiovascular effects, such as increased heart rate, may result from the use of sympathomimetic drugs, including stimulants such as amphetamine or prescription drugs such as salbutamol, in combination with tropane alkaloids. Additive sedative effects are elicited when combined with CNS depressants.

Harm Minimisation:

The use of scopolamine and related plants should be actively discouraged; a person received by drug care facilities under the effects of tropanes must have their vital signs monitored at all times, whilst emergency medical intervention is sought. If the person’s behaviour is presenting a risk of harm to themselves or to others, some form of physical restraint should be employed in an appropriate manner. Seeking immediate emergency medical intervention is the recommended course of action, since absorption is so unreliable and toxic effects may not present until well after the individual was initially intoxicated. Any dose presenting as severe intoxication should be treated as an overdose.

Overdose:

Overdose symptoms will include disorientation and delirium. Dilated pupils along with flushed skin, fever and an absence of sweating may indicate that an individual has consumed tropanes, although these are signs common to many other psychoactive states as well. Overdose on anticholinergic tropane alkaloids is life threatening.



ABOUT THE PUBLISHER

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organisation. Since our founding in 1986, MAPS has raised over \$36 million to develop psychedelics and marijuana into prescription medicines and to educate the public honestly about the risks and benefits of these substances.

Learn more about our work at maps.org.

MAPS works to create medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by:

- Developing psychedelics and marijuana into prescription medicines
- Training therapists and working to establish a network of treatment centres
- Supporting scientific research into spirituality, creativity, and neuroscience
- Educating the public honestly about the risks and benefits of psychedelics and marijuana.

Our top priority is developing MDMA-assisted psychotherapy into an approved treatment for posttraumatic stress disorder (PTSD). MAPS has completed six Phase 2 clinical trials into the safety and efficacy of MDMA-assisted psychotherapy for PTSD, and is beginning Phase 3 clinical trials in 2017. Data from Phase 3 clinical trials will be submitted to the U.S. Food and Drug Administration (FDA) and European regulatory agencies, with approval anticipated as soon as 2021. With promising results and growing support from medical and therapeutic professionals, the main challenge is to raise the funds necessary to support this vital research.

For more about how you can help make psychedelic therapy a legal treatment, visit maps.org.

At the time of this publication, there is no funding available for these studies from pharmaceutical companies or major foundations. This means that—at least for now—the future of psychedelic and medical marijuana research rests in the hands of individual donors.

Please join MAPS in advancing the expansion of scientific knowledge in the promising area of psychedelic research. Progress is only possible with the support of those who care enough to take individual and collective action.

Learn more and sign up for our monthly newsletter at maps.org, or write to us at askMAPS@maps.org.

Why Give?

maps.org/donate

Your donation will help create a world where psychedelics and marijuana are available by prescription for medical uses, and where they can safely and legally be used for personal growth, creativity, and spirituality.

Every dollar we spend on this work has come from visionary individuals committed to our mission. For-profit drug companies don't invest because there is no economic incentive to develop these drugs; these compounds cannot be patented and are taken only a few times. We're encouraging government agencies and major public foundations to support our research. For now, however, it's up to individuals like you to support the future of psychedelic medicine.

To thank you for your contribution to MAPS, we offer these benefits:

Give \$50 or more (\$60 for international donors):

Receive the tri-annual *MAPS Bulletin*

Give \$100 or more (\$120 for international donors):

Receive a free MAPS-published book

Give \$250 or more: Receive a copy of *Modern Consciousness Research and the Understanding of Art* by Stanislav Grof, or another MAPS-published book. We'll also send a one-year *Bulletin* subscription to a friend or colleague.

Give \$1,000 or more: Receive invitations to attend special interactive webinars with MAPS' executive staff, and a silver MAPS logo pendant.

Each giving level includes the benefits for the levels listed above.

Donations are tax-deductible as allowed by law, and may be made by credit card, or by personal cheque made out to MAPS. Gifts of stock are also welcome, and we encourage supporters to include MAPS in their will or estate plans.

maps.org/bequests

MAPS takes your privacy seriously. The MAPS email list is strictly confidential and will not be shared with other organizations. The MAPS *Bulletin* is mailed in a plain white envelope.

Sign up for our monthly email newsletter at **maps.org**.

MAPS

PO Box 8423, Santa Cruz, CA, 95061 USA

Phone: 831-429-MDMA (6362) • Fax: 831-429-6370

E-mail: askmaps@maps.org

Web: **maps.org** | **psychedelicsscience.org**



More Books Published by MAPS

maps.org/store

Ayahuasca Religions:

A Comprehensive Bibliography & Critical Essays

by Beatriz Caiuby Labate, Isabel Santana de Rose,
and Rafael Guimarães dos Santos

translated by Matthew Meyer

ISBN: 978-0-9798622-1-2 \$11.95

The last few decades have seen a broad expansion of the ayahuasca religions, and (especially since the millennium) an explosion of studies into the spiritual uses of ayahuasca. *Ayahuasca Religions* grew out of the need for a catalogue of the large and growing list of titles related to this subject, and offers a map of the global literature. Three researchers located in different cities (Beatriz Caiuby Labate in São Paulo, Rafael Guimarães dos Santos in Barcelona, and Isabel Santana de Rose in Florianópolis, Brazil) worked in a virtual research group for a year to compile a list of bibliographical references on Santo Daime, Barquinha, the União do Vegetal (UDV), and urban ayahuasqueiros. The review includes specialised academic literature as well as esoteric and experiential writings produced by participants of ayahuasca churches.

Drawing it Out: Befriending the Unconscious

by Sherana Harriette Frances

ISBN: 0-9669919-5-8 \$19.95

Artist Sherana Frances' fascinating exploration of her LSD psychotherapy experience contains a series of 61 black-and white illustrations along with accompanying text. The book documents the author's journey through a symbolic death and rebirth, with powerful surrealist self-portraits of her psyche undergoing transformation. Frances' images unearth universal experiences of facing the unconscious as they reflect her personal struggle towards healing. An 8.5-by-11 inch paperback with an introduction by Stanislav Grof, this makes an excellent coffee table book.

Healing with Entactogens: Therapist and Patient Perspectives on MDMA-Assisted Group Psychotherapy

by Torsten Passie, M.D.; foreword by Ralph Metzner, Ph.D.

ISBN: 0-9798622-7-2 \$12.95

In this booklet, Torsten Passie, M.D., a leading European authority on psychedelic compounds, explores MDMA and other entactogens as pharmacological adjuncts to group psychotherapy. He presents intimate insights into entactogenic experiences from first-hand accounts of clients who participated in group therapy sessions, and crucial background on the neurobiological and psychospiritual components of those experiences. The word "entactogen" refers to compounds that "produce a touching within," and is derived from the roots *en* (Greek: within), *tact's* (Latin: touch), and *gen* (Greek: produce). Entactogen is used to describe a class of psychoactive substances that decrease anxiety; increase trust, self-acceptance, and openness; and allow easier access to memories, providing fertile ground for transformative healing.

Honor Thy Daughter: A Family's Search for Hope and Healing

by Marilyn Howell, Ed.D.

ISBN: 0-9798622-6-4 \$16.95

This is an intimate true story by Marilyn Howell, Ed.D., about her family's search for physical, emotional, and spiritual healing as her daughter struggles with terminal cancer. The family's journey takes them through the darkest corners of corporate medicine, the jungles of Brazil, the pallid hallways of countless hospitals, and ultimately into the hands of an anonymous therapist who offers the family hope and healing through MDMA-assisted psychotherapy. The story was originally featured in a 2006 Boston Globe article entitled "A Good Death" in which Howell's identity was concealed. With psychedelic medicine increasingly a part of the mainstream vocabulary, in this poignant new book Howell comes out of the closet and shares with us how psychedelic therapy helped heal the bonds ripped apart by illness.

Ketamine: Dreams and Realities (out of print)

by Karl Jansen, M.D., Ph.D.

ISBN: 0-9660019-7-4 \$14.95

London researcher Dr. Karl Jansen has studied ketamine at every level, from photographing the receptors to which ketamine binds in the human brain to observing the similarities between the psychoactive effects of the drug and near-death experiences. He writes about ketamine's potential as an adjunct to psychotherapy, as well as about its addictive nature and methods of treating addiction. Jansen is the world's foremost expert on ketamine, and this is a great resource for anyone who wishes to understand ketamine's effects, risks, and potential.

LSD: My Problem Child

by Albert Hofmann, Ph.D. (4th English edition, paperback)

ISBN: 978-0-9798622-2-9 \$15.95

This is the story of LSD told by a concerned yet hopeful father. Organic chemist Albert Hofmann traces LSD's path from a promising psychiatric research medicine to a recreational drug sparking hysteria and prohibition. We follow Hofmann's trek across Mexico to discover sacred plants related to LSD and listen as he corresponds with other notable figures about his remarkable discovery. Underlying it all is Dr. Hofmann's powerful conclusion that mystical experience may be our planet's best hope for survival. Whether induced by LSD, meditation, or arising spontaneously, such experiences help us to comprehend "the wonder, the mystery of the divine in the microcosm of the atom, in the macrocosm of the spiral nebula, in the seeds of plants, in the body and soul of people." Nearly eighty years after the birth of Albert Hofmann's "problem child," his vision of its true potential is more relevant—and more needed—than ever. The eulogy that Dr. Hofmann wrote himself and was read by his children at his funeral is the foreword to the 4th edition.

LSD Psychotherapy

by Stanislav Grof, M.D. (4th Edition, Paperback)

ISBN: 0-9798622-0-5 \$19.95

LSD Psychotherapy is a complete study of the use of LSD in clinical therapeutic practice, written by the world's foremost LSD psychotherapist. The text was written as a medical manual and as a historical record portraying a broad therapeutic vision. It is a valuable source of information for anyone wishing to learn more about LSD. The therapeutic model also extends to other substances: the MAPS research team used *LSD Psychotherapy* as a key reference for its first MDMA/PTSD study. Originally published in 1980, this 2008 paperback 4th edition has a new introduction by Albert Hofmann, Ph.D., a foreword by Andrew Weil, M.D., and colour illustrations.

*Modern Consciousness Research and the Understanding of Art;
including the Visionary World of H.R. Giger*

by Stanislav Grof, M.D.

ISBN: 0-9798622-9-9 \$29.95

In 200 spellbinding pages—including over 100 large, full-colour illustrations—*Modern Consciousness Research and the Understanding of Art* takes readers on an enchanting tour of the human psyche and a visual tour of the artwork of H.R. Giger. In this book, Grof illuminates themes related to dreams, trauma, sexuality, birth, and death, by applying his penetrating analysis to the work of Giger and other visionary artists.

The Ketamine Papers

edited by Phil Wolfson, M.D., and Glenn Hartelius, Ph.D.

ISBN: 0-9982765-0-2 \$24.95

The Ketamine Papers opens the door to a broad understanding of this medicine's growing use in psychiatry and its decades of history providing transformative personal experiences. Now gaining increasing recognition as a promising approach to the treatment of depression, posttraumatic stress disorder (PTSD), and other psychological conditions, ketamine therapies offer new hope for patients and clinicians alike. With multiple routes of administration and practices ranging from anesthesia to psychotherapy, ketamine medicine is a diverse and rapidly growing field. *The Ketamine Papers* clarifies the issues and is an inspiring introduction to this powerful tool for healing and transformation—from its early use in the 1960s to its emerging role in the treatment of depression, suicidality, and other conditions. This comprehensive volume is the ideal introduction for patients and clinicians alike, and for anyone interested in the therapeutic and transformative healing power of this revolutionary medicine.

The Secret Chief Revealed

by Myron Stolaroff

ISBN: 0-9660019-6-6 \$12.95

The second edition of *The Secret Chief* is a collection of interviews with "Jacob," the underground psychedelic therapist who is revealed years after his death as psychologist Leo Zeff. Before his death in 1988, Zeff provided psychedelic therapy to over 3,000 people. As "Jacob," he relates the origins of his early interest in psychedelics, how he chose his clients, and what he did to prepare them. He discusses the dynamics of the individual and group trip, the characteristics and appropriate dosages of various drugs, and the range of problems that people worked through. Stanislav Grof, Ann and Alexander Shulgin, and Albert Hofmann each contribute writings about the importance of Leo's work. In this new edition, Leo's family and former clients also write about their experiences with him. This book is an easy-to-read introduction to the techniques and potential of psychedelic therapy.

The Ultimate Journey: Consciousness and the Mystery of Death

by Stanislav Grof, M.D., Ph.D. (2nd edition)

ISBN: 0-9660019-9-0 \$19.95

Dr. Stanislav Grof, author of *LSD Psychotherapy* and originator of Holotropic Breathwork, offers a wealth of perspectives on how we can enrich and transform the experience of dying in our culture. This 360-page book features 50 pages of images (24 in colour) and a foreword by Huston Smith. Grof discusses his own patients' experiences of death and rebirth in psychedelic therapy, investigates cross-cultural beliefs and paranormal and near-death research, and argues that—contrary to the predominant Western perspective—death is not necessarily the end of consciousness. Grof is a psychiatrist with over sixty years of experience with research into non-ordinary states of consciousness and one of the founders of transpersonal psychology. He is the founder of the International Transpersonal Association, and has published over 140 articles in professional journals. The latest edition of *The Ultimate Journey* includes a new foreword by David Jay Brown, M.A., and Peter Gasser, M.D.

Shipping and Handling

Shipping varies by weight of books.

Bulk orders are welcome. Please contact MAPS for details.

Books can be purchased online by visiting maps.org (credit card or Paypal), over the phone by calling +1 831-429-MDMA (6362), or through your favorite local bookstore.

You may also send orders by mail to:

MAPS

P.O. Box 8423

Santa Cruz, CA, 95061

Phone: +1 831-429-MDMA (6362)

Fax: +1 831-429-6370

E-mail: orders@maps.org

Web: maps.org

mdmaptsd.org

psychedelicscience.org



The Manual of Psychedelic Support is a comprehensive guide to setting up and running compassionate care services for people having difficult drug experiences at music festivals and similar events. The Manual grew out of the work of KosmiCare, a psychedelic care service at the biennial Boom Festival in Portugal. Psychedelic harm reduction services have been in operation for decades, and have grown in number and scope in the past few years. This Manual provides professional guidelines for establishing and providing these services at events, addressing the principles of care, legal considerations, recruiting and training a team, setting up the space, working with outside organisations, case studies, risk management, and much more.

Whether you're an event organiser, harm reduction volunteer, mental health provider, medical professional, or just want to learn more about psychedelics, *The Manual of Psychedelic Support* is the perfect companion to bring with you into the field. With wide-ranging contributions from international experts in psychedelic research, education, and harm reduction, plus inspiring visionary art throughout, this useful guide has the tools you need to provide compassionate care services in a safe, effective, and sustainable way.

The Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organisation that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

ISBN 978-0-9982765-1-9 \$19.95



6 02573 23039 8

Sales of this book will help fund psychedelic harm reduction.



MAPS
MULTIDISCIPLINARY ASSOCIATION
FOR PSYCHEDELIC STUDIES
maps.org